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Abstract
The alpha-synucleinopathies are a group of neurodegenerative disorders characterised by the 
accumulation and aggregation of the presynaptic protein alpha-synuclein. Though not currently 
considered to play a major role in any neurodegenerative condition, gamma-synuclein shares many 
characteristics with alpha-synuclein. The expression pattern of gamma-synuclein does however differ 
from alpha-synuclein, predominantly localised in cell bodies, neurites and synapses of motor and 
sensory neuron populations. In this thesis we have characterised the phenotype developed by a line of 
mice expressing high levels of gamma-synuclein throughout their nervous system. The pattern of 
neurodegeneration developed by the animals bore striking resemblance to that seen in the motor 
neuron disease amyotrophic lateral sclerosis. Accumulation and aggregation of gamma-synuclein was 
detected throughout the nervous system. Upper and lower motor neuron populations were lost in a 
selective manner, with neurons of the sensory system spared.
As a result of these findings we assessed the distribution of gamma-synuclein in spinal cord samples 
of sporadic and familial amyotrophic lateral sclerosis. Though not a component of any typical ALS- 
associated inclusion bodies, we identified gamma-synuclein positive structures in the corticospinal 
tracts of several of the cases examined. All these cases shared a common pronounced loss of upper 
motor neurons and demyelination of the spinal cord portion of their axons. We thus propose that the 
unidentified gamma-synuclein positive structures represent a novel corticospinal tract inclusion 
structure or alternatively present a novel marker of a subtype of amyotrophic lateral sclerosis with 
pronounced upper motor neuron involvement.
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. Introduction
Through the vast advances in healthcare made over the past century, we currently live in a society 
with an increasing life expectancy. The benefits of this are clearly numerous, but longer lifespan within 
the population has also led to a massive increase in the number of people suffering from aging 
associated disorders. If we are to treat these diseases it is essential we unravel their pathogenesis 
and ultimately develop effective therapies against them. Included in these aging-associated disorders 
are degenerative diseases of the nervous system, two of which shall be introduced to provide context 
for this thesis.
1.1. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease, with an 
incidence of 1:50,000 people in the UK (Worms 2001). ALS exists in both sporadic and familial forms 
(discussed below), the latter accounting for approximately 5-10% of cases (Byrne et al. 2010). In the 
late nineteenth century Jean-Martin Charcot systematically described the clinical manifestation of ALS. 
Average age of onset is 55 years, with a life expectancy of three to five years (Haverkamp et al. 1995). 
Typically patients develop asymmetrical muscle weakness in one of the limbs often preceded by 
involuntary twitching, and cramps in the affected limb (Wijesekera and Leigh 2009). The “Babinski 
sign” is often seen in the feet during early stages of ALS, where stimulation of the lateral portion of the 
sole results in involuntary flexing and fanning of the toes. Over the course of disease atrophy spreads 
to all limbs, gradually leaving the patient immobilised. Degeneration of bulbar muscles including the 
tongue causes loss of speech, difficulty eating and drooling (Kawai et al. 2003). Occulomotor function 
is generally remarkably well preserved (Gizzi et al. 1992). Eventual atrophy of respiratory muscles 
results in respiratory and pulmonary difficulties that are generally the cause of death (Wijesekera and 
Leigh 2009). Symptoms of ALS are predominantly motor, though changes in sensitivity have been 
reported by patients including burning and numbness in the extremities and loss of sensation 
(Andersen et al. 1996; Dyck et al. 1975; Kawata et al. 1997). The conservation of sensory and 
cognitive function unfortunately leave patients in the later stages of disease in a “locked-in” state, 
where the paralysed body is supported by assisted respiration but mental capacity is intact 
(Wijesekera and Leigh 2009).
1.1.1. Histopathology of amyotrophic lateral sclerosis
The neuronal degeneration in ALS has been well defined. Neuromuscular deficits are induced by 
substantial dystrophy of motor neurons populations in the spinal cord, brainstem and neurons within 
cortical motor regions. The most substantial and consistent loss of motor neurons is seen in the 
ventral horn of the spinal cord, the population of which has been reported to be reduced by as much 
as 50% (Wijesekera and Leigh 2009). A distinct pattern of damage has been reported in the efferent 
axons. Large caliber fibres with the fastest conduction velocities were found to be substantially more 
vulnerable compared to small caliber fibres, with the slowing of conduction velocities and selective 
loss of fibres reported (Bradley et al. 1983; Kawamura et al. 1981; Theys et al. 1999). In accordance 
with the preservation of occulomotor activity, motor neurons of the abducens, trochlear and
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occulomotor nuclei appear to be consistently resistant to the dystrophy seen in other brainstem 
population such as the hypoglossal, facial and motor trigeminal nuclei (DePaul et al. 1988; Kiernan 
and Hudson 1991; Okamoto et al. 1993a). In addition to disruption of lower motor neurons, damage to 
upper motor neurons, or Betz cells, is also a feature of ALS. Abnormal morphological changes and 
degeneration of pyramidal Betz cells, accompanied by substantial levels of gliosis, is seen within the 
primary motor region of the cerebral cortex. (Hammer et al. 1979; Kiernan and Hudson 1991; 
Wijesekera and Leigh 2009).
In contrast to the motor system, sensory and cognitive systems are considered more tolerant 
(Wijesekera and Leigh 2009). In spite of this, limited changes have been reported in 10-20% of ALS 
patients (Isaacs et al. 2007; Pugdahl et al. 2007). Slowing of conduction velocities and action potential 
have been recorded in the several sensory nerves (Hammad et al. 2007; Isaacs et al. 2007; Pugdahl 
et al. 2007; Theys et al. 1999). Loss of fibres and changes in the myelination of axons has been 
detected in various sensory nerves and ascending sensory columns of the spinal cord (Bradley et al. 
1983; Dyck et al. 1975; Hammad et al. 2007; Heads et al. 1991; Kawamura et al. 1981). As with motor 
axons, the largest caliber of sensory fibre appear most vulnerable to degeneration (Hammad et al. 
2007; Heads et al. 1991; Kawamura et al. 1981). There is little evidence of damage to sensory neuron 
cell bodies, though morphological changes have been noted in mitochondria of the dorsal root ganglia 
(Sasaki et al. 2007).
The formation of proteinacious intracellular inclusion bodies is seen in ALS. Small, eosinophilic, 
intracellular structures termed “Bunina bodies” found in motor neurons of the spinal cord and 
brainstem are considered a hallmark of the disease (Okamoto et al. 2008). Rarely ubiquitinated, the 
only species of protein currently identified as consistent components of Bunina bodies are cystatin C 
(Okamoto et al. 1993b) and transferrin (Mizuno et al. 2006). In addition to Bunina bodies, “Lewy body­
like” and “skein-like” inclusion bodies are also commonly identified in ALS affected motor neurons. 
Intracellular skein-like inclusions consist of bundled fibrils staining intensely for ubiquitin (Leigh et al. 
1988). The composition of the hyaline Lewy-body-like class of inclusions is better defined, with several 
proteins having been identified frequently in the structures in addition to ubiquitin (Leigh et al. 1988). 
Furthermore analysis of the genes encoding several of these component proteins has provided 
valuable evidence regarding genetic risk factors and cellular mechanisms potentially underlying ALS 
pathology. The three most common of these shall be discussed.
1.1.2. Cu/Zn superoxide dismutase (SOD1)
SOD1, an antioxidant enzyme that converts superoxide radicals (0 2~) to oxygen and hydrogen 
peroxide, was the first gene to be associated with fALS (Rosen et al. 1993) and to have its protein 
product detected in both sALS and fALS inclusion bodies (Shibata et al. 1996). Currently over 100 
unique mutations have been identified in the gene (Valentine et al. 2005), accounting for
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approximately 20% of fALS cases (Majoor-Krakauer et al. 2003) and ~5% of sALS (Byrne et al. 2010; 
Orrell et al. 1999).
Though it was initially hypothesised that loss of normal antioxidant function of SOD1 may be the 
underlying cause of ALS, subsequent generation of SOD1-mutant or null mice did not recaptiulate 
motor neuron disease (Reaume et al. 1996). It thus appears that mutations that alter the structure of 
SOD1 are responsible for toxicity, most likely through a gain of function mechanism leading to the 
protein’s aggregation. Wild type SOD1 is an exceptionally stable molecule: active SOD1 has been 
isolated from uncontaminated brain tissue of a 3000-year old Egyptian mummy (Weser et al. 1989). 
When both Cu2+ & Zn2+ binding sites are filled the enzyme is able to retain functional activity after 
exposure to temperatures of almost 80°C, chemical denaturing in 10.0M urea and exposure to 4% 
SDS (Forman and Fridovich 1973). Mutant forms of SOD1 have been found to be only slightly less 
stable under similar conditions (Rodriguez et al. 2002), suggesting that morphologic changes 
increasing aggregation occur whilst the protein is in its native state (Shaw and Valentine 2007). The 
mechanism by which aggregation induces toxicity is the source of much debate (Ross and Poirier
2005). Though large SOD1 containing inclusion bodies are commonly found in motor neurons and 
some glial cells of ALS patients, these most likely represent a defensive mechanism to sequester 
smaller toxic species of intermediate protein oligomers. Mutant forms of SOD1 are able to produce a 
number of these intermediate structures including dimers, pore-like structures and spheroids (Ray et 
al. 2004; Shaw and Valentine 2007).
1.1.3. TDP-43 & FUS/TLS
For many years SOD1 was considered both the predominant component of inclusion bodies in ALS 
and major genetic cause of fALS. However the identification of mutations in genes encoding two 
DNA/RNA binding proteins and the detection of these proteins within inclusion bodies in typical cases 
of both fALS and sALS has vastly changed this doctrine. Both proteins are believed to normally be 
involved in several aspect of RNA processing, including the regulation of transcription, splicing and 
processing of microRNAs (reviewed in Lagier-Tourenne et al. 2010). The first of these to be described 
was TAR DNA binding protein (TDP-43) (Neumann et al. 2006) a conserved DNA/RNA binding protein 
expressed in most human and eukaryotic cell types, originally identified through its ability to bind and 
repress the transcription of TAR DNA sequence motifs in HIV1 (Ou et al. 1995). Hyperphosphorylated 
TPD-43 was found to translocate from its normal localization in the nucleus to the perikaryal soma of 
ALS affected motor neurons and glial cells, where it formed spherical and skein-like inclusion 
(Neumann et al. 2006). This relocalisation is now believed to represent an early aberrant change in 
ALS pathogenesis (Giordana et al. 2010). Similar TDP-43 positive inclusion bodies were also detected 
in the hippocampus, frontal and temporal cortex (Arai et al., 2006; Neumann et al. 2006). Following 
the identification of TPD-43 protein within ALS inclusion bodies, screening of its encoding gene in 
cases of fALS and sALS identified several autosomal dominant missense mutations, several of which 
produced truncated products missing their DNA targeting motif (Arai et al. 2006; Gitcho et al. 2008;
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Kabashi et al. 2008; Sreedharan et al. 2008). Currently over 38 mutations have been identified in TDP- 
43, predominantly contained within the glycine rich C-terminus (Lagier-Tourenne et al. 2010). Such 
mutations account for approximately 3% of fALS and 1.5% of sALS cases (Lagier-Tourenne et al. 
2010). The role of TDP-43 in neurodegeneration does not appear to be restricted to ALS, with TDP43 
positive inclusion bodies detected in cases of frontotemporal lobar degeneration, a condition that is 
often accompanied by the development of ALS (Neumann et al. 2006). Furthermore the protein has 
been detected in inclusion bodies found in conditions including Alzheimer’s disease (Lippa et al.
2009), Parkinson’s disease (Nakashima-Yasuda et al. 2007), Huntington’s disease (Schwab et al. 
2008) and Down’s syndrome (Lippa et al. 2009) amongst others (Lagier-Tourenne et al. 2010).
Following the identification of TDP-43, two groups independently investigating a region of 
chromosome 16 with linkage to fALS detected autosomal dominant and recessive missense mutations 
in the gene encoding a second widely expressed DNA/RNA binding protein, fused in 
sarcoma/translated in liposarcoma (FUS/TLS) (Kwiatkowski et al. 2009; Vance et al. 2009), an RNA 
binding protein originally identified as a chromosomal translocating fusion protein in liposarcoma 
(Rabbitts et al. 1993). As with TPD-43 the normal nuclear localization of FUS/TLS was lost, with 
perikaryal inclusion bodies present in ALS affected motor neurons but not glial cells (Kwiatkowski et al. 
2009; Vance et al. 2009). Currently 30 mutations have been identified in FUS/TLS, mostly within the 
C-terminus, accounting for approximately 4% fALS (Lagier-Tourenne et al. 2010). FUS/TLS positive 
inclusion bodies have also been detected in rare cases of FLTD (Neumann et al. 2009). Notably TDP- 
43 is absent from these structures, as FUS/TLS is absent from inclusion bodies in cases of FTLD with 
TDP-43 inclusions (Lagier-Tourenne et al. 2010; Neumann et al. 2009). Intra-nuclear inclusion bodies 
containing FUS/TLS have also been detected in several polyglutamine disorders, including 
Huntington’s disease (Doi et al. 2008) and spinocerrebellar ataxia (Doi et al. 2010).
1.1.4. Neurofilaments
Intermediate cytoskeletal neurofilament proteins are frequently found to accumulate in ALS. 
Neurofilament proteins have been identified in Lewy-body-like inclusions and atypical, multifocal 
hyaline conglomerate inclusion bodies within the perikaryal cytoplasm and swollen regions of proximal 
axon (Hirano et al. 1984; Rouleau et al. 1996). Rare mutations have also been identified in 
neurofilament heavy subunit (NF-H) (Figlewicz et al. 1994; Tomkins et al. 1998; Al-Chalabi et al.
1999). Such mutations have been predicted to account for approximately 1% of cases of fALS 
(Menzies et al. 2002). Currently all reported mutations in NF-H are located within a C-terminal domain 
containing 43 repeats of the three-residue motif Lys-Ser-Pro (KSP), a target site for Ser/Thr protein 
kinases, suggesting that the changes in the state of neurofilament phosphorylation might contributed 
to pathogenesis.
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1.1.5. Other fALS associated genes
In addition to those of SOD1, TDP-43, FUS/TLS and NF-H, a number other mutantions have been 
associated with very rare cases of familial ALS. Several autosomal dominant mutations have been 
detected in ANG, encoding the angiogenesis promoting protein angiogenin (Cronin et al. 2006). Rare 
autosomal recessive mutations to alsin, a protein carrying several guanine-exchange factors for 
GTPases, result in a juvenile onset form of ALS (Yang et al. 2001). Linkage analysis has detected 
association between autosomal dominant fALS and several regions, for example 9p21.2 and 19p13.3 
(Pearson et al. 2010; van Es et al. 2009).
Several of these rare mutations implicate the disruption of internal trafficking of vesicles and cellular 
components in the pathogenesis of ALS. Autosomal dominant mutation has been detected in the 
dynactin component p150Glued, an essential component of the retrograde transport system facilitating 
the movement of cargo along microtubules (Puls et al. 2003). Mutations have also been found in 
vesicle-associated membrane protein/synaptobrevin-associated membrane protein B (VAPB), a 
protein that binds both intracellular vesicles and microtubules (Nishimura et al. 2004). Both autosomal 
dominant and recessive mutations have been identified in OPTN, the gene encoding optineurin 
(Maruyama et al. 2010). The precise function of optineurin is unclear, though roles in golgi function 
and exocytosis have been suggested (Sahlender et al. 2005). The autosomal dominant E478G 
mutation induced the accumulation of optineurin ALS associated Lewy-body-like, intracellular spheroid 
inclusion bodies (Maruyama et al. 2010). The protein was also identified as a component of skein-like 
and Lewy-body-like inclusions in cases of sALS and fALS. Interestingly optineurin has also been 
identified as a causative mutation in glaucoma, a progressive form of blindness characterised by the 
degeneration of retinal ganglion cells. Mutations in OPTN, the gene encoding optineurin, were found in 
16.7% of families affected by a dominant-negative form of primary open angle glaucoma (Rezaie et al. 
2002).
1.1.6. Rodent models of amyotrophic lateral sclerosis
Though the symptoms and histopathological patterns of neuronal loss and protein aggregation seen in 
ALS are well defined, the mechanisms underlying this damage are poorly understood. This is due in 
part to modern medicine allowing patients to be supported until late into disease progression. 
Consequentially most post-mortem neuronal tissue is in a highly degenerate condition when 
examined. This gap in knowledge can be overcome through the study of animal models of ALS, in 
particular models developed in the mouse, with its central nervous system (CNS) relatively 
homologous to that of humans. The identification of heritable mutations has allowed the development 
of numerous lines of mice expressing increased levels or null for ALS linked genes. In such model 
systems ALS pathology can be observed from its earliest, pre-clinical stages, and followed through to 
complete penetrance of disease.
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SOD1
Several lines have been generated expressing high levels of wild type and mutant forms of S0D1. 
Though overexpression of wild type SOD1 does not consistently induce a ALS-like phenotype 
(Ceballos-Picot et al. 1991; Epstein et al. 1987; Gurney et al. 1994; Jaarsma et al. 2000), transgenic 
mice overexpressing gain-of-function mutations SOD1G93A (Gurney et al. 1994) and SOD1G85R (Bruijn 
et al. 1998) under the control of its endogenous human promoter develop substantial 
neurodegeneration and are currently the most commonly studied and best-characterised models 
(reviewed in Kanning et al. 2010). Both lines of mice developed classic murine motor neuron disease, 
characterised by weakness in the limbs, first visible in the hind limbs from 3-4 months of age, followed 
by the involuntary clasping of limbs towards the abdomen (Gurney et al. 1994). At approximately 5- 
months the limbs of the affected animal become paralysed, resulting in significantly reduced 
movements. Consequentially normal activity such as feeding and grooming become limited, and the 
mouse is euthanised, normally during the fifth to sixth month.
Motor symptoms were caused by the progressive loss of motor neuron populations in the spinal cord 
(Gurney et al. 1994), accompanied by increasing levels of both micro- and astrogliosis (Fischer et al. 
2004; Saxena et al. 2009). Substantial slowing of axonal transport (Williamson and Cleveland 1999) 
was found to lead to accumulation of synaptic vesicles and accumulation of cytoskeletal neurofilament 
components within the perikaryal cytoplasm (Pun et al. 2006). Fragmentation of the golgi apparatus is 
also detected early in disease (Mourelatos et al. 1996). In a pattern matching that seen in human 
cases of ALS, brainstem motor neurons of the occulomotor nuclei were found to be selectively 
resistant to SOD1 induced dystrophy, whereas other brainstem motor neuron populations were 
depleted (Ferrucci et al. 2010). Further parallels with human ALS were detected in the selective 
pattern of motor axon loss, the largest caliber of fibre being considerably more vulnerable to damage 
than smaller fibres, with significant loss of fibres detectable from as early as P20, suggesting a “dying 
back” mechanism of motor neuron loss (Bruijn et al. 1998; Fischer et al. 2005; Fischer et al. 2004; 
Kong and Xu 1998). Furthermore degeneration and disconnection of the largest, fastest-firing fibres 
from their neuromuscular junctions is one of the earliest detectable events in modeled SOD1 
pathology (Frey et al. 2000; Pun et al. 2006). Again the smaller, slower firing fibres do not degenerate 
until considerably later in disease (Frey et al. 2000; Pun et al. 2006). Sensory phenotype in SOD1G93A 
mice is limited, though morphological changes have been reported (Guo et al. 2009). In addition to the 
selective loss of motor neurons, SOD1 mutant mice develop widespread neuronal deposition of SOD1 
immunoreactive inclusion bodies, matching in structure to those seen in human ALS (Bruijn et al. 
1998). Small inclusions initially develop in the synapses and axonal cytoplasm of affected neurons, 
spreading over the course of disease to the perikaryal cytoplasm where large inclusion bodies form 
(Kanning et al. 2010).
Surprisingly however, when restricted to neuronal cell types increased SOD1 expression is insufficient 
to induce motor neuron loss. When overexpressed in all cell types, SOD1G37R induces an ALS-like
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phenotype similar to that seen in SOD1G93A mice (Wong et al. 1995b). Neuron specific overexpression 
of SOD1G37R under transcriptional control of the neurofilament light chain (NF-L) promoter did not 
however induce any behavioural abnormalities (Pramatarova et al. 2001). Assessment of spinal cord 
motor neuron populations found neither loss nor signs of dystrophy. A full complement of motor axons 
was found in lumbar ventral nerve roots. No protein aggregation was reported. A similar pattern was 
detected when the overexpression SOD1G93A and SOD1G85R was restricted to neuronal cell types by 
transcription control under a Thy1 promoter (Lino et al. 2002). Though both proteins were found to 
accumulate in the soma and axons of motor neurons, no behaviour deficits were recorded and 
thorough histopathological analysis of the cell bodies, axons and neuromuscular junctions reveal not 
evidence of pathology. In addition to complimentary evidence obtained from primary cultures of mutant 
SOD1 expressing motor neurons (Nagai et al. 2007), these data suggest that mutant forms of SOD1 
are alone insufficient to induce motor neuron degeneration, and that either the involvement of 
additional mechanisms beyond protein aggregation or further cell types is critical for motor neuron 
degeneration. Astrocytes have been suggested as a candidate cell type (Di Giorgio et al. 2007; Nagai 
et al. 2007), however selective overexpression of SOD1G86R in astrocytes does not lead to motor 
neuron loss in mice (Gong et al. 2000).
TDP-43
Mouse models aberrantly expressing TDP-43 have recently been developed. The first of these 
expressed mutant human TDP-43A315T driven by a prion promoter (Wegorzewska et al. 2009). High 
levels of TDP-43A315T were expressed in the CNS and lower levels in other tissues. Mice developed 
motor neurodegeneration identical to that seen in mutant SOD1 transgenic mice, with premature death 
occurring at five months. Spinal pools of motor neuron cell bodies and axons were depleted by 
approximately 20%. Despite high levels of expression, T D P ^ ^ 151 was not detected in inclusion 
bodies, though large ubiquitin positive structures were observed. Accumulation of ubiquitin followed a 
pattern similar to that seen in human ALS, with high levels found in spinal motor neurons and 
selectively in layer 5 of cortical motor regions.
Two further lines of TDP-43 transgenic mice have been developed, expressing high pan-neuronal 
levels of wild type human TDP-43 driven by a Thy1 promoter (Shan et al. 2010; Wils et al. 2010). As 
with TDP-43A315T these mice developed an ALS-like behavioural phenotype associated with the loss of 
spinal motor neurons and a shift toward smaller caliber axons in the ventral root axons. Immature 
development of neuromuscular junction and a reduction in muscle fibre size indicated neuromuscular 
atrophy. In contrast to overexpression of the mutant TDP-43A315T, small intranuclear TDP-43-positive 
inclusion bodies were detect in spinal motor neurons, as were larger cytoplasmic structure containing 
both TDP-43 and ubiquitin. Surprisingly a portion of the intranuclear structures also contained 
FUS/TLS (Shan et al. 2010).
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1.2. Parkinson’s disease
Parkinson’s disease (PD) is the most common neurological motor condition, with a prevalence of 1-2% 
in people aged over 65 (de Rijk et al. 1997), with an estimated 120,000 people affected in the UK 
(Parkinson’s Disease society). Both idiopathic and familial forms of the disease exist, the latter 
currently accounting for 5-10% of cases (Lesage and Brice 2009). James Parkinson first described the 
clinical symptoms of PD in his 1817 publication “An essay on the shaking palsy”. Symptoms of both 
the familial and idiopathic forms of PD include four cardinal clinical signs; resting tremor, bradykinesia, 
rigidity and postural instability (Stewart 2002). One of the first symptoms of resting tremor to be 
recognised by patients is generally an involuntary, low frequency, pill-rolling motion occurring between 
the index finger and thumb of one hand. Over the course of disease progression this resting tremor 
spreads first to either the other upper limb or the ipsilateral leg and eventually encompasses the entire 
body, head and torso included. Bradykinesia, the slowing of voluntary movement, manifests in many 
forms in PD patients. Normal movements become progressively slower with disease, eventually 
resulting in akinesia, where initiation of voluntary movement is lost. In the final stages of disease 
progression patients may ultimately become entirely paralysed. Notable features of bradykinesia 
include the slurring of speech, micrographia (reduction in handwriting size) and the loss of arm 
movement when walking. Characteristic features of the rigidity seen in PD included difficulty initiating 
large movement, such as walking, and “cog-wheel” movement of the limbs, where by smooth 
movements become disjointed. The effects of slowing of movement and tremor lead to further deficits 
in postural stability, gait and balance. PD patients typically develop a hunched posture and reduced 
stride length, resulting in a characteristic shuffling gait. Motor symptoms are often accompanied by 
non-motor symptoms including sleep disturbance, depression and in some cases cognitive impairment 
and dementia (Stewart 2002).
1.2.1. Histopathology of Parkinson’s disease
The clinical symptoms of both idiopathic and familial PD are associated with a common pattern of 
pathophysiological changes seen in most, but not all cases. The discovery by Fredrick Heinrich Lewy 
in 1912 of “Lewy bodies” within the brainstem of PD patients demonstrated a defining feature of the 
disease. Lewy bodies are large, eosinophilic structures composed of densely packed, filamentous 
protein found in the perikaryal cytoplasm. Similar structures termed “Lewy neurites” have also been 
identified in degenerating neurites. The main component of Lewy bodies was found to be the protein 
alpha-synuclein (Spillantini et al. 1997), the significance of which shall be discussed in much detail 
below. Lewy bodies have been identified in various regions of the PD brain, including the locus 
coeruleus (Greenfield and Bosanquet 1953), dorsal vagus nuclei (Wakabayashi et al. 1999) and 
cerebral cortex (Ikeda et al. 1978) amongst others. Their presence in the substantia nigra pars 
compacta (SNpc) of PD patients has been most scrutinised due to a second histopathological hallmark 
of the disease, the loss of catacholaminergic neurons. Substantial numbers of dopaminergic neurons 
are lost from the SNpc, with post-mortem examination of the brains of PD patients revealing losses of 
up to 85% (Stewart 2002, the earliest research in the field is discussed by Greenfield and Bosanquet
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1953). Many of the remaining dopaminergic neurons appear dystrophic or to contain Lewy bodies. 
Further neuronal loss has also been reported in regions including the locus coeruleus (van Dongen 
1981), raphe nucleus (Halliday et al. 1990) and dorsal vagal nuclei (Gai et al. 1992).
The formation of Lewy bodies and subsequent loss of SNpc dopaminergic neurons provided early 
evidence of the major functional disruption underlying PD pathology. Research carried out by Ehringer 
and Horneykiewicz in 1960 identified this dysfunction. Levels of the catecholemines noradrenaline and 
dopamine were measured in post-mortem brains of control patients and those with postencephalitic or 
idiopathic PD. Levels of dopamine in the caudate nucleus and putamen of the Parkinsonian groups 
were found to be reduced by 70-95% (Ehringer and Hornykiewicz 1960). Both the SNpc and caudate- 
putamen (the latter collectively termed the “dorsal striatum”) are nuclei of the basal ganglia, and 
compose the nigra-striatal pathway, an essential neuronal circuit controlling voluntary movement 
(Kandel 2000). The striatum is predominantly comprised of GABA-ergic medium spiny neurons. These 
modulate the activation of movement through two pathways. The direct pathway promotes movement 
through the inhibition of the internal globus pallidus (GPi), reducing GPi inhibition of the movement 
promoting activity of the thalamocortical pathway. The indirect pathway inhibits subthalamic nucleus 
via the enternal globus pallidus (GPe), promoting GPi inhibition of the thalamocortical movement 
promotion (Kandel 2000). Release of dopamine by axons projecting from the SNpc to the dorsal 
striatum modulates the activation of the direct and indirect striatal pathways. Dopamine activates the 
direct pathway through binding to D1-receptors promoting movement, whereas its binding to D2- 
receptors inhibits the indirect pathway responsible for the inhibition of movement (Kandel 2000). PD is 
caused by the diminished SNpc stimulation of the striatum, resulting in disinhibition of the indirect 
pathway. Consequentially the normal reduced inhibition of thalamocortical pathway is lost, leading to 
unrestricted inhibition of the corticospinal circuitry (Kandel 2000).
The precise mechanism of PD pathology development and progression has yet to be fully elucidated, 
with both environmental and genetic factors being implicated. The identification of many of these 
factors has allowed us to develop animal models of PD, as shall be discuss below.
1.2.2. MPTP, pesticides and mitochondrial dysfunction
Several compounds and gene mutations have been linked to development of PD through their ability 
to disrupt the normal function of the mitochondria, through either the inhibition of the ATP generating 
electron transfer chain or by making the organelles more susceptible to oxidative stress. The strongest 
evidence in support of the importance of mitochondria dysfunction in the development of PD was 
obtained in the early 1980s, when the neurologist J W Langston described six remarkable cases of 
young people developing devastating advanced stage PD within a matter of weeks (Langston et al. 
1983, eloquently documented in his book “The Case of the Frozen Addicts”, J W Langston 1995). 
Langston was presented with six Californian drug users who had self-administered a compound 
purported to be a new “synthetic heroin”, the meperidine analogue 1-methyl-4-phenyl-propionoxy-
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piperidine (MPPP). The users reported unexpectedly strong heroin-like sensations upon intravenous 
administration of the compound. Over the following six weeks the users rapidly developed resting 
tremors, loss of intelligible speech and developed a gait, followed by paralysis throughout their bodies. 
Analysis of the compound administered revealed that though it contained a high concentration of 
MPPP, it was contaminated with approximately 3% 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). Due to the Parkinsonian nature of their symptoms all patients were treated with L-dopa and 
dopamine agonists, to which they responded well. In addition to these patients, re-evaluation of 
available literature identified a similar case where a 23-year old man had injected a meperidine 
congener, also suspected to have been contaminated with MPTP (Davis et al. 1979).
Investigation of MPTP action in animals has revealed the drug induces toxicity through the highly 
selective disruption of mitochondrial complex 1 function in the dopaminergic neurons of the SNpc. This 
analysis was not without early problems. Rats treated with a sample of the compound self­
administered by the individual reported in Davis et al. 1979 did not develop any detectable phenotype. 
Subsequent assessment following the cases reported by Langston et al has shown that rodents are 
sensitive to MPTP, but have a considerably higher tolerance than primates. Though mice do not 
develop any Parkinsonian motor symptoms or Lewy body pathology, they have shown significant loss 
of dopaminergic neurons in the SNpc (Heikkila et al. 1984). Further testing of MPTP has shown this 
loss of SNpc dopaminergic neurons to be consistent in primates, dogs, guinea pigs, frogs and several 
other species as well as in the brains of individuals who have self-administered the substance 
(reviewed in Kopin and Markey 1988).
Thorough assessment of MPTP in these model systems has elucidated the mechanism by which 
toxicity is induced. The specific cell loss induced by MPTP administration is not caused directly by the 
molecule, but though its metabolite 1-methyl-4-phenylpyridinium ion MPP+. The highly 
lipophillic/hydrophobic nature of MPTP allows it to easily cross the blood brain barrier where it is 
converted to MPP+ by monoamine oxidase type B (MAO-B) within glial cells (Chiba et al. 1984; Di 
Monte et al. 1996). MPP+ is then selectively taken up into the dopaminergic neurons of the SNpc by 
the dopamine transporter (DAT) as efficiently as dopamine (Javitch et al. 1985). Once within 
dopaminergic neurons, MPP+ accumulates in mitochondria and inhibits NADH 
dehydrogenase/complex I of the electron transfer chain, resulting in a loss of energy production and 
increased production reactive oxygen species (Vyas et al. 1986).
Further evidence linking mitochondrial function disrupting compounds with PD was presented by 
epidemiological studies that linked exposure to pesticides or herbicides with a significant increased 
risk of developing PD (Gorell et al. 1998; Menegon et al. 1998). Mice systematically infused with 
rotenone, a commonly used insecticide acting through the inhibition of mitochondrial NADH 
dehydrogenase/complex 1, developed behaviour deficits accompanied by selective loss of 
dopaminergic synapses and neuronal cell bodies from the nigra-striatal system (Betarbet et al. 2000).
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Inclusion bodies were also observed within dopaminergic neurons of the SNpc (Betarbet et al. 2000), 
with subsequent analysis detecting alpha-synuclein as a component (Sherer et al. 2003). 
Concentration of rotenone in the brain was relatively low, resulting in only partial inhibition of NADH 
dehydrogenase/complex 1. The authors thus speculated that oxidative stress was the likely factor 
inducing cell death, a hypothesis support by the attenuation of rotenone induced apoptosis by treating 
cultured dopaminergic neurons with antioxidants (Seaton et al. 1997). Systematic exposure of mice to 
the naturally occurring herbicide paraquat has also been demonstrated to induce selective loss of 
nigra-striatal dopaminergic neurons and induce a Parkinsonian phenotype (Brooks et al. 1999). 
Though the mechanism of toxicity is less clear than that of rotenone, it has been speculated that 
paraquat also induces oxidative stress through disruption of mitochondrial complex 1 activity (Dinis- 
Oliveira et al. 2006).
Finally, rare autosomal recessive mutations have been identified in the genes encoding DJ-1 and 
PINK1 (Bonifati et al. 2003a; Bonifati et al. 2003b; Valente et al. 2004). The precise function of these 
proteins is ill defined, though both have been found to associate with mitochondria and appear to play 
a role in protection of the organelles against damage induced by oxidative stress (Bonifati et al. 2003b; 
Valente et al. 2004). DJ-1 has recently been demonstrated to attenuate the effects of oxidative stress 
induced by dopaminergic neurons (Guzman et al. 2010). Both DJ-1 and PINK1 have been 
demonstrated to protect mitochondria against rotenone induced fragmentation, leading to speculation 
that both might be involved in the same process protecting against oxidative damage (Thomas et al.
2010). It thus seems feasible their loss of their function through mutation might contribute to the 
development of PD.
1.2.3. Disruption of the ubiquitin proteasome system
The aberrant deposition of protein into Lewy bodies has led to speculation that disruption of the 
neuronal protein degradation pathways might be responsible for the underlying toxicity (McNaught et 
al. 2001). This hypothesis was given support by the identification of several autosomal recessive 
mutations identified in two genes encoding components of the ubiquitin proteasome system (UPS).
The UPS is responsible for the degradation of damaged, misfolded and sort-lived proteins. At the 
centre of the UPS is the ATP-dependent 20S proteolytic core particle of the proteasome, which 
degrades large proteins into small fragments. A highly specialised structure, the 20S core is composed 
of a cylindrical structure of two core heptameric rings of proteolytic p-subunits, the access to which is 
gated by two heptameric outer rings of a-subunits (Groll et al. 2000). Two mechanisms of protein 
degradation are mediated by the proteasome. Ubiquitin independent degradation utilises just the 20S 
proteolytic core particle. The second more complex process of ubiquitin depended degradation allows 
for the tightly regulated targeting of proteins for proteosomal degradation. For ubiquitin-dependent 
degradation, the cylindrical 20S core particle co-assembles with two additional 19S regulatory particle 
“lids”, forming a structure termed the “26S proteasome” (Voges et al. 1999). The 19S regulatory
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particles carry out a number of functions, including facilitating the unfolding of proteins for access to 
the proteosome, but more importantly restrict the access of proteins to the catalytic core to those 
labelled with ubiquitin (Voges et al. 1999). Proteins are targeted for 26S-mediated degradation by the 
activity of three of enzymes. Briefly, monomeric ubiquitin is activated by E1 enzymes and transferred 
to an ubiquitin-conjugating E2 enzyme. An E3 ubiquitin-ligase then facilitates the covalent binding of 
the C-terminal of the activated ubiquitin molecule to a lysine residue of the target protein. Successive 
rounds of ubiquitination produce a branched poly-ubiquitin chain on the target protein, allowing the 
19S regulatory particle to recognise the labelled protein as a substrate for degradation. Following 
targeting the substrate protein is deubiquitinated and degraded by the 20S core. The separated poly- 
ubiquitin chain is hydrolysed into subunits that are subsequently reused (McNaught et al. 2001; Pickart 
2000).
The ability of a small number of toxins to inhibit normal mitochondrial function was described above. 
The disruption UPS function by toxic substances has also been proposed as a pathway to 
development of PD, in part due the natural occurrence of some proteasome inhibitors (Kisselev and 
Goldberg 2001). In 2004, McNaught et al published data demonstrating that systematic exposure of 
rats to the synthetic proteasome inhibitor Z-lle-Glu(OtBu)-Ala-Leu-CHO (PSI) induced a phenotype 
with remarkable similarity to that seen in human PD (McNaught et al. 2004). Behavioural abnormalities 
synonymous with nigra-striatal system were visible two weeks after treatment induced. Populations of 
neurons within the SNpc, locus coeruleus and dorsal vagal nucleus were depleted, as was striatal 
dopamine release. Lewy-body like inclusion structures were observed throughout the SNpc and locus 
coeruleus, and were found to contain alpha-synuclein and ubiquitin amongst several other proteins. 
The remarkable nature of these finding has since become viewed with some caution, due to 
inconsistent finding by groups replicating the work. Two independent laboratories produced results 
confirming the work of McNaught et al (Schapira et al. 2006; Zeng et al. 2006). Other groups however 
found no evidence of pathology, despite every effort to replicate the original study being taken (to the 
extent of the original authors visiting one group to demonstrate preparation and administration of the 
PSI) (Bove et al. 2006; Kordower et al. 2006; Manning-Bog et al. 2006). This disparity has been 
blamed on possible differences in the properties of PSI used, such as potency and solubility, or local 
environmental factors (McNaught and Olanow 2006).
Genetic modelling has also demonstrated the relevance of the UPS to PD. A phenotype bearing 
remarkable similarity to PD was described in mice where 26S proteasome formation was selective 
disrupted through the conditional inactivation of PSMC1, an essential component of the 19S regulatory 
particle (Bedford et al. 2008). These mice developed substantial loss of SNpc dopaminergic neurons 
and reductions in striatal dopamine concentration. Lewy-body/pale-body like inclusion bodies 
containing densely accumulated alpha-synuclein were also present. Though PSMC1 has not been 
linked to PD pathology, several mutations have been identified in genes coding for components of the 
UPS. The most common of these mutations are autosomal recessive mutation in PARK2, a gene
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encoding the E3 ubiquitin-protein ligase parkin (Shimura et al. 1999). Several point mutations and/or 
deletions result in a loss of normal parkin function (Farrer et al. 2001; Kitada et al. 1998; Mori et al. 
1998; Pramstaller et al. 2005; Shimura et al. 2000; Shimura et al. 1999). Mice null for parkin develop 
deficits in neurotransmitter handling and release in their nigra-striatal system, including increased 
striatal dopamine content, decreased synaptic vesicle release and increased dopamine metabolism. 
These changes result in behavioural abnormalities typical of reduced dopamine signalling, such as 
diminished basal locomotor activity. Loss of SNpc dopaminergic neurons however was not detected 
(Goldberg et al. 2003; Itier et al. 2003). In addition to these recombinant model animals, mice carrying 
a spontaneous deletion of parkin were also identified. The “quaking viable” mice develop severe CNS 
demyelination, increased dopamine metabolism, and reduced locomotor activity (Lockhart et al. 2004).
Genetic analysis has identified a second UPS-associated protein linked to familial cases of PD. 
Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is one of the most abundant proteins in the brain, 
accounting for 1-2% of total protein (Wilson et al. 1988). UCH-L1 facilitates neuron specific 
deubiquitination of proteins and hydrolysis of polyubiquitin chains, though when dimerised the protein 
has been reported to also carry out the opposing function of ubiquitin ligation (Liu et al. 2002; 
Wilkinson et al. 1989). Several findings have demonstrated the association of UCH-L1 with PD. Wild 
type UCH-L1 has been identified as a component of Lewy bodies, though it should be noted these 
were identified in cases of diffuse Lewy body disease (Lowe et al. 1990). A genetic link was made 
between UCH-L1 and PD, following the identification of a rare I93M autosomal dominant mutation in a 
German family with typical PD (Leroy et al. 1998). UCH-L1I93M was associated with a 50% reduction in 
the proteins deubiquitination activity (Leroy et al. 1998). The authors suggested that the reduced 
catalytic activity of UCH-L1I93M might result in the accumulation of unidentified ubiquitinated substrates. 
The association between UCH-L1l93M and PD was corroborated by the development of a line of mice 
expressing high levels of UCH-L1I93M under the control of the platelet-derived growth factor (PDGF) 
promoter (Setsuie et al. 2002). These were found to develop a reduction of the SNpc dopaminergic 
neuron population with age, in addition to a lower concentration of striatal dopamine. Such changes 
were not detected in a line of UCH-L1m  developed in parallel to the UCH-L1I93M line. In contrast to the 
increased risk of PD associated with UCH-L1I93M, an apparently protective S18Y polymorphic variant 
of UCH-L1 has also been identified, associated with a reduced susceptibility to PD (Carmine Belin et 
al. 2007; Facheris et al. 2005; Maraganore et al. 2004; Wintermeyer et al. 2000). In vitro analysis of 
mutant UCH-L1S18Y found an association with a reduced ability to dimerise, resulting in limited ligase 
activity, though hydrolysis activity was normal (Liu et al. 2002). These data suggest that the protective 
action of UCH-L1S18Y might be facilitated through the limiting of the proteins ability to ubiquitinate 
particular unknown substrates. Interference of UCH-L1 dimerisation may thus be a viable therapy for 
PD (Liu et al. 2002).
Further evidence of a role for UCH-L1 dysfunction in PD was presented by a line of mice that were 
found to develop spontaneous gracile axonal dystrophy, termed “GAD mice” (Yamazaki et al. 1988).
14
Genetic analysis found that these mice carried a sporadic deletion of UCH-L1 coding exons 7 and 8, 
truncating the catalytic site of the protein (Saigoh et al. 1999). GAD mice develop a sensory ataxia and 
motor deficits associated with the degeneration of gracile tract of the spinal cord and medulla 
oblongata and of spinal motor neurons (Saigoh et al. 1999; Wang et al. 2004; Yamazaki et al. 1988). 
Neurodegeneration of the gracile tract was associated with the formation of ubiquitinated axonal 
spheroid inclusion bodies (Osaka et al. 2003; Wu et al. 1995), composed of several aggregation prone 
proteins including amyloid-beta (Saigoh et al. 1999) and synuclein proteins (Wang et al. 2004).
1.2.4. LRRK2 and increased kinase activity
PD associated familial mutations have also been detected in non-mitochodria/UPS associtated 
proteins. Of these the most prominent are autosomal dominant mutations in leucine rich repeat kinase- 
2 (LRRK2) (Kachergus et al. 2005; Paisan-Ruiz et al. 2004; Zimprich et al. 2004). Though these 
mutations represent a particularly common form of familial* PD with typical features (Zimprich et al. 
2004), the function of LRRK2 in degeneration is poorly defined. LRRK2 is believed to be a GTP- 
dependent protein kinase, due to the fact it carries several well-defined domains that facilitate protein- 
protein interaction, including leucine rich repeat, GTPase and a MAPK region (Anand et al. 2009). It 
has been proposed that changes in this kinase function might be responsible for neurodegeneration in 
PD.
In vitro studies have demonstrated that several heritable mutations within the domains highlighted 
above increase the kinase activity of LRRK2 (Gloeckner et al. 2006; Smith et al. 2006; Smith et al. 
2005; West et al. 2007). More so, LRRK2 kinase activity promoting mutations, including G2019S and 
R1441C, have been found to induce degeneration of neurons in vitro (Greggio et al. 2006; Smith et al.
2006). A role for LRRK2 kinase activity in promoting dopamine release was reported following the 
investigation of a line of mice expressing high levels of wild type LRRK2 under transcriptional control 
of a bacterial artificial chromosome (BAC) (Li et al. 2010). Evoked dopamine release experiments 
found LRRK2wt overexpressing mice had increased release of striatal dopamine. This change in 
dopamine handling was associated with both hyperactivity and enhanced performance in behavioural 
tests. These changes in motor function were found to be ameliorated in mice expressing knocked-in 
mutant L f t f lK ^ 14410 (Tong et al. 2009) or overexpressing high levels of LRRK^ 14410 (Li et al. 2010) 
and LRRK£?2cn9S (Li et al. 2009), though deficits in dopamine handling were detected. These included 
reduced striatal dopamine content, decrease dopamine uptake, reduced vesicle release and an 
absence of locomotor activity increase following treatment with amphetamine (Li et al. 2010; Tong et 
al. 2009). Changes in striatal dopamine were not detected in mice null for LRRK2 (Andres-Mateos et 
al. 2009; Tong et al. 2010), though interestingly alpha-synuclein was found to accumulate in the 
kidneys of affected animals (Tong et al. 2010).
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1.3. Alpha-synuclein
Of all genes, mutations and proteins associated with the development of PD, alpha-synuclein has 
become the most intensely studied. Several mutations have robustly linked the gene encoding alpha- 
synuclein to PD, as well as several other neurodegenerative disorders. Furthermore alpha-synuclein is 
a major component of the Lewy bodies seen in PD. To provide context for this thesis the 
characteristics of alpha-synuclein, and the small family of synuclein proteins of which it is a member, 
shall be described in more detail. Both the normal function of the synucleins and their known roles is 
disease shall be discussed.
Alpha-synuclein is the most studied member of a small family of conserved presynaptic proteins 
consisting of three members; alpha-, beta- and gamma-synuclein. Alpha-synuclein was first identified 
in the cholinergic presynaptic nerve terminals of the Pacific electric ray Torpedo californica (Maroteaux 
et al. 1988) and found to consist of a 143-residue, 17.5kDa protein, containing six imperfect repeats of 
an 11-residue unit with a hydrophilic core motif of Lys-Thr-Lys-Glu-Gly-Val (KTKEGV), and a 
hydrophobic C-terminus (Maroteaux et al. 1988). The homologous human alpha-synuclein protein is 
coded for by the six-exon SNCA gene, located on chromosome 4q21.3-q22 (Spillantini et al. 1995; 
Touchman et al. 2001). The protein has been found to be highly conserved in vertebrate evolution, 
with the rodent and zebrafinch proteins showing 95 and 86% homology to human respectively, with 
the most frequent variation found in the hydrophobic C-terminus (George et al. 1995; Goedert 1997; 
Maroteaux et al. 1988; Ueda et al. 1993). Alpha-synuclein has been predominantly associated with 
CNS presynaptic terminals and their vesicles, including those of the cerebral cortex, hippocampus, 
amygdala and olfactory tubercle (George et al. 1995; Iwai et al. 1995; Jakes et al. 1994).
1.3.1. Alpha-synuclein structure
Alpha-synuclein carries several distinct morphological features. Though less well conserved between 
species than the N-terminus, the acid and hydrophobic nature of alpha-synucleins C-terminus remains 
consistent (Maroteaux et al. 1988). N-terminal residues 1-102 are able to interact and bind lipid 
membranes, an ability that can be disrupted by the introduction of charged residues (Perrin et al.
2000). This ability correlates with the localization of alpha-synuclein to presynaptic terminal vesicles, 
suggesting that the protein may act in synaptic processes such as vesicle release (George et al. 1995; 
Iwai et al. 1995; Jakes et al. 1994). Alpha-synuclein resides in a “natively unfolded” conformation 
when in solution, lacking typical secondary structural features such as a hydrophobic core (Weinreb et 
al. 1996), though the N-terminus has been found to have a slight helical tendency (Eliezer et al. 2001). 
When bound to lipid membranes the N-terminus takes on a more helical conformation, though the C- 
terminus retains its disordered morphology (Eliezer et al. 2001; Sung and Eliezer 2007). The 
intrinsically disordered nature of alpha-synuclein leaves many hydrophobic residues exposed, and 
thus it has been attributed to the protein’s high propensity to aggregate (Weinreb et al. 1996, see 
below). One region in particular, the 35-residue non-amyloid-p component (NAC), contains a high 
concentration of hydrophobic residues and is found to interact with the acidic C-terminus (Sung and
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Eliezer 2007). A fragment of the NAC has been identified in 10% of the amyloid-plaques typical of 
Alzheimer’s disease (Han et al. 1995; Ueda et al. 1993).
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The amino acid sequences of alpha- beta- and gamma-synuclein. Blue highlighting = alpha-synuclein; 
Green = non-amyloid component region; Red = imperfect KTKEGV repeat motifs (adapted from Sung 
and Eliezer 2007).
1.3.2. Alpha-synuclein function
The normal physiological role of alpha-synuclein is yet to be fully elucidated. A vast number of proteins 
have been claimed to interact with alpha-synuclein, though the evidence supporting many of these is 
limited (reviewed in Dev et al. 2003). Research focused on the dopaminergic system has suggested 
the protein might play a role in regulation of dopamine production. Alpha-synuclein was found to co- 
immunoprecipitate with tyrosine hydroxylase (TH) in rat brain homogenate and stable dopaminergic 
MN9D cells (Perez et al. 2002). Concentration of dopamine in the MN9D cells moderately 
overexpressing alpha-synuclein was found to be reduced, due not to increased dopamine degradation, 
but to an increased proportion of a less active non-phosphorylated form of TH. A yeast two-hybrid 
study also demonstrated the ability of alpha-synuclein to interact with the dopamine transporter (Lee et 
al. 2001). Overexpression was also found to increase the concentration and activity of the dopamine 
transporter (DAT) on the membrane of cultured HEK293 cells (Lee et al. 2001). Due to the predicted 
lipid binding morphology of the N-terminus of alpha-synuclein, association between the protein and 
presynaptic vesicles was made soon after its discovery (George et al. 1995; Jakes et al. 1994). The 
most compelling evidence supporting a normal function of alpha-synuclein has come from 
investigation of its role in synaptic function, particularly the release of synaptic vesicles. Much of this 
has been carried out in synuclein-null mouse models and shall be discussed below.
1.3.3. SNCA, mutations and Parkinson’s disease
Interest in alpha-synuclein exploded in 1997 following the publication of two seminal works of PD 
research, demonstrated that changes in alpha-synuclein were associated with both idiopathic and 
familial forms of the disease. In the first of these studies, an autosomal dominant mutation in the 
SNCA gene was identified in a large Italian family and three smaller Greek families with a relatively
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early onset form of familial PD (Polymeropoulos et al. 1997). A single base pair substitution of guanine 
209 to adenine resulted in the coding of threonine as position 53 instead of the wild type alanine 
(S/VCAA53T). This variation was predicted to disrupt the regions normal alpha-helical structure and 
extend an adjacent beta-sheet region, resulting in a protein with a more aggregation prone structure 
(Polymeropoulos et al. 1997). Since the identification of the A53T mutant, mutations in SNCA have 
been robustly linked to PD. Two further autosomal-dominant point mutations have been identified, 
A30P (Kruger et al. 1998) and E46K (Zarranz et al. 2004). In addition to point mutations, the 
autosomal-dominant duplication (Ibanez et al. 2004); (Chartier-Harlin et al. 2004) and triplication 
(Singleton et al. 2004) of SNCA have also been linked to familial PD. Linkage analysis has detected 
polymorphisms within the SNCA promoter region associated with an increased risk of susceptibility to 
PD, specifically a haplotype spanning 15.3kb that was found to be significantly more frequent in PD 
patients (Pals et al. 2004). The most robust genetic evidence of alpha-synucleins role in PD has come 
from four recently completed genome wide association studies. (Edwards et al. 2010; Pankratz et al. 
2009; Satake et al. 2009; Simon-Sanchez et al. 2009). Sample groups made up of individuals of 
European (Edwards et al. 2010; Pankratz et al. 2009; Simon-Sanchez et al. 2009) or Asian ancestry 
(Satake et al. 2009), with familial forms of PD of unidentified genetic origin, were assessed for genetic 
association with the disease. Prior to investigations, individuals carrying known PD associated 
mutations were removed from the sample groups. In addition to SNPs previously identified in known 
PD risk loci, including genes encoding microtubule associated tau (Edwards et al. 2010; Pankratz et 
al. 2009; Simon-Sanchez et al. 2009) and LRRK2 (Satake et al. 2009), each of the four studies 
independently identified several SNPs reaching genome wide significance within the SNCA locus. The 
significance of several of the SNPs identified was further confirmed by replication of the GWAS in 
additional sample groups (Satake et al. 2009; Simon-Sanchez et al. 2009).
1.3.4. Alpha-synuclein aggregation and synucleinopathy diseases
A second major development in PD research was the identification of alpha-synuclein amyloid fibrils 
as a key component of Lewy bodies (Spillantini et al. 1997). Analysis of SNpc post mortem tissue 
collected from six cases of idiopathic PD revealed dense staining of alpha-synuclein within 
cytoplasmic and extracellular Lewy bodies. The localization of alpha-synuclein within Lewy bodies in 
PD has been robustly demonstrated by countless groups and is now considered a hallmark 
histopathological feature of the disease. In addition to PD, alpha-synuclein positive inclusion bodies 
have been identified in several other neurodegenerative disorders, all of which are characterised by 
neuronal and/or glia protein aggregation. Collectively termed “synucleinopathies” these disorders 
include dementia with Lewy bodies (Galvin et al. 1999; Spillantini et al. 1998b; Spillantini et al. 1997), 
multiple system atrophy (Gai et al. 1998; Spillantini et al. 1998a; Tu et al. 1998), Lewy body variant of 
Alzheimer’s disease (Lippa et al. 1998) and Hallervorden-Spatz syndrome (Galvin et al. 2000; Tu et al. 
1998).
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In vitro research of alpha-synuclein protein has further confirmed the link between alpha-synuclein and 
Lewy body formation, and also offered some insight into the mechanism underlying synucleinopathy 
pathogenesis. Both wild type and mutant proteins readily aggregate in solution and form fibrils similar 
to those seen in human disease (Conway et al. 1998). The rate of this aggregation is depended on 
several factors, including temperature, agitation, buffer composition, concentration and protein species 
(Conway et al. 1998; Uversky et al. 2001; Uversky et al. 2002). Alpha-synuclein aggregation followed 
a classical nucleation or “seeding” mechanism of fibrilisation in solution, where by a lag period occurs 
prior to fibril formation, during which small oligomeric seeds form onto which fibrils develop (Uversky et 
al. 2002). The A53T and A30P mutant variants have been demonstrated to have greater propensity to 
form fibrous structures than the wild type protein, with the A53T mutant form aggregating most 
efficiently (Conway et al. 1998; Narhi et al. 1999). It is thus feasible that familial mutations that alter the 
morphology of alpha-synuclein (Kruger et al. 1998; Polymeropoulos et al. 1997; Zarranz et al. 2004) or 
increase the intracellular concentration of the protein (Ibanez et al. 2004; Chartier-Harlin et al. 2004; 
Singleton et al. 2004), result in the promotion of alpha-synuclein protein aggregation leading to the 
generation of toxic protein species.
The mechanism by which aggregation induces toxicity, if at all, is the source of debate. In particular 
the question of whether Lewy bodies are toxic or the result of an intrinsic mechanism to protect the 
neuron from hazardous intermediate species remains to be answered (Tompkins and Hill 1997). The 
latter hypothesis is supported by both lack of Lewy body pathology in some cases of familial PD and in 
transgenic alpha-synuclein mice with clear evidence of degenerative changes in their nervous system 
(see below, (Hardy 2010; Masliah et al. 2000) and conversely by the detection of Lewy bodies in the 
brains of individuals with no evidence of neurodegenerative disease of any sort (Goldberg and 
Lansbury 2000). There are several possible route by which alpha-synuclein may produce large 
structures such as Lewy bodies, some of which require the formation of intermediate structures which 
may include small oligomers, pore-like structures and protofibrils. The concentration of such oligomeric 
forms of alpha-synuclein is significantly elevated in post-mortem cerebrospinal fluid of PD patients (El- 
Agnaf et al. 2006). Wild type, A53T and A30P forms of alpha-synuclein have been shown to produce 
both pores and protofibrils, with the mutant forms forming such structures with greater efficiency than 
the wild type (Conway et al. 2000; Lashuel et al. 2002; Li et al. 2001). The pore-like annular protofibrils 
structures were demonstrated to be able to bind synthetic phospholipid membranes resulting in the 
formation of aberrant channels (Lashuel et al. 2002). Protofibrils have similarly been found to bind to 
and permeabilise membranes (Voiles et al. 2001). Such disruption of membranes may have serious 
consequences on the health of the neuron, for example it might cause changes in calcium 
homeostasis through leakage of extracellular calcium (Kawahara and Kuroda 2000). Alternatively, 
permeabilisation of synaptic vesicles in dopaminergic presynaptic terminals would lead to increased 
concentration of free cytoplasmic dopamine, which is toxic and causes oxidative damage of synapses 
(Chen et al. 2008).
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Finally much research regarding the ability of alpha-synuclein aggregation to induce neuronal toxicity 
has been carried out in transgenic mice expressing high levels of wild type or mutant SNCA. This data 
shall be discussed below.
1.4. Beta synuclein
Following the discovery of alpha-synuclein, a second synuclein protein was identified in humans 
(Jakes et al. 1994). A 134-residue protein sharing 61% homology (Goedert 1997) and similar 
anatomical distribution to human alpha-synuclein was identified in the tissue of healthy and 
Alzheimer’s disease afflicted human brains (Jakes et al. 1994). This protein shared homology with a 
previously identified, KTKEGV motif containing protein termed PNP14, identified in bovine brain, 
rodents, chickens, frogs and fish (Nakajo et al. 1993). Due to the high level of homology between 
PNP14 and alpha-synuclein, the protein was renamed beta-synuclein (Jakes et al. 1994). The beta- 
synuclein gene SNCB, mapped to chromosome 5q35, is relatively homologous to SNCA being 
composed of 6 exons, five of which are coding (Lavedan et al. 1998c; Spillantini et al. 1995). The most 
notable difference between SNCA and SNCB is the truncation of exon 4 in the latter. This results in an 
eleven-residue deletion in the transcribed protein that encompasses a large portion of the NAC region 
and a KTKEGV motif that would be present in alpha synuclein (Sung and Eliezer 2007; Ueda et al. 
1993). The free-state secondary structure of beta-synuclein is thus less organised than that of alpha- 
synuclein, being less helical and more random-coil like (Sung and Eliezer 2007). Due to the disruption 
of the negatively charged NAC region, interaction between the acidic C-terminus and N-terminus of 
beta-synuclein is negligible (Sung and Eliezer 2007).
1.4.1. Beta-synuclein aggregation
As a result of structural differences, beta-synuclein possesses a propensity to aggregate far limited 
compared to that of alpha-synuclein (Park and Lansbury 2003; Uversky et al. 2002). At a neutral, 
physiological pH, beta-synuclein was incapable of producing stable oligomers, even after several 
weeks of incubation, in contrast to alpha-synuclein that forms aggregate structures within a matter of 
hours (Uversky et al. 2002). Furthermore beta-synuclein was not found to produce the oligomeric 
pore-like structures formed by alpha-synuclein (Park and Lansbury 2003). The contrasting in vitro 
behaviour of alpha- and beta-synuclein was most notably demonstrated following investigation of their 
ability to interact with one another in solution. Beta-synuclein was found to inhibit the aggregation of 
alpha-synuclein in solution. A 1:1 ratio of alpha- to beta-synuclein led to significant retardation of 
alpha-synuclein fibrilisation, with fewer aggregates being produced though significantly slower 
aggregation kinetics. Increasing the proportion of beta-synuclein to 4:1 was found to almost entirely 
block alpha-synuclein fibrilisation (Uversky et al. 2002). Both the inability of beta-synuclein to 
aggregate and its ability to disrupt alpha-synuclein aggregation in vitro appear to be paralleled in vivo. 
Animal models of wild type beta-synuclein overexpression have failed to induce a phenotype 
comparable to that seen in alpha-synuclein overexpression models. Remarkably, modeling in rodents 
has also revealed that the disruption of alpha-synuclein aggregation by beta-synuclein occurs in vivo,
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and results in a significantly attenuated phenotype (Fan et al. 2006; Hashimoto et al. 2001). Findings 
from these models of beta-synuclein overexpression shall be discussed in further detail below.
1.4.2. Beta-synuclein and disease
Beta-synuclein is not considered a normal component of any common inclusion bodies such as Lewy 
bodies, and has only very rarely been detected in atypical structures. Rare examples of such 
structures have been identified in cases of PD, Lewy body dementia and Hallervorden-Spatz 
syndrome, where axonal spheroids containing beta synuclein were reported (Galvin et al. 2000; Galvin 
et al. 1999). Genetic analysis has determined that mutations in SNCB are unlikely to be a common 
contributing factor in human disease. No mutations in SNCB have been associated with PD (Lavedan 
et al. 1998a). Two rare mutations have however been associated with another synucleinopathy, 
dementia with Lewy bodies, though their role in the disease is highly unclear (Ohtake et al. 2004). The 
mutations, V70M and P123H, are both contained within a highly conserved region of beta-synuclein 
and were predicted to cause significant alteration of structure. Surprisingly however, though alpha- 
synuclein positive Lewy bodies were present in the brain of the SNCEf'23H patient, the mutation did 
not result in accumulation of beta-synuclein. It was thus predicted that these mutations represented an 
increased risk factor for dementia with Lewy bodies, most likely acting through loss of a protective 
mechanism mediated by beta-synuclein, for example the disruption of alpha-synuclein aggregation. 
Animal modeling of P123H mutant beta-synuclein overexpression have however suggested that this 
hypothesis may be untrue and shall be discussed below.
1.5. Gamma-synuclein
The last identified and least studied member of the synuclein family is gamma-synuclein (Buchman et 
al. 1998b; Ji et al. 1997; Lavedan et al. 1998b). The human gamma-synuclein gene SNCG consists of 
~5kbp, composing 5-coding exons (Lavedan et al. 1998b; Ninkina et al. 1998). In contrast to alpha- 
and beta-synucleins, the 10q23 gamma-synuclein locus does not contain non-coding exons, though 
regions of exon-intron junction remain homologous (Lavedan 1998). The expressed protein is highly 
conserved in vertebrate evolution, with the human protein sharing approximately 68% homology with 
that of the chordata lamprey (Petromyzon marinus). Comprising of 127 amino acids, gamma-synuclein 
shares 55.9% homology with alpha-synuclein and 54.3% with beta-synuclein (Lavedan et al. 1998b). 
The acidic C-terminus of gamma-synuclein is the most diverse region, the N-terminus carrying both 
the six copies of the KTKEGV repeat motif and full NAC region found in alpha-synuclein (Lavedan et 
al. 1998b). The free-state residual secondary structure of gamma-synuclein has a tendency to form 
helical structures and thus is more similar to alpha-synuclein than the more random-coil structure of 
beta-synuclein (Sung and Eliezer 2007). The transient lipid-bound structure however is more 
comparable to beta-synuclein (Sung and Eliezer 2007).
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1.5.1. Gamma-synuclein cellular distribution
As well as being structurally distinct from alpha- and beta-synuclein, both the anatomical expression 
profile and intracellular compartmentalisation of gamma-synuclein are also markedly different. The 
development and postnatal expression of both alpha and beta-synuclein is predominantly restricted to 
the brain, whereas gamma-synuclein is found in select populations of CNS neurons (Buchman et al. 
1998b). These include lower motor neurons in the spinal cord and brain, sensory neurons of the dorsal 
root and various cranial ganglia, upper motor neurons in the cerebral cortex and dopaminergic 
neurons of the SNpc (Buchman et al. 1998b; Ninkina et al. 2003). Moreover, the intracellular 
compartmentalisation of alpha- and beta-synuclein is restricted to the presynaptic terminals of 
neurons, where as gamma-synuclein is found diffusely throughout the cytoplasm of the synapses, 
neurites and cell bodies. During the development of mice (E13), gamma-synuclein protein initially 
localised to the perikaryal cytoplasm, however by E18 compartmentalisation shift to both the perikaryal 
and axonal cytoplasm of motor and sensory neurons (Ninkina et al. 2003). Post-natal localization 
remains consistent in sensory populations, however differs slightly in motor neuron populations, with 
little protein remaining in the perikaryal cytoplasm (Ninkina et al. 2003). Post-natal cortical expression 
of gamma-synuclein increases with age, in contrast to the decreasing expression of alpha-synuclein 
(Buchman et al. 1998b).
Gamma-synuclein has also been identified in non-neuronal cell populations, though its function within 
these cells is unclear. Both SNCG mRNA and gamma-synuclein protein have been identified within 
the stratum granulosum of the skin of embryonic and post-natal mice (Ninkina et al. 1999). Gamma- 
synuclein is present in the white adipose tissue of mammals and in humans its expression is 
increased in obese individuals (Oort et al. 2008). The relationship between gamma-synuclein and diet 
induced obesity is currently being investigated by our laboratory (manuscript in preparation). Much 
interest in gamma-synuclein has also come from the proteins identification as a marker of malignant 
breast carcinomas, leading to it initially being named breast cancer specific gene 1 (BCSG1) (Ji et al. 
1997). Though this nomenclature is no longer in use, gamma-synuclein up regulation has become 
associated with numerous further forms of cancer, including ovarian, cervical, colon, gastric, prostate 
and lung (Bruening et al. 2000; Ji et al. 1997; Liu et al. 2010; Liu et al. 2005). Unfortunately current 
opinion regarding the function of gamma-synuclein in oncological diseases is mostly conjecture. 
Discussion of these data is beyond the scope of this thesis, though interested readers may refer to a 
review published by Ahmad et al. 2007.
* ★ ★
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Gamma-synuclein expression in the developing mouse CNS. In situ hybridization with DiG labeled 
probes against SNCG mRNA show expression of gamma-synuclein in whole mounted E11 mouse 
embryos. DRG = dorsal root ganglion; GG = geniculate ganglion, JG = jugular ganglion, MN = spinal 
cord motor neurons, NG = nodose ganglion, TG = trigeminal ganglion, VG = vestibular ganglion 
(Image taken from Buchman et al. 1998b).
*  *  *
1.5.2. Gamma-synuclein function and aggregation
Though the anatomical and intracellular localization of gamma-synuclein is well defined in the CNS, 
very little is known with regard to the normal physiological function of the protein. Acute 
overexpression of SNCG was not found to induce death in cultured sensory neurons (Buchman et al. 
1998a). Interestingly however, overexpression was found to cause disruption to the cytoskeleton of 
approximately 80% of these neurons. Immunohistochemical staining of these cultured detected 
decreased staining of neurofilaments-H, -L and -M . Such changes were not detected in the levels of 
microtubules, actin or peripherin. Western blot analysis revealed a smear of small polypeptides of NF- 
H, though not -L  or -M . Addition of calpeptin, an inhibitor of the calcium-dependent calpain class of 
protease, blocked the degradation of the neuronal cytoskeleton. It was proposed that gamma- 
synuclein may play a currently unidentified role in human neurodegeneration, influencing the health of 
neurons by disrupting the stability of their neuronal cytoskeleton.
Cell-free investigation of the aggregation kinetics of gamma-synuclein also suggests the protein might 
have a role in human disease. Though less efficient than alpha-synuclein, gamma-synuclein is able to 
form stable oligomers and protofibrils in solution (Park and Lansbury 2003; Uversky et al. 2002). 
Analysis of the fibrils formed by gamma-synuclein by electron microscope found them to be identical in 
appearance to those formed by alpha-synuclein (Uversky et al. 2002). Surprisingly however gamma- 
synuclein appeared to also share a defining characteristic of beta-synuclein, being able to efficiently
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disrupt the fibrilisation of alpha-synuclein at a ratio of 1:1 (Uversky et al. 2002). Gamma-synuclein was 
not however able to disrupt the aggregation of A53T alpha-synuclein (Park and Lansbury 2003).
1.5.3. Gamma-synuclein in disease
Gamma-synuclein is not currently considered to be a common risk factor in human 
neurodegeneration. No PD and ALS associated polymorphisms have been detected within the SNCG 
locus (Flowers et al. 1999; Kruger et al. 2001; Lavedan et al. 1998a; Lincoln et al. 1999), though it 
should be noted that a significant non-coding polymorphism has recently been identified in a study of 
diffuse Lewy body disease (Nishioka et al. 2010). Most evidence of gamma-synuclein’s possible 
involvement in neurodegeneration has been taken from assessment of inclusion bodies in human 
disorders. Though it has not been detected in any common inclusion bodies such as Lewy bodies or 
amyloid plaques, axonal spheroids containing gamma-synuclein have been detected in the molecular 
layer of the hippocampal dentate gyrus of patients suffering from PD and Lewy body dementia (Galvin 
et al. 1999), and also in the mid-frontal and cingulated gyrus of Hallervorden-Spatz syndrome patients 
(Galvin et al. 2000). Axonal spheroids positive for gamma-synuclein have also been detected in the 
mouse models of neurodegeneration, in particular GAD mice (see above), where eosinophilic 
spheroids positive for gamma-synuclein were detected in the degenerating spinal gracile tract and 
nucleus (Wang et al. 2004).
The most robust evidence of the involvement of gamma-synuclein in human neurodegeneration has 
come from studies of glaucoma, the second most frequent cause of permanent blindness, 
characterised by an increased intraocular pressure and the substantial loss of retinal ganglion cells 
(RGCs) and the portion of their axon within the optic nerve (Quigley and Broman 2006). Gamma- 
synuclein is specifically expressed in both adult and developing RGCs, compartmentalising in the 
perikaryal and axonal cytoplasm (Farkas et al. 2004; Mu et al. 2004; Surgucheva et al. 2002; 
Trimarchi et al. 2007). SNCG expression in RGCs is promoted by Brn3B, a transcription factor 
essential for their normal differentiation and development (Mu et al. 2004). A distinct change has been 
reported in gamma-synuclein expression in patients with glaucoma, the normal localisation seen in 
RGC axons becoming diminished (Surgucheva et al. 2002). More so, a subset of astroglia within the 
lamina cribrosa portion of the optic nerve were found to be aberrantly expressing gamma-synuclein 
and contained atypical inclusion bodies positive for the protein (Surgucheva et al. 2002). Similar 
changes have been reported in animal models of glaucoma. Astrocytes containing atypical 
cytoplasmic inclusion bodies positive for gamma-synuclein were reported in rats with mechanically 
increased IOP (Surgucheva et al. 2002). In DBA/2J mice, a strain that spontaneously develop 
glaucoma, a progressive down regulation of SNCG expression has been reported, correlating with the 
progressive loss of RGCs (Buckingham et al. 2008). Spheroid inclusion bodies containing gamma- 
synuclein have however been identified in these animals (Nguyen et al. 2011), suggesting the down 
regulation might occur in response to the proteins accumulation. Decreased expression correlated with 
the loss of retrograde labelling in individual cells, suggesting the disconnection of the RGCs with their
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targets within the cortex (Soto et al. 2008). Decreased mRNA expression in the RGCs of DBA/2J mice 
was not however restricted to SNCG, appearing to be a general early process of pathology. 
Furthermore many RGCs were found to continue expressing gamma-synuclein after becoming 
disconnected from their neurites, suggesting its loss was not an essential event in degeneration.
1.6. Synuclein knock out mouse models
Attempts to characterise the function of the synuclein proteins in both normal physiology and 
pathophysiology have led to the generation of several lines of knock out and transgenic mice.
1.6.1. Alpha-synuclein null mice
Knock out mouse models of all three synuclein proteins individually and in all possible combination 
have been developed by various laboratories. Due to its identification in PD pathogenesis, alpha- 
synuclein knock out models were the first to be generated, the earliest described by Abeliovich et al 
2000. The mice showed an 18% reduced in striatal dopamine concentration and a reduced locomotion 
response to amphetamine treatment, suggesting impaired dopamine production and release 
(Abeliovich et al. 2000). Other groups however have not detected decreased dopamine concentration 
in the striatum of mice of this line on a pure C57BI6J genetic background, however modest reduction 
of SNpc dopaminergic cells has been reported (Robertson et al. 2004). Changes in striatal dopamine 
concentration were also not detected in other lines of alpha-synuclein null mice (Chandra et al. 2004; 
Schluter et al. 2003). Further discrepancy to the data reported by Abeliovich et al was detected in 
alpha-synuclein null mice produced by Cabin et al (2002), which had a normal response to 
amphetamine treatment. Synaptic function deficits were detected in primary cultured hippocampal 
neurons derived from alpha-synuclein null animals. These neurons had a reduced reserve pool of 
synaptic vesicles and showed deficits in synaptic response following repetitive electrical stimulation 
(Cabin et al. 2002). No changes in the normal behaviour of alpha-synuclein null mice have been 
reported by any of the above research groups. In summary ablation of alpha-synuclein appears to 
have only limited to negligible effects on the murine CNS, a point supported by the identification of a 
commercial line of “wild type” C57BI6J mice with no behavioural or physiological abnormalities 
supplied by Harlan UK that we found to carry a spontaneous deletion encompassing the entire SNCA 
locus (Specht and Schoepfer 2001).
An unexpected characteristic of alpha-synuclein null mice is their reduced sensitivity to the 
mitochondria inhibitor MPTP (see above). Dauer et al. 2002 showed that alpha-synuclein null mice 
were almost entirely resistant to both acute and chronic exposure to MPTP. The SNpc population was 
insignificantly affected in knock out mice, as were striatal dopamine concentrations (Dauer et al. 2002; 
Robertson et al. 2004). The finding should be treated with some caution, as tolerance to MPTP 
appears to be dependent on strain differences. Mice carrying a spontaneous deletion of alpha- 
synuclein were found to be equally vulnerable to MPTP toxicity as wild type control mice (Schluter et
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al. 2003). If correct however the above data indicates that the normal physiological function of nigra- 
striatal alpha-synuclein might lie within the dopamine handling system.
1.6.2. Beta-synuclein null mice
Due to evidence suggesting a possible neuroprotective function possessed by beta-synuclein, SNCB 
null mice were generated (Chandra et al. 2004). Similar to alpha-synuclein null mice however the beta- 
synuclein null mice developed no discernable phenotype. The lack of overt phenotype in both alpha- 
and beta-synuclein null mice was suggested to be due in part to their close structural homology and 
matching pattern of localization leading to functional redundancy. Chandra et al thus produced mice 
doubly null for alpha- and beta-synuclein by breeding the individual knock out lines. Though no 
changes were observed in synaptic morphology, synaptic plasticity, vesicle handling or release in 
alpha-/beta-synuclein null mice, a modest reduction in striatal dopamine concentration was detected. It 
was concluded that there might be some degree of functional redundancy between alpha- and beta- 
synuclein, though the possibility of subtle deficits might occur (Chandra et al. 2004).
1.6.3. Gamma-synuclein null mice
Similar to alpha- and beta-synuclein null mouse lines, endogenous gamma-synuclein null mice 
develop no overt phenotype (Ninkina et al. 2003). Ablation of gamma-synuclein had no impact upon 
the size of the neuron populations in which it is normally expressed (Ninkina et al. 2003; Papachroni et 
al. 2005; Robertson et al. 2004). Behavioural analysis detected neither motor nor sensory deficits. The 
SNpc dopaminergic neuron population was slightly depleted, though striatal dopamine concentration 
was found to be normal (Robertson et al. 2004). Similar to alpha-synuclein ablation, gamma-synuclein 
knock out mice were found to be resistant to MPTP, suggesting some functional homology between 
the proteins (Robertson et al. 2004). This latter point is supported by the identification of altered 
expression of a number of overlapping genes in both alpha- and gamma-synuclein knock out mice 
(Kuhn et al. 2007). The products of several of these genes have been implicated in the modulation of 
tyrosine hydroxylase activity, including 14-3-3 and MAPK1, and thus changes in alpha- and gamma- 
synuclein function might have a direct impact upon dopamine production.
1.6.4.Triple-synuclein null mice
Evidence of synuclein family functional redundancy has necessitated the development of mice triply 
null for all three family members (TKO). Recent collaborative efforts by several groups have led to the 
generation and study of these animals (Burre et al. 2010; Greten-Harrison et al. 2010, our unpublished 
findings -  in press). During the first year of life TKO appeared indistinguishable from control animals. 
At the age of ten months however significant deficits in balance, coordination and strength were 
detected by behavioural analysis (Burre et al. 2010, our unpublished findings -  in press). A significant 
number of mice went on to develop a clasping reflex during the second year (Burre et al. 2010). 
Subsequently a significant number of TKO mice died a premature death. Significant
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neurodegeneration was not reported (Burre et al. 2010; Greten-Harrison et al. 2010; our unpublished 
findings -  in press).
In spite of apparently normal morphology several lines of evidence suggested that subtle changes did 
occur within the CNS of TKO mice, particularly affecting the function of various synapses. TKO mice 
carried a full complement of SNpc dopaminergic neurons, however striatal dopamine concentrations 
were depleted by approximately 40% (our unpublished findings -  in press). In contrast to mice 
individually null for alpha- or gamma-synuclein, TKO mice were found to be as sensitive to exposure to 
MPTP as control animals (our unpublished finding -  in press). Synaptic density, neuronal density and 
inducible synaptic function in the hippocampus were found to be unchanged in ten-month old TKO 
mice (Burre et al. 2010). Subtle changes were however detected in the size of the presynaptic terminal 
in both the CA1 and CA3 regions of three-month old TKO hippocampus, both presenting a significant 
decrease in area (Greten-Harrison et al. 2010). Deficits in retina function and vision were also noted in 
aged TKO mice (Greten-Harrison et al. 2010).
The most striking changes in TKO synaptic function were detected in the assembly of the SNARE 
complexes essential for facilitating vesicle fusion at the presynaptic terminal. From whole brain 
homogenate of one-month old TKO mice, Burre et al detected a significant 25% reduction in the co- 
immunoprecipitated levels of the three core SNARE complex components; SNAP25, syntaxinl and 
synaptobrevin 2A/AMP. This reduction increased to over 50% in ten-month old mice. The level of 
synaptobrevin 2A/AMP was significantly reduced in the both age groups of TKO mice (Burre et al. 
2010). Contrasting changes in SNARE complex component levels were reported by Greten-Harris et 
al, who detected a significant 20% increase in levels of synaptobrevin 2A/AMP, but additionally 
detected a 20% decrease in levels of SNAP25 (Greten-Harrison et al. 2010). Assessment of SNARE 
complex components in the striatum of four-month old TKO mice however failed to detect any changes 
in their levels (our unpublished findings -  in press). In summary, data from TKO mice suggests the 
synuclein proteins might play a role in normal presynaptic function in a subset of CNS neurons.
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1.7. Synuclein transgenic mice
Several factors have linked aberrant forms of alpha-synuclein with PD; autosomal dominant mutations 
in SNCA, the increased propensity of mutant protein forms to aggregate and the presence of alpha- 
synuclein protein in inclusion bodies found in both idiopathic and familial forms of PD. These findings 
have led to the generation of numerous lines of mice that express high levels of human wild type or 
mutant forms of SNCA in an effort to unravel the pathophysiology of alpha-synuclein. Several lines of 
mice were generated expressing varying increased levels of human wild type SNCA (hSNCAWT) under 
the transcriptional regulation of the non-specific platelet derived growth factor promoter PDGFp 
(Masliah et al. 2000). Alpha-synuclein positive inclusion bodies were detected in all lines produced, 
most frequently within the cortex, but also observed in the CA3 region of the hippocampus, olfactory 
bulb and SNpc. Overexpression of PDGFp-hS/VCA^ induced a dose-dependent neurodegeneration. 
Alpha-synuclein positive inclusion bodies were most abundant in the highest expressing line “D”. 
Striatal TH levels, TH activity and striatal dopaminergic terminals were all significantly diminished in 
the most affected animals, though it should be noted SNpc population size was not investigated. 
Furthermore behavioural deficits, assessed by rotarod, were only detected in line D.
1.7.1. Alpha-synuclein overexpression: PrP-promoter
Utilising the mouse/hamster prion promoter (PrP), several lines of mice have been generated 
overexpressing hSNCAVJJ (Giasson et al. 2002; Gispert et al. 2003; Gomez-lsla et al. 2003; Lee et al. 
2002) and the human mutants A53T (hSA/CAA53T) (Giasson et al. 2002; Gispert et al. 2003; Gomez- 
lsla et al. 2003; Lee et al. 2002) or A30P (hSNCAM0P) (Gomez-lsla et al. 2003; Lee et al. 2002) 
specifically in neurons. In spite of high-level expression, PrP-hSA/CAm  transgenic mice were 
consistently found not to develop any perceptible neurodegenerative phenotype (Giasson et al. 2002; 
Gispert et al. 2003; Gomez-lsla et al. 2003; Lee et al. 2002). PrP-hSA/CAA53T overexpression induced 
dose dependent neurodegeneration with signs of defective motor function (Gispert et al. 2003). 
Accumulation and ionic-detergent insoluble aggregation of mutant alpha-synuclein was detected in the 
various regions including cerebellum, cortex, pons and spinal cord (Giasson et al. 2002; Lee et al. 
2002), though it should be noted one line expressing high levels of PrP-hS/VCAA53T developed no 
inclusion bodies (Gispert et al. 2003). Dystrophic axons were detected in the spinal cord and ventral 
nerve roots of one line of mice (Giasson et al. 2002). High-level expression of hSNCAM0P also induced 
motor dysfunction accompanied with increased CNS astrogliosis, though mutant alpha-synuclein 
aggregation was not reported (Gomez-lsla et al. 2003).
1.7.2. Alpha-synuclein overexpression: Thy1-promoter
Neuron specific alpha-synuclein overexpression mouse models have also been generated using the 
Thy1 promoter, a useful promoter since it is activated from P4-10 (Aigner et al. 1995), allowing any 
changes observed to be attributed to the transgene product. Overexpression of Thy1-hSA/CAm , Thy1- 
hSNCAA53T and Thy1-hSNCA*30* has been shown to induce neurodegeneration (Chandra et al. 2005; 
Rockenstein et al. 2002; van der Putten et al. 2000). Thy1 expression was found to produce more
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widespread neuronal expression of higher levels of alpha-synuclein than previously seen in the 
PDGFp-h S/VCAWT overexpression model, though it was conceded that the latter model produced a 
more physiologically relevant pattern of expression (Rockenstein et al. 2002). Overexpression of 
Thyl-mSA/CA^was not found to induce any signs of pathology (Chandra et al. 2005). Thy1-hSA/CAWT 
mice however were found to develop somatomotor abnormalities, including deficits in footplacing, co­
ordination and strength (Fleming et al. 2004). Inclusion bodies containing alpha-synuclein were 
widespread in the cortex and striatum (Rockenstein et al. 2002; van der Putten et al. 2000). 
Investigation of Thy1-hSA/C>4WT transgenic mice did reveal some contrasting data. High levels of wild 
type alpha-synuclein accumulation have been reported in spinal motor neurons (van der Putten et al. 
2000), as has the depletion of spinal motor neuron cell bodies and their neurites (Chandra et al. 2005). 
No accumulation of alpha-synuclein was detected in neurons of the SNpc (van der Putten et al. 2000). 
In contrast Rockenstein et al detected substantial accumulation of wild type alpha-synuclein in the 
SNpc, but found no evidence of protein accumulation in spinal cord motor neurons (Rockenstein et al. 
2002). Similar results were detected in the pathology presented in mice overexpressing Thy1- 
hSNCAA53T (Chandra et al. 2005; van der Putten et al. 2000) and Thy1-hS/S/CAA30P (Chandra et al. 
2005; Rockenstein et al. 2002). The reason for the discrepancy was unclear, though strain differences 
were proposed as a potential cause.
1.7.3. Alpha-synuclein overexpression: TH-promoter
Though many of the above alpha-synucleinopathy mouse models result in a movement disorder 
associated with the accumulation of alpha-synuclein, their use as clinically relevant model of human 
PD is debatable. The motor deficits developed by these animals were often attributed to spinal cord 
dystrophy, not considered a normal feature of PD pathology. Clinically relevant levels of nigra-striatal 
dysfunction or SNpc dopaminergic neuron loss were not reported. Furthermore, though alpha- 
synuclein inclusion bodies were detected, none of these were reported to possess the hallmark Lewy 
body structures. Attempts were made to produce more accurate recapitulation of the dopaminergic 
system dysfunction typical of PD through the generation of mice expressing alpha-synuclein under the 
control of the dopaminergic neuron specific tyrosine hydroxylase (TH) promoter. The results of these 
studies have unfortunately been underwhelming. Mice expressing high levels of the wild type, A30P or 
A53T forms of human alpha-synuclein were not found to develop any signs of overt 
neurodegeneration or deficits in motor function (Matsuoka et al. 2001). Quantification of SNpc 
dopaminergic neuron population and striatal dopamine concentration also failed to detect any changes 
(Matsuoka et al. 2001; Rathke-Hartlieb et al. 2001). An independently produced line of mice 
expressing wild type human alpha-synuclein under TH-promoter control also failed to develop any 
detectable phenotype (Richfield et al. 2002). Though specific to dopaminergic neurons, the TH 
promoter results in relatively weak transgene expression. It appears that such selective and low levels 
of transgene are insufficient to induce the damage seen in other alpha-synuclein transgenic lines. The 
most severe synucleinopathy phenotype produced by utilising the TH promoter was observed in a line 
of mice expressing a doubly mutant form of alpha-synuclein carrying both the A30P and A53T
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mutations. In contrast to the wild type and single mutant mice, the TH-hS/VCAA30P/A53T line developed 
an age-related decrease in locomotor activity, associated with a reduced concentration of striatal 
dopamine and loss of SNpc dopaminergic neurons (Richfield et al. 2002; Thiruchelvam et al. 2004). 
Though a neurodegenerative phenotype was observed, the models can be criticized due to the non- 
physiologically relevant nature of the mutations. Furthermore these findings were not however seen in 
a second independently produced line of TH-hSA/CAA30P/A53T mice, though mitochondria dysfunction 
was reported (Maskri et al. 2004; Stichel et al. 2007).
In summary, though numerous lines of mice overexpressing alpha-synuclein have been generated, 
these models all have various faults. To date none of these models result in a phenotype that fully 
recapitulates all the typical clinical features of PD. The non-specific expression of many of the 
promoters used often leads to the strongest transgene expression being localised to populations not 
normally associated with the disease, for example spinal motor neurons. When more selective 
promoters such as TH are used, alpha-synuclein expression induces little discernable phenotype, 
suggesting that alpha-synuclein overexpression alone is unlikely to be the sole underlying pathology of 
PD.
1.7.4. Alpha-synuclein overexpression on an endogenous SNCA null background
The endogenous SNCA alleles have been suggested to confer a degree of protection in transgenic 
mice expressing high levels of human alpha-synuclein (Cabin et al. 2005). Cabin et al. demonstrated 
that in comparison to transgenic mice carrying the wild type SNCA allele, those null for endogenous 
SNCA developed a more pronounced pathology when overexpressing PrP-hSA/CAA53T. Though 
histopathological signs were similar in both groups of animals, the exacerbated pathology was 
characterised by an earlier death and accelerated progression of disease. Cabin et al. suggested that 
the protective effect might be due to disruption of transgenic human alpha-synuclein aggregate 
seeding by the less aggregate prone endogenous murine protein. The possibility of strain differences 
was also raised, due to the endogenous alpha-synuclein null animals being derived from a mixed 
129/FVB background, where as the SA/CAA53T transgenic mice were on a more pure FVB/N 
background.
1.7.5. Alpha-synuclein overexpression on a CSPa null background
SNCA overexpression has been used to elucidate the normal function of alpha-synuclein and have 
yielded remarkable data. Mice null for CSPa, a presynaptic terminal, vesicle-associated protein with 
chaperone-like activity (Tobaben et al. 2001), developed an aggressive form of neurodegeneration, 
associated with stunted development and death by p80 (Fernandez-Chacon et al. 2004). Substantial 
motor deficits were observed, caused by the progressive degeneration of synapses including 
neuromuscular junctions (Fernandez-Chacon et al. 2004), associtated with reduced levels of the 
SNARE complex component SNAP25 (Chandra et al. 2005). In 2005, Chandra et al demonstrated the
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surprising finding that both human and mouse SNCAm  overexpression were able to rescue CSPa-null 
mice from neurodegeneration (Chandra et al. 2005). Conversely ablation of alpha- and beta-synuclein 
exacerbated the CSPa-null phenotype. Interestingly bSNCAA53J was also able to ameliorate 
symptoms, however hSNCAM0P was not. Spinal gliosis and neuromuscular junction degeneration were 
reduced in hSNCA™7 but not by hSNCAM0P groups. Thyl-hS/N/CA^7 overexpression partially rescued 
the defective SNARE complex assembly seen in CSPa-null mice, however this was not achieved 
through rescue of SNAP25 levels. Complementary to its inability to ameliorate the CSP null 
phenotype, hSNCAA30P was also ineffective in rescuing SNARE complex assembly. The authors 
speculated that though alpha-synuclein possesses no chaperone activity and is neither structurally nor 
functionally homologous to CSPa, the two proteins may act within a similar protective pathway in the 
presynaptic terminal (Chandra et al. 2005). Recent investigation has fuelled this speculation, following 
the identification of a highly significant doubling of CSPa protein levels in whole brain homogenate of 
triply synuclein null mice (Burre et al. 2010). This change is not however universal across the brain, as 
CSPa levels were unchanged in the striatum of TKO mice (our unpublished findings -  in press).
1.7.6. Beta-synuclein transgenic mice
Though it has been identified in rare inclusion bodies (see above), there is scant data implementing 
the direct involvement of beta-synuclein in the pathogenesis of the synucleinopathies (Ohtake et al. 
2004). Accordingly overexpression of SNCBm  was found to induce neither a behavioural phenotype 
nor changes in neuronal function, and that the proteins limited capacity to aggregate in vitro is 
mirrored in vivo. (Hashimoto 2001; Fan 2006). Hashimoto et al developed a line of beta-synuclein 
transgenic mice expressing high levels of bSNCBm  under the transcriptional control of a Thy1 
promoter (Thy1-hSNCB™7) (Hashimoto et al. 2001). Despite producing near double the level of protein 
to a comparable Thy1-hSA/CAm  line, no signs of behavioural or histological pathology were detected. 
In an independently produced line of Thyl-hSNCB™1 mice that again developed no pathology, Fan et 
al detected a modest decrease in endogenous alpha-synuclein protein level, suggesting functional 
redundancy between the two synucleins, though it should be noted beta-synuclein levels are 
unchanged in alpha-synuclein transgenic mice (Fan et al. 2006). These findings raise the possibility 
that beta-synuclein might be able to actively reduce alpha-synuclein levels as part of a protective 
mechanism.
Remarkably, the co-overexpression of Thy1-hS/VCB^ drastically ameliorated the neurodegeneration 
seen in PDGFp-hS/VCAWT mice (Hashimoto et al. 2001). The loss of striatal dopaminergic synapses 
normally seen in PDGFp-hSNCA™7 mice was significantly reduced in the bigenic mice. The apparent 
neuroprotection provided by beta-synuclein overexpression was also observed in a line of mice co­
overexpressing PrP-hSNCAA53T and PrP-hSNCB'"1, where motor performance and lifespan were 
improved significantly in comparison to control alpha-synuclein overexpression mice (Fan et al. 2006). 
Interestingly in all lines of bigenic mice developed, alpha-synuclein positive inclusion bodies were
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significantly less abundant than in control alpha-synuclein transgenic mice. Both groups suggested 
differing explanations for this reduction. Fan et al proposed that beta-synuclein overexpression 
resulted in a down-regulation of alpha-synuclein expression, limiting the amount of protein available to 
produce inclusion bodies. Hashimoto et al proposed an alternative hypothesis, suggesting that beta- 
synuclein inhibited the aggregation of alpha-synuclein through direct interaction with the protein. This 
hypothesis was supported by co-immunoprecipitation experiments in transfected cell lines, where 
beta-synuclein was found to directly interact with soluble alpha-synuclein. These in vivo findings 
appear to parallel in vitro data demonstrating alpha-synuclein fibrillation and pore formation being 
disrupted by co-incubation with beta-synuclein (Park and Lansbury 2003; Tsigelny et al. 2007; 
Uversky et al. 2002). Furthermore the findings raise the question of whether beta-synuclein may 
function as an endogenous regulator of alpha-synuclein aggregation, a scenario that has been 
proposed as having potential therapeutic use (Hashimoto et al. 2004; Masliah and Hashimoto 2002).
Recently however the widely accepted view that beta-synuclein was limited to a benign or protective 
role in human disease has been called into question, following the identification of mutant forms of 
SNCB in familial cases of dementia with Lewy bodies (Ohtake et al. 2004). Though the role of these 
mutant forms of beta-synuclein in the disease were suggested to be a possible loss of normal 
neuroprotective studies, the recent development of a line of transgenic mice expressing the human 
form of SNCEf'23H under Thy1 transcriptional control (Thy1-hSCA/Bp123H) have suggested an 
alternative hypothesis (Fujita et al. 2010). The Thy1-hSCA/Sp123H mice were found to develop mild 
abnormalities in cognitive and motor function. In contrast to the absence of beta-synuclein positive 
inclusion bodies found in the brains of dementia with Lewy body patients carrying SNCBP123H (Ohtake 
et al. 2004), such structures were widespread in the brains of Thy1-hSCNBp123H mice. Accumulated 
mutant beta-synuclein was detected in dendrites within the hippocampus and cortex, with dense 
“globules” of the mutant protein identified in the striatum. These data are further supported by an 
earlier finding that both P123H and V70M have a slight propensity to aggregate, substantially greater 
than the negligible kinetics of the wild type protein (Park and Lansbury 2003; Uversky et al. 2002; Wei 
et al. 2007). To further investigate the role of mutant beta-synuclein in disease, a line of bigenic mice 
co-overexpressing Thyl-hS/VCfl*3123” and Thy1-hS/N/CAWT were generated (Fujita et al. 2010). The 
resulting mice were found to develop an augmented neurodegenerative phenotype compared to that 
seen in the control singly transgenic mice. Significantly higher levels of neuropathology were detected, 
most prominently in the hippocampus where high levels of apoptosis and neuron loss were described. 
This latter finding suggested that the association of SNCEP'23H with dementia with Lewy bodies might 
not be through loss-of-function in the transcribed protein, but that mutated beta-synuclein may be 
actively promoting alpha-synuclein pathology.
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1.7.7. Gamma-synuclein transgenic mice
Though gamma-synuclein null mice have been produced, prior to this thesis no model of gamma- 
synuclein overexpression has been reported. Such a model merits research for several reasons. 
Gamma-synuclein shares several structural and functional characteristics with alpha- and beta- 
synuclein. Of these the most fascinating is the propensity of the gamma-synuclein to aggregate. 
Though not as efficient as alpha-synuclein, it is able to form stable oligomers in vitro (Park and 
Lansbury 2003; Uversky et al. 2002). However similar to beta-synuclein it is also able to disrupt alpha- 
synuclein fibrillation (Uversky et al. 2002). It is thus unclear whether gamma-synuclein is likely to 
follow the trend of wild type and mutant forms of alpha-synuclein to induce neurodegeneration of the 
mouse CNS, or whether the protein is more benign, as in the case of beta-synuclein. Secondly both 
the anatomical distribution and cellular compartmentalisation of gamma-synuclein differ from the other 
synuclein proteins. Where alpha- and beta-synuclein predominantly localised to presynaptic terminals 
in the brain, gamma-synuclein is found diffusely throughout perikaryal, axonal and synaptic cytoplasm 
of select groups of CNS and PNS neurons, in particular those of the SNpc, motor nuclei and sensory 
ganglia (Buchman et al. 1998b). A flaw of the above alpha- and beta-synuclein overexpression models 
is the non-physiological cellular and anatomical distribution of their overexpressed protein. The 
consequence of this is most manifest in the loss of spinal motor neurons in alpha-synuclein transgenic 
mice, as the population does not express the protein in normal physiological conditions. Use of the 
same pan-neuron promoters would however give a more physiologically relevant pattern of expression 
if gamma-synuclein were expressed in the place of the other synucleins. Finally gamma-synuclein 
have emerged as a possible contributing factor in several neurodegenerative conditions. Several 
studies have reported the accumulation of gamma-synuclein in atypical inclusion bodies (Galvin et al. 
2000; Galvin et al. 1999; Wang et al. 2004). Changes in the expression of SNCG have recently been 
identified as a risk factor in diffuse Lewy body disease (Nishioka et al. 2010). Furthermore inclusion 
bodies containing gamma-synuclein and changes in the expression of SNCG have been detected in 
both human and animal models of glaucoma (Mu et al. 2004; Nguyen et al. 2011; Soto et al. 2008; 
Surgucheva et al. 2002).
A Thy1 promoter was chosen to drive gamma-synuclein overexpression for several reasons. Firstly, 
the promoter has been used by several other groups to generate alpha- (Chandra et al. 2005; 
Rockenstein et al. 2002; van der Putten et al. 2000) and beta-synuclein (Hashimoto et al. 2001) 
transgenic mouse lines on C57BI/6J backgrounds. This allows any phenotype we see in the gamma- 
synuclein transgenic mice to be comparable with these models. Due to the promoter having been used 
in these animals, and also in several other murine models of protein overexpression (for example 
Aigner et al. 1995, Caroni et al. 1997, Belle et al . 2007, Allen et al. 2002), we also have a relatively 
clear idea of the spatial and temporal expression profile of the promoter. In most neurons the Thy1 
promoter is not active until post-natal days 4-10 (Aigner et al. 1995, Caroni et al. 1997), though a 
subset of neurons in the cerebellum have been shown to express the promoter slightly earleir, though 
still postnatally (Carnoni et al. 1997). Such late expression of the promoter in development will allow
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us to attribute any pathological changes that may occur in the gamma-synuclein transgenic mice to 
post-natal transgene overexpression, and not to a disruptive influence by the transgene product during 
embryonic development. With regard to the spartial profile of Thy1 expression, in situ hybridisation 
experiments carried out by Carnoi et al. 1997 in several lines of mice with Thy1-driven overexpression 
of neuron growth-assocaited proteins demonstrated high levels expression in the cerebral cortex, 
thalamus, amygdala, brain stem motor nuclei, all regions of the hippocampus and cerebellum (Caroni 
et al. 1997). The expression of Thy1 in the CNS is not however universal, with the nigrastriatal system, 
hypothalamus and globus pallidum expressing only limited levels of Thy1 in comparison to other 
regions of the CNS (Caroni et al. 1997, Van der Putten et al. 2000). The highest levels of expression 
were consistently found to be within spinal cord motor neurons (Caroni et al. 1997, Allen et al. 2002, 
van der Putten et al. 2007). Thy1-driven overexpression of green fluorescent protein (GFP) has also 
demonstrated the intense activation in sensory neurons of the dorsal root and trigeminal ganglia (Belle 
et al. 2007). The strong expression of Thy1 in the sensory, cortical and motor neuron populations 
makes the promoter a particularly valid choice for gamma-synuclein overexpression, as the protein is 
most strongly expressed in these populations under normal physiological conditions.
It is important to note however that although Thy1 is able to drive the expression of a transgene, all 
mRNA produced is not necessarily translated into the final protein, and furthermore this protein may 
be rapidly degraded. Thus the expression pattern described above might not precisely match that 
seen in the gamma-synuclein transgenic mice generated, and thus the anatomical distribution of the 
protein shall be assessed as part of this project.
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1.8. Generation and early characterisation of gamma-synuclein transgenic mice
1.8.1. Generation of gamma-synuclein transgenic mice
Work detailing the generation of the gamma-synuclein transgenic mice used in this project has been 
published in Ninkina 2009, in which the author of this thesis is a co-author. A line of gamma-synuclein 
overexpressing mice was generated by our laboratory in collaboration with Dr Herman van der Putten 
of the Novartis Institute for Biomedical Research. The ThylmySN line was produced by a standard 
protocol for generating transgenic overexpression models. Expression was driven by a neuron specific 
Thy1 cassette, which has previously been used to generate various transgenic mouse lines, including 
alpha-synuclein (Chandra et al. 2005; Rockenstein et al. 2002; van der Putten et al. 2000) and beta- 
synuclein (Hashimoto et al. 2001) overexpressing mice. A gamma-synuclein clone was previously 
isolated from cDNA library, derived by a subtractive cloning protocol designed to isolate mRNA highly 
expressed in E13 mouse trigeminal ganglion but not in E13 forebrain (Buchman et al. 1998b). This 
clone, termed “pD53”, contains the 5’ untranslated region (UTR), full gamma-synuclein cDNA and 3’ 
UTR with its polyadenylation signal. Primers were designed to target the 5’ and 3’ UTRs of the pD53 
gamma-synuclein fragment. These primers additionally contained Xhol linkers to facilitate cloning into 
an Xhol site contained the Thy1 promoter plasmid (see below). Using pD53 as a PCR template, the 
primers amplified murine gamma-synuclein cDNA along with 34bp and 64bp of the 5’ and 3’ 
untranslated regions, flanked by Xhol linkers.
Primers:
mgSN Xhol-F: 5’-CTACTGTCCGCTCGAGCTTGCAGCAGCCAGGTTC-3’
mgSN Xhol-R: 5’-CTACTGTCCGCTCGAGGCCTTCTAGTCTTCTCCAC-3’
The amplified fragments were ligated into the Thy-1 promoter plasmid 323-pTSC21k (Luthi et al 1997), 
facilitated by an Xhol restriction site between exons II and IV of the Thy1 gene (Fig. 1). Not1 restriction 
enzymes were used to cut the final eukaryotic insert from the plasmid. The resulting fragment was 
then purified using a commercial kit (QIAgen) and injected into the pronucleus of mouse oocytes 
derived from a pure C57BI6 line, where the linear construct randomly integrated into the genome. 
Transformed oocytes were then transferred to foster mothers. Founder animals were selected for 
presence in the genome of the transgene cassette using PCR analysis of genomic DNA extracted 
from ear biopsies. Detection of 1kb product in a PCR reaction with the primers below indicated 
transgene presence.
Primers:
Gamma-synuclein: Forward 5’-ACACCCCTAAAGCATACAGTCAGACC-3’
Gamma-synuclein: Reverse 5’-GGCCTTCTAGTCTTCTCCACTCTTG-3’
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Fig. 1. The ThylmySN plasmid. Map showing the final ThylmySN expression plasmid and restriction 
sites. The insert fragment was cut from the construct by digestion with Notl, purified and injected in 
C57BI6 oocytes.
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1.8.2. Initial observations of phenotype
Two lines of hemizygous gamma-synuclein overexpressing mice were produced. Mice of an initial line 
in which transgene expression was low were viable and developed normally and showed no overt 
phenotype. Mice of the second line (herein termed ‘ThyfmySN”), in which gamma-synuclein 
expression was at a substantially higher level, were viable and for approximately nine months looked 
indistinguishable from wild type mice. After this point however the hemizygous animals began to 
develop initial signs of motor dysfunction. In an attempt to augment the neurodegenerative phenotype, 
homozygous mice were produced by intercrossing. These showed similar signs of degeneration as 
seen in the hemizygous animals but more prominent, with a significantly earlier age of onset. 
Therefore, gamma-synuclein-induced neurodegeneration in this line of transgenic mice is both age 
and dose-dependent.
1.8.3. Development of experimental cohorts
The observed phenotype of the Thy1 mySN line appeared to warrant study, thus the line was selected 
for further investigation and experiment cohorts were bred. Hemizygous Thy1 mySN mice were 
backcrossed with wild type C57BI6 mice for a minimum of six generations to ensure the genetic 
stability of the genotype prior to generation of experimental cohorts. Final cohorts of wild type control, 
and experimental hemizygous and homozygous mice were produced by intercrossing of hemizygous 
Thy1 mySN mice. Normal Mendelian distribution of genotypes was observed in resulting litters at the 
time of weaning. Quantitative real-time PCR was used to discriminate between hemi- and 
homozygous transgenic animals.
1.8.4. Confirmation of Thy 1 mySN transgene expression
Expression of gamma-synuclein was assessed in various regions of the nervous system of Thy1 mySN 
mice. As the trigeminal ganglion of newborn mice consists of a relatively homologous population of 
sensory neurons expressing high endogenous levels of gamma-synuclein, it was used as a reference 
tissue to compare levels of gamma-synuclein expression from endogenous promoter in the wild type 
mice and Thy1 promoter in ThylmySN mice. Transgene expression within the spinal cord of eight 
week hemizygous Thy1 mySN mice was found to be 10-fold that of the baseline trigeminal ganglion 
level (Fig. 2b.). The level of expression in the spinal cord of eight-week old homozygous mice was 
found to be approximately double the level in matching hemizygous animals (17 times higher than the 
baseline trigeminal ganglion level Fig. 2b.). The level of expression in dorsal root ganglia of twelve­
month old Thylm  ySN mice was found to be approximately 7 times higher than the level in the same 
tissue of wild type animals, with spinal cord expression level approximately 11 times above this 
baseline (Fig. 2c.). It should be noted that endogenous spinal cord gamma-synuclein mRNA 
expression is normally difficult to detect, being restricted to motor neurons that account for only a 
fraction of cells within this portion of the CNS. Accurate quantification of spinal cord transgene 
expression (as folds of the endogenous expression) is therefore complicated by the nature of Thy1 
cassette, which drives transgene expression in the majority of neurons of the nervous system,
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including all neuronal populations of the spinal cord. Thus all measurements of spinal cord expression 
need to be interpreted with a degree of caution.
Western blot analysis confirmed that high levels of gamma-synuclein transgene expression resulting in 
significantly increased levels of the corresponding protein throughout the brain and spinal cord of both 
hemi- and homozygous Thy1 mySN mice (Fig. 2d, e). Homozygous Thy1 mySN tissue contained 
substantially higher levels of gamma-synuclein protein than that detected in hemizygous mice. The 
increased expression of gamma-synuclein had no impact on the levels of alpha- or beta-synuclein 
expression in the nervous system (Fig. 2e.). Thus any phenotype observed could be attributed to the 
increased neuronal gamma-synuclein content and not changes in beta- or alpha-synuclein.
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Fig. 2. Gamma-synuclein expression in Thy1 mySN mice. The Thy1 mySN expression cassette, 
containing a fragment of murine gamma-synuclein cDNA inserted between exons II and IV of murine 
Thy-1 (a). Bar charts (mean±SEM) showing gamma-synuclein expression in the murine nervous 
system (b, c). Gamma-synuclein mRNA expression in the spinal cord of 8-week old hemi- and 
homozygous ThylmySN mice, compared against a reference level in the trigeminal ganglia of 
newborn wild type mice (b). Expression in the dorsal root ganglia and spinal cord of 12-month old 
Thy1 mySN mice was compared to the reference level of age-matched wild type tissues (c). Gamma- 
synuclein protein levels in the spinal cord of wild type and Thy1 mySN mice assessed using Western 
blot analysis (d, e). Normalised Western blots probed with antibodies against gamma-synuclein, with 
GAPDH control (d). The lower panel shows undiluted wild type samples compared with 1:1000, 1:500 
and 1:250 diluted samples from homozygous Thy1 mySN spinal cord (d). Representative Western 
blots showing levels of alpha-, beta- and gamma-synuclein in the brain and spinal cord (e). Gamma- 
synuclein overexpression does not affect the expression of alpha- or beta-synuclein. Adapted from 
Ninkina et al 2009.
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1.9. Aims
Using the Thy1 mySN mouse line we aim to investigate several lines of enquiry.
1. Investigate whether the overexpression of gamma-synuclein induces a neurodegenerative 
phenotype in a manner similar to wild type and mutant forms of alpha-synuclein, or whether a 
more benign scenario occurs as is the case for wild type beta-synuclein overexpression. To 
achieve this we shall characterise several features of the mouse CNS.
a. The survival and morphological condition of motor and sensory neuron cell body 
populations
b. The survival and morphological condition of motor and sensory neuron axon 
populations in the peripheral nerves and spinal nerve roots
2. Investigate the effects of gamma-synuclein overexpression on the cell bodies and axons of 
retinal ganglion cells.
3. Investigate the effect of the absence of endogenous gamma-synuclein on the phenotypic 
manifestation of murine gamma-synuclein overexpression by producing a line of gamma- 
synuclein transgenic mice on an endogenous SNCG null background.
4. Investigate whether overexpression of gamma-synuclein is able to rescue the 
neurodegeneration induced by ablation of CSPa by producing and studying a line of gamma- 
synuclein null mice on a CSPa null background.
Finally we aim to investigate the presence of gamma-synuclein in the human CNS in healthy and 
disease samples. We have been given access histological samples of spinal cord and frontal lobe 
tissue donated by healthy individuals and patients with sporadic and familial forms of ALS and FTLD.
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2. Methods
2.1. Generation of transgenic mice
2.1.1. ThylmySN mice
A line of C57BI6/J mice expressing high levels of gamma-synuclein under the transcriptional control of 
a neuron specific thyl promoter was developed prior to the onset of this project (Ninkina et al. 2009). 
The generation of these ThylmySN mice is described in the introduction.
2.1.2. Gamma-synuclein null mice
The generation of gamma-synuclein null has been described previously (Ninkina etal. 2003).
2.1.3. Thy 1 mySN/CSPaKO
CSP+/' mice on an Ola129/C57BI6 background were kindly gifted by Professor T C Sudhof (University 
of Texas). The CSPa+A genotype was transferred to a pure C57BI/6J background through six round of 
backcrossing. CSPa+/‘ mice were then mated to produce CSPA mice. Further CSPa+/' mice on the 
C57BI/6J background were intercrossed with homozygous mGammaThyl (Thy1 mySNTG/TG) to 
produce CSPa/+ Thy1mySN[9/JG mice. These were then mated to produce both CSPa'/Thy1mvSN,9/TG 
and CSPa'AThy1 mySNTG/TG genotypes. Gamma-synuclein transgene expression was detected as 
described above.
2.1.4. Husbandry information
Mice were held in two animal units, caged either individually or in small groups (<5 per cage), with a 
light cycle of 12 hours light/12 hours dark and ad libitum access to food and water. All work on animals 
was carried out in accordance with the United Kingdom Animals (Scientific Procedures) Act (1986) 
and European Directive EC 86/609.
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2.2. Genotyping
2.2.1. ThylmySN
Though standard PCR could be used for detection of the ThylmySN transgene in the mouse genome, 
the technique is unable to differentiate between hemi- and homozygous transgenic mice. To overcome 
this issue we utilised quantitative real-time PCR to measure levels of genomic ThylmySN transgene. 
Forward and reverse primers were designed based on the sequence of the ThylmySN transgene and 
the housekeeping gene GAPDH as an internal control.
Gamma-synuclein: Forwards 5’-CCATGGACGTCTTCAAGAAAGG-3’
Gamma-synuclein: Reverse 5’-CGTTCTCCTTGG I I I IGGTG-3’
GAPDH: Forwards 5’-CACTGAGCATCTCCCTCACA-3’
GAPDH: Reverse 5’-GTGGGTGCAGCGAACTTTAT-3’
Genomic DNA was purified from ear biopsy tissue using a commercial kit (Promega Wizard SV 
Genomic DNA purification kit). Quantitative real-time PCR was then performed using a DyNAmo HS 
SYBR Green qPCR kit (Finnzymes) in a thin-walled 48-well PCR plate (Bioplastics) on an Applied 
Biosystems StepOne thermal cycler. A stock solution of reaction buffer was prepared according to the 
manufacturers instructions. The DyNAmo HS SYBR Green supermix contains all reagent required, 
including hot-start DNA polymerase. ROX, a passive reference dye used for equipment calibration was 
also added.
Master mix solution (sufficient for two 48 well plates)
Water 200pi
DyNAmo qPCR kit (2x) 250pl
ROX 5.0pl
Forward primers 2.5pl
Reverse primers 2.5pl
To ensure accuracy samples were loaded in triplicate. 2pl of purified genomic DNA was added to a 
well with 18pl of master mix solution. Samples underwent the following protocol in the qPCR thermal 
cycler.
Initial denaturation: 95°C 10min
40 cycles of...
Denaturation: 95°C 15 sec
Annealing/Extension: 60°C 60 seconds
Step-wise melt curve determination was additionally carried out in increments of 0.3°C. Fold change 
was calculated using the 2 AACt comparative method using StepOne v2.0 software.
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2.2.2. SNCG'a Thy1mYSNTG/TG & C SPa* Thy1 mYSNTG/TG
Standard PCR protocols described in previous publications (Fernandez-Chacon et al. 2004; Ninkina et 
al. 2003) were used to discriminate between wild type and null alleles of SNCG or CSPa genes. 
Genomic DNA was purified from digested ear biopsy tissue using a commercial kit (Promega Wizard 
SV Genomic DNA purification kit). In both cases the knockout allele was detected using an upstream 
primer common to both alleles, with downstream primers specific to the wild type and knockout alleles. 
Stock solutions of primers were made up at a concentration of 100pM.
For endogenous gamma-synuclein genotyping:
Common upstream 5’-AGTCCTGGCACCTCTAAGCA-3’
Wild type downstream 5’-GGGCTGATGTGTGGCTATCT-3’
Knock-out downstream 5’-GAAGAACGAGATCAGCAGCC-3’
A wild-type band of 480bp and a knock out band of 397bp were detected. 
For endogenous CSPa genotyping:
Common upstream 5’-AAAGTCCTATCGGTAAGCAGC-3’
Wild type downstream 5’-CTGCTGGCATACTAATTGCAG-3’
Knock-out downstream 5’-GAGCGCGCGCGGCGGAGTTGTTGAC-3’
A wild-type band of 607bp and a knock out band of approximately 400bp were detected.
Reaction buffer containing dNTPs, primers and taq polymerase was produced in a sufficient volume 
for the number of reactions required.
For 10 reactions 
dH20  440nl
PCR buffer (x10) 50fil
dNTPs (25mM) 4^ 1
Common primers 2.5|xl
Wild type primers 2.5[aI
Knock-out primers 2.5fil
Taq Pol 2.5nl
5|xl of purified genomic DNA (Promega Wizard SV Genomic DNA purification kit) was loaded into PCR 
reaction tubes. To this 45^ ,1 of reaction buffer was added. Mixtures underwent the following reaction in 
the PCR thermal cycling apparatus (see over).
44
Initial denaturation 94°C 2 minutes
45 cycles of...
Denaturation 94°C 30 seconds
Annealing 60° 30 seconds
Extension 72° 40 seconds
After reaction cycling was completed, samples were run on a 2% agarose gel until resolved sufficiently 
for viewing.
TAE 100ml
Ethidium bromide 4jxl
Agarose 2g
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2.3. Behavioural testing
2.3.1. Rotarod
The rotarod is a horizontal rotating beam used to test balance of mice. Beneath the beam is a trip 
switch operated timer. Mice are placed on the beam and the latency to fall recorded when the animal 
is no longer able to remain on the beam. The apparatus (Ugo Basil 7650 Rotarod) has two test 
settings.
• Constant mode: Four-minute trial period with the rotarod rotating at 24rpm
• Accelerating mode: Five-minute test period where the rotarod accelerated from 4 to 40rpm in 
30-second intervals
Mice were moved into the test procedure room in their home cages 60-minutes before testing and 
allowed to acclimatize. Prior to testing mice underwent a practice session upon the constant speed 
mode rotarod, followed by a 60-minute rest period. Mice were tested on each mode three times, with a 
minimum rest period of 40-minutes between tests. The mean latency to fall on each mode was 
recorded for each mouse (Robertson etal. 2004).
2.3.2. Inverted grid test
To assess coordination and strength, a mouse was placed onto a 30cm by 30cm square mesh 
consisting of 5mm squares of 0.05mm diameter wire. The grid was slowly rotated to inverted position 
and held 30cm above the surface of a thick layer of bedding material. If a mouse fell from the inverted 
grid earlier than the maximum test time of one minute the latency to fall was noted and after an 
appropriate rest in the home cage the test was repeated. The best time from three attempts was used 
for statistical analysis.
2.3.3. Horizontal beam walking
Co-ordination and balance of the was tested on a raised wooden rod, of 500mm length and 20mm 
diameter, with a baited escape box at one end. Mice were place at the free hanging end, facing away 
for the escape box. The length of time taken by the mice to turn a full 180°, with all four paws on the 
beam, and the subsequent time taken to traverse the beam to the escape box were measured. The 
mean times for each stage were recorded.
2.3.4. Auditory startle test
Mice were physically restrained in clear Perspex tubes. These were placed upon a base mounted with 
piezoelectric sensors contained within a darkened startle test chambers (SR Lab software San Diego 
Instruments Startle Response Testing System). After a five-minute acclimatization period under 70dB 
white noise, mice were exposed to pseudo-randomized 30ms startle stimuli at 120 or 105dB. Peak
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startle responses were measured by the piezoelectric sensors beneath the animal. In addition to the 
basic startle test, prepulses of 0, 2, 4, 8 and 16dB over background noise were also sounded 20ms 
prior to startle stimuli. Tests were separated by variable intervals of 20 to 30 seconds. Each stimulus 
was tested 10 times during the test period.
2.3.5. Analysis of hind paw withdrawal threshold following tactile stimulation
Mice were placed in a plastic cage with a mesh base composed of 5mm squares of 0.5mm diameter 
wire and allowed 30 minutes to habituate. Tests were only carried out when the animal was still, with 
all four paws on the cage surface. Von Frey hairs (SOMEDIC, Sweden) of varying force (0 .12g -  
6.20g) were applied from beneath the animal to the plantar surface, taking care to avoid the footpads, 
for approximately 2 seconds. Each hair was applied ten times, alternating between the left and right 
foot. Increasing force of von Frey hair was used until either the highest force hair or the 100% 
withdrawal threshold was met. Responses considered valid were the lifting of paws from surface of the 
grid or the spanning of digits upon stimulation. The latter response was frequently observed when the 
lowest force hairs were used.
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2.4. Protein and neurotransmitter quantification
2.4.1. Western blotting
One of the standard procedures in molecular biology, Western blotting can be used to assess the 
proportion of total protein content made up by single protein. Total tissue proteins were extracted from 
fresh/snap frozen tissue by homogenization in the SDS gel-loading buffer (Laemmli 1970) followed by 
a ten-minute incubation at 100°C. The mass of sample and volume of buffer used for homogenization 
were recorded for future reference. Prior to running proteins on SDS-PAGE, protein levels were 
normalised to ensure comparable levels of total protein were being assessed. Total proteins 
concentration was measured using a commercial protein assay kit (BioRad), based on the Bradford 
procedure (Bradford 1976). Homogenized protein samples were passed through a two layer 
polyacrylamide gel, consisting of a 6% upper “stacking gel” layer, followed by a higher concentration 
“resolving gel”, typically 10-20% acrylamide. The percentage of polyacrylamide contained in the 
resolving gel was altered according to the weight of proteins being assessed. Generally for smaller 
weight proteins a high percentage gel was used, slowing the movement of the proteins through the gel 
and allowing a greater degree of protein separation. Normalised levels of protein were loaded into the 
stacking gel wells. Prestained protein weight marker ladder (Fermentas PageRuler Plus) was added to 
an additional well. Voltage and length of run time varied depending on the molecular weight of the 
protein being assessed.
Stacking gel
dH20
Acrylamide (30%)
6% gel 
1.65ml 
0.50ml
Tris (pH 6 .8) 
SDS (10%) 
APS (10%) 
TEMED
310pl 
25 pi 
3pl 
2pl
Resolving gel
10% gel 16% gel
2 .00ml
5.30ml
2.50ml
100pl
100pl
10pl
dH20
Acrylamide (30%)
3.97ml
3.33ml
2.5ml
100pl
100pl
10pl
Tris (pH 8.8) 
SDS (10%) 
APS (10%) 
TEMED
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Following electrophoresis, proteins were transferred from the polyacrylamide resolving gel to a PVDF 
membrane, using the high efficiency iBIot dry transfer system following the manufacturer instructions 
(Invitrogen). Membranes were blocked in a solution of 3% non-f^t milk (Marvel) in TBS-T for one hour. 
Blocking solution was removed and the membrane incubated in primary antibodies in 3% non-fat milk 
(Marvel) in TBS-T for overnight at +4°C. Primary antibody solution was removed and the membrane 
washed thoroughly in TBS-T. Samples were then incubated with anti-rabbit or anti-mouse secondary 
HRP conjugated antibodies (Amersham) for 1-2 hours. Protein bands were then imaged using the ECL 
or ECL+ chemiluminescent detection systems in accordance with the manufacturers instructions 
(Amersham). Band intensities were analysed using Alphalmager 2200 analysis software. Following 
analysis, membranes were washed with TBS-T to remove ECL/ECL+. Membranes were reblocked 
and probed with antibody against GAPDH. Relative concentrations of test protein in samples were 
calculated by normalising band intensities against intensities of GAPDH.
2.4.2. Sequential protein extraction from neural tissue samples
Protocol was carried out as described in Giasson et al. 2002. Fresh tissue was collected from twelve­
month old wild type and symptomatic ThylmySN mice. Samples were homogenized in a high salt 
buffer at a sample to buffer ratio of 1:5. Post-mitochondrial (PM) fractions were isolated by 
centrifugation at 12000g for 15 minutes. The supernatant was transferred to a fresh tube from which a 
sample aliquot was collected and mixed with the gel loading buffer. The rest of supernatant was 
centrifuged at 100,000g at 4°C for 20 minutes. Resulting supernatant was removed, a sample aliquot 
collected and mixed with the gel loading buffer (HS fraction). The pellet was washed with high salt 
buffer and resuspended in high salt buffer containing 1% Triton-X10o- Samples were again spun at 
100,000g at 20 minutes. The process of supernatant sample collection and pellet resuspension was 
repeated with RIPA buffer. The final pellet was resuspended in 50^1 of gel loading buffer and boiled for 
5 minutes.
2.4.3. Immunoprecipitation
Fresh spinal cords were collected from twelve-month old wild type and symptomatic ThylmySN mice 
and ~100pg homogenized in 0.5ml of immuno-precipitation buffer. Triton X10o soluble fractions were 
isolated by centrifugation homogenates at 10,000g for 10 minutes at 4°C. A small quantity of cytosolic 
fraction was collected as an input reference for immunoprecipitation. To each sample was added 
antibodies raised against either NF-L (5pl) or gamma-synuclein (20pl) and 50pl of Protein G 
Sepharose beads. The suspension was rotated for two hours at 4°C. Sepharose beads were collected 
by centrifugation at 1000g for one minute. IP buffer was added to wash the beads, which were again 
centrifuged at 1000g for one minute. This process was repeated four times. Bound proteins were then 
eluted from the beads by adding 50pl of the SDS gel loading buffer followed by boiling for 10 minutes. 
Immunoprecipitated and co-immunoprecipitated proteins were detected by Western blot analysis using 
corresponding primary and secondary antibodies. Protocol has been described in Ninkina et al. 2009.
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2.4.4. Neurotransmitter measurement
Levels of striatal neurotransmitters were measured by high-performance liquid chromatography 
(HPLC). Approximately 5mg of freshly dissected dorsal striatum was homogenized in 0.5ml of 0.06M 
HCIO4 and the homogenate centrifuged at 16000g for 15 minutes (4°C). Striatal neurotransmitters 
were measured by HPLC with a 4.6 x 150mm electrochemical detection microsorb C18 reverse-phase 
column (Varian) and Decade II ECD with a Glassy carbon-working electrode set to +0.7V, with a 
Ag/AgCI reference electrode (Antec Leyden). Mobile phase consisted of 12% methanol, 0.1 M 
monosodium phosphate, 0.68mM EDTA and 2.4mM 1-octane sulphonic acid (pH 3.1).
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2.5. Histology
2.5.1. Tissue fixation and paraffin embedding
For general histology and immunohistochemistry mice were sacrificed by a Schedule 1 method and 
the tissues rapidly collected. Sample were placed in labeled plastic cassettes and immersion fixed 
overnight at +4°C in one of the following fixative solutions:
• Carnoy’s fixative: 60% ethanol, 30% chloroform, 10% glacial acetic acid_(Bancroft and Gamble
2002).
• 4% paraformaldehyde in phosphate buffered saline (pH 7.4)
• 10% neutral buffered formalin (Pre-prepared Sigma-Aldrich)
Tissues were then dehydrated through one of the following series.
For 4% PFA or 10% NBF:
PBS
70% ethanol
95% ethanol
100% ethanol
100% ethanol
1:1 ethanol :chloroform
Chloroform
Chloroform (+4°C)
15 mins (x4) 
Overnight 
5 mins (x3) 
10 mins 
30 mins 
30 mins 
60 mins 
Overnight
For Carnoy’s fixative 
95% ethanol 
100% ethanol 
100% ethanol 
1:1 ethanokchloroform 
Chloroform 
Chloroform (+4°C)
5 mins (x3) 
10 mins 
30 mins 
30 mins 
60 mins 
Overnight
Following final dehydration in chloroform, tissues were infiltrated in paraffin wax (RA Lamb) at 60°C for 
three hours. Tissues were then placed in stainless steel moulds that were subsequently filled with 
paraffin wax, a labeled plastic base mounted and left to set on a chilled ice plate.
2.5.2. Sectioning and mounting of samples
To prepare slides for use in histological staining techniques, 8pm sections were cut from samples 
contained in paraffin blocks using a microtome fitted with a razor-cutting blade. Sections were floated
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upon the surface of dH20  heated in a 40°C water bath. Sections were collected onto poly-L-lysine 
coated slides (Thermo-Fischer) and allowed to dry overnight at room temperature.
2.5.3. Haemotoxalin and eosin staining
Samples were processed by an automated system. Sections were dewaxed in xylene and brought to 
water. Sections were then incubated in Gill’s haemotoxylin (Leica) for 5 mins. Excess staining was 
washed under running H20, followed by a 30 second differentiation in acidified ethanol (1% glacial 
acetic acid). Following further washing in H20  samples were incubated in 1% eosin for 5 minutes. 
Samples were again washed, brought to xylene and glass coverslips mounted with DPX.
2.5.4. Fluorescent Congo red staining
Sections were dewaxed and brought to water, followed by incubation in 0.5% Congo red in 50% 
ethanol for 7 minutes. Slides were washed with 50% ethanol followed by differentiation of staining with
0.2% potassium hydroxide in 80% ethanol for 5 minutes. Sections were then thoroughly washed with 
dH20  and glass coverslips mounted with aqueous media (Thermo Scientific). Slides were allowed to 
dry and stored in the dark at +4°C. For quantification of amyloid positive structures, sections were 
randomly selected from all regions of the spinal cord. A 0.1mm2 field of the ventral horn was 
photographed under fluorescent microscope, the number of structures strongly stained with Congo red 
were counted. Final means were calculated for the cervical, thoracic and lumbar spinal cord 
separately. Protocol adapted from Bancroft and Gamble 2002.
2.5.6. Thioflavin-S staining
For qualitative aggregate detection, sensory ganglion sections were incubated in 1% thioflavin S 
(Sigma-Aldrich, MO) in dH20  for 5 minutes, followed by differentiated in 70% alcohol for 5 minutes. 
Sections were then washed in dH20  and mounted with aqueous mounting media (Thermo-Fisher 
Scientific, MA). Protocol adapted from Bancroft and Gamble 2002.
2.5.7. Nissl staining
Sections were dewaxed and brought to water. Samples were stained in 0.5% cresyl violet acetate in 
dH20  followed by thorough washing. Staining was then dissociated in 0.25% acetic acid in 100% 
ethanol. Sections were again washed with dH20 , taken to xylene and glass coverslips mounted with 
DPX. Following Nissl staining cranial and spinal motor neuron cell bodies and also the sensory cell 
bodies located within the dorsal root ganglia are easily identifiable. All have particularly large cell body 
densely stained with Nissl granules. The nuclear envelope remains clear but the nucleolus remains 
intensely stained, the presence of which is used to determine which cells are counted. Protocol 
adapted from Bancroft and Gamble 2002.
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2.5.8. Spinal motor neuron cell body quantification
Sections were randomly selected from all levels of the spinal cord. The number of motor neuron cell 
bodies within each ventral horn was quantified separately. Final means were calculated for the 
cervical, thoracic and lumbar spinal cord separately.
2.5.9. Cranial motor neuron cell body quantification
Serial sections of the abducens, facial and trigeminal motor nucleus were collected with every 10th 
section sampled. The fractionator technique of correction used to estimate total neuron populations.
2.5.10. Dorsal root ganglion sensory cell body quantification
Serial sections of L4/5 dorsal root ganglion were collected with every 6th section sampled. The 
fractionator technique of correction was used to give estimate the total population.
2.5.11. The fractionator correction technique
The fractionator correction technique (Howard and Reed, 1998) allows a total population to be 
estimated from quantification of a smaller sample fraction, using the following formula.
N t= 1/fxNf,
Where Nt = total population, Nf = number counted in the fraction, 
f = sampling fraction (i.e. for DRG population “6”).
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2.6. Immunostaining
2.6.1. Standard immunohistochemistry
Sections were cleared in xylene and brought down to water. Antigen retrieval was carried out by 
microwaving at 750W for ten minutes in 10mM sodium citrate (pH 6.0). Endogenous peroxidase 
activity was quenched by incubation with 3% hydrogen peroxide in methanol. Tissues were then 
washed with PBS and a blocking solution of 10% appropriate serum (i.e. horse, goat) in PBS 
containing 0.4% triton-Xioo was applied for 30 minutes. Sections were incubated in primary antibodies 
in blocking solution either overnight (+4°C) or for 2 hours at room temperature. Tissues were then 
washed with PBS, followed by incubation in a corresponding biotinylated secondary antibodies 
(Vector) in 0.4% T-PBS, for an hour. The tissues were washed, followed by incubation in ABC solution 
(Vector) containing avidin-biotin HRP complex, applied for 30 minutes at room temperature. After 
washing with dH20  tissues were incubated with the HRP substrate 3,3'-diaminobenzidine (DAB) 
(Sigma) until brown colouring was sufficient. If necessary colouring reaction speed could be slowed 
down through use of diluted DAB. Tissues were then washed in dH20  and, if required, counterstained 
by immersion in haematoxylin solution for 30 seconds. Samples were then taken to xylene and a glass 
coverslip mounted with DPX (RA Lamb).
2.6.2. Fluorescent immunostaining
Tissues were dewaxed and brought to water. Antigen retrieval was carried out, by microwaving at 
750W for ten minutes in 10mM sodium citrate (pH 6.0). The sections were then washed with PBS and 
a blocking solution of 3% bovine serum albumin and 5% goat serum in PBS applied for one hour. 
Tissues were incubated in primary antibodies in blocking solution for two hours. The sections were 
then washed in PBS followed by a one-hour incubation in secondary Alexafluor conjugated antibodies 
(Molecular Probes). The sections were then washed and a glass cover slip mounted with aqueous 
mounting media (Thermo Scientific). Slides were stored in the dark at +4°C. Fluorescent images were 
captured using a Leica TCS SP2 laser scanning confocal microscope (Leica Microsystems, Germany) 
or Olympus BX61 fluorescent microscope (Olympus, PA).
2.7.3. Quantification of dopaminergic neurons in the substantia nigra pars compacta and ventral 
tegmental area.
The number of dopaminergic neurons within the substantia nigra pars compacta (SNpc) and (ventral 
tegmental area) VTA were counted using a previously described protocol (Robertson et al. 2004). 
Prior to staining, whole SNpc and VTA were serial sectioned and mounted onto polysine coated slides 
(Thermo-Fisher) in a pattern producing two duplicate sets of slides as shown below.
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One set of slides was stained, with the second kept for any further analysis or repetition required. 
Staining was carried out using the standard immunostaining method described above, using mouse 
primary antibodies raised against tyrosine hydroxylase at a 1:1000 dilution. All counts were carried out 
blindly. From the first slide of the series containing SNpc/VTA, a section was randomly selected i.e. 
section “2”. The total number of nuclei of tyrosine hydroxylase-positive cell bodies was counted for 
both the left and right regions of the SNpc and VTA at 40x magnification and recorded seperately. This 
was then repeated on every tenth section of the series throughout the entire SNpcA/TA region i.e. “2”, 
“12”, “22" etc. The mean nuclear diameter of 30 TH-positive was recorded for each set of tissue 
analysed (AnalySIS imaging software). Total cell populations were estimated using the Abercrombie 
correction technique (Abercrombie 1946):
P= (1/f) x A(M/D+M)
Where P=corrected cell count; f=frequency of cell count (i.e. 1/10=0 .1); M=section thinness (pm);
D=average nuclear diameter.
2.7.4. DiOlistic labelling of retinal ganglion cells
DiOlistic staining is a recently developed technique that allows the fluorescent imaging of both living 
and fixed cells (Gan et al. 2000). Staining is achieved by firing tungsten beads coated with the 
lipophilic fluorescent dyes 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1'-dioctadecyl- 
3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil). DiOlistic staining was carried out in 
collaboration with the laboratory Prof. James Morgan in the Cardiff University School of Optometry, 
with kind assistance from Peter Williams.
Firstly tungsten particle were coated with the fluorescent dyes. This process may be carried out in 
advance as the dye-loaded “bullets” produced can be stored for several months. 2mg of Dil (Sigma) or 
4mg of DiO (Sigma) were suspended in 200pl of methylene chloride by vortexing. The dissolved dye 
was then added to 200mg of 1.3-1.7pm tungsten particles placed upon a glass slide. The dye and 
tungsten particle mixture was spread out into a thin film and allowed several minutes to dry. The dried 
powder was then transferred to a 15ml falcon tube to which 5mls of MilliQ dH20  was added, followed 
by 3-5 minutes further vortexing. Using a syringe the slurry was drawn into silicon tubing coated with 
polyvinyl pyrrolidone (Sigma) to facilitate particle sticking to the tubing walls and allowed several minute 
to settle. A syringe was then used to draw remaining water from the tubing. The coated tubing was then 
dried with a flow of nitrogen (0.2-0.4lpm) and cut to the required “bullet” length (approx. 2cm).
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For labelling of RGCs, intact retina were rapidly dissected from the eyes of twelve month old wild type 
and Thy1mySNJGnG mice, whole-mounted on a glass coverslip and allowed 5 minutes adhere. The 
coverslips were then placed beneath a membrane filter with 3pm pores (Falcon tissue culture inserts), 
dye coated bullets were loaded into a gene gun and the tungsten beads contained fired into the tissue 
at a pressure of 60-120psi. Labeled tissue was then incubated at 37.5°C for 20 minutes to allow 
diffusion of lipophilic dye across the RGC phospholipid membranes. Tissues were then fixed with 4% 
PFA for 10 minutes, washed with PBS and mounted to a glass slide with aqueous mounting media. 
The fluorescent staining by DiO/Dil has a relatively short lifespan and so it is essentially to image the 
samples within 48-hours of staining. 20x magnification Z-stack images encompassing all visible 
neurites emerging from one RGC were produced by fluorescent confocal microscopy, taking care not 
to image any amacrine cells that may have also been labeled. Scholl analysis, the measurement of 
dendritic branching at various distances from the soma, was carried out using ImageJ.
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2.7. Transmission Electron Microscopy:
2.7.1. Tissue preparation
Nerves were dissected from twelve-month-old animals as required and immediately immersion fixed in 
a glass bijou containing cold 2% PFA 2% gluteraldehyde in 0.1 M Sorensons PB overnight at 4°C. 
Samples were then washed thoroughly in 0.1 M Sorensons PB and post-fixed in 1% osmium tetraoxide 
for two hours at room temperature. Samples were again washed followed by block stained in 0.5% 
uranyl acetate overnight at +4°C. After samples were washed in dH20  they were passed through a 
graded dehydration series. It is critical that this stage is carried out slowly and carefully. Both sudden 
osmotic changes and the consequence incomplete dehydration on subsequent steps in the protocol 
can cause substantial damage to the myelin sheaths surrounding axons resulting in useless samples. 
The concentration of alcohol bathing the sample was increased every 5 minutes in increments of 5%. 
The samples were then bathed in a final solution of 100% ethanol for 90 minutes, with the solution 
replaced four times. 100% ethanol was then replaced with by propylene oxide, which was again 
replaced by fresh solution after 10 minutes and allowed a further 20-minute incubation. Pure propylene 
oxide was then replaced by a solution of 1:1 propylene oxide and araldite solution for overnight 
infiltration. The samples were removed from this final solution and embedded in pure araldite for 48 
hours at 60°C. Protocol adapted from Hayat 1989.
2.7.2. Sectioning
Plastic-embed section cannot be cut using the apparatus used for standard histological section, due to 
both the relative bluntness of a standard razor blade and the inability of the equipment to accurately 
section below 1 pm. For ultra-thin sectioning we used a diamond knife (Diatome) attached to a small 
bath of dH20 . The cutting equipment is mounted in an ultra-tome (Reichert-Jung Ultracut E 
microtome), apparatus specifically designed for cutting sections on a nanometer scale. Two types of 
section, each with differing applications, can be cut:
1. Semi-thin sections
Varying in colour, these >0.1 pm section were used for tolouidine staining, a quick means of assessing 
the quality and morphology of prepared tissue. To mount semi-thin sections, a bubble of dH20  was 
formed on the surface of a poly-L-lysine coated slide (Thermo-Fischer). Samples were collected on the 
tip of a nylon filament and transferred to the bubble. The slide was then placed on a hot plate (80- 
100°C) and the bubble allowed to dry. For tolouidine staining, a drop of 1% tolouidine blue, 1% borax 
in dH20  was place upon the dried sections. The slide was again returned to the hotplate and dried. 
Residual staining solution was then removed by washing the slide under a running tap. The slide was 
then dried upon the hot plate, allowed to cool and a coverslip mounted with DPX.
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2. Ultra-thin sections
Silver-gold in colour, these sections were used for high quality transmission electron microscopy. 
Mounting and preparation of ultra-thin sections is more complpx than semi-thin. A glass slide was 
briefly soaked in a solution of 0.8% pioloform in chloroform. The slide was removed and allowed to 
dry. The edges of the slide were then scoured with a razor blade and the slide slowly dipped vertically 
into a bath of dH20  to remove the pioloform film from the slides surface. 3mm diameter copper and 
nickel grids with a 2x1 mm slot cut into their centre (Agar) were placed upon the floating layer of film 
and given several minutes to adhere. A clean layer of parafilm was then placed upon the floating 
film/grids and slowly pulled from the water surface, bringing with it the film coated grids. After being 
allowed to dry at room temperature the grids were ready for use.
Following cutting, ultra-thin sections were collected from the surface of the water bath onto a film 
coated copper or nickel slot grid and allowed to dry. For counterstaining, sections carrying grids were 
floated upon a drop of 0.5% uranyl acetate for 10 minutes, followed with two 5-minute washes upon a 
drop of dH20 . Sections were further counter-stained with Reynold’s lead citrate solution (Reynolds 
1963) for 5 minutes, followed by a further two dH20  washes and drying to room temperature. Stained 
tissues were then visualized under a Philips TEM 208 transmission electron microscope.
2.7.3. Morphometric analysis: Sciatic nerve and spinal nerve roots
Myelinated A-fibres and unmyelinated C-fibre were counted at 2.0kx magnification. All A-fibres were 
counted recording their morphological condition, with fibres classed as either normal or damaged. 
Healthy fibres were defined as those with both axons and myelin sheath intact. Unhealthy fibres had 
dense, vacuous or absent axons, substantial abnormalities in the myelin sheath, or a combination of 
both. Damaged axons fully enveloped by phagocytes were not counted as the digestive process of 
these cells made accurate quantification impossible. C-fibres were classified as either normal, with a 
turgid cluster of fibres engulfed by a Schwann cell, or atypical, where turgidity is lost and the bundle 
morphology was consequently abnormal. All counts were normalized to a 100pm2.
2.7.4. Morphometric analysis: Optic nerve
Myelinated A-fibres were quantified at 6.3kx magnification. As few damaged fibres were detected, only 
total number of fibres was recorded. All counts were normalized to a 100pm2.
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2.8. Statistics
All statistics was carried out on Minitab 15th Edition except the x  test, for which Microsoft Excel was 
used. Guidance for testing was taken from Minitab Workbook for Biosciences: Minitab 14 edition. DW 
Bowker & PF Randerson. Cardiff School of Biosciences. 2004/5.
Statistical analysis was performed to reveal whether differences seen were mathematically significant, 
or if not then negligible. A p-value is generally calculated, representing the probability that the 
hypothesis being tested is true, and did not occur by chance, with a low value denoting higher 
probability, and accordingly increased confidence. Generally, it is the likelihood of H0 occurring by 
chance that is being tested. A p-value *0.05 confers a 5% chance of this occurrence, and is widely 
accepted as the level at which H0 is rejected. Three levels of confidence were used in the analysis of 
the data collected below and are annotated with asterisks as shown:
p-value *0.05 * “Significant”
p-value *0.001 ** “Highly significant”
p-value *0.0001 *** “Very highly significant”
Where there were more than two groups in an experiment, One Way Analysis of Equal Variance tests 
(ANOVA) were used to test for differences. Prior to testing with ANOVA, it is essential to test whether 
the observations conform to a number of assumptions test makes. These are that the data is 
distributed normally (i.e Gaussian distribution) and the variance is equal between curves. Anderson- 
Darling test was employed to test for normality of distribution of data and Bartlett’s test used to test the 
homogeneity of variance between datasets. Data that conformed to the assumption made by ANOVA 
was deemed parametric and tested using a one-way ANOVA test. Data violating either/both 
assumptions was deemed non-parametric and tested using a Kruskal-Wallis test; a less powerful 
means of analysis that does not assume equal variance. Untransformed data was used throughout. If 
significance was detected, pairwise post-hoc testing was then carried out with Fisher’s a priori test to 
detect differences between specific pairs.
Where differences between only two datasets were being investigated, a two-sample t-test or its non- 
parametric equivalent, the Mann-Whitney U-test, were utilised. These test investigate the hypothesis 
that all data has come from an equivalent dataset. Again, prior to analysis, the conformity of the data 
to two assumptions must be tested. Anderson-Darling testing was again used to test normality of 
distribution. An F-test was used to investigate the equality of variance between the datasets. 
Specifically, this test measures the ratio of variance between the groups differs significantly from 1.0. 
Again, data violating either/both assumptions was deemed non-parametric and tested accordingly.
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Significant differences in the observed percentage of groups able to complete a test (i.e. the 
percentage of mice able to complete the beam test) were investigated using a Chi-squared goodness 
of fit test (x2 test). The x2 test analyses the H0 that the observed djata does not differ from the expected 
data, using the equation...
The x2 number is then tested against a critical value at p=0.05. If the x  value calculated is greater 
than the critical value, H0 is rejected. The critical figure is derived from a statistics table and is selected 
dependant of the number of degrees of freedom (DF) in the test. The DF is value calculated from the 
number of independent datasets minus one. As all tests which used % analysis contained two 
datasets, control and experimental, there was only ever one degree of freedom.
The expected result for the experimental group was calculated from the proportion of control mice able 
to complete the test from the total number tested. This was then compared against the observed 
number of experimental mice able to complete the test. Thus in the below hypothetical experiment...
X 2 = S((0-Ef/E)
Where 0=observed data, E=expected data.
Control Group 
(n=50) 
Expected 50
Observed 34
Experimental Group 
(n=70)
34/50 x 70 = 47.6 
23
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2.9. Solutions
Congo Red
Congo red 0.5%
50% ethanol
Diaminobenzidine solution 
Supplied by Sigma:
3,3’-Diaminobenzidine 
Urea Hydrogen Peroxide 
Tris buffer
High Salt Buffer with 1 % Triton-X100 
Tris-HCL (pH 7.5)
NaCI
Triton-X10o
Protease inhibitors, according 
Immunoprecipitation buffer
Tris-HCL (pH 7.5) 50mM
NaCI 150mM
MgCI2 1.5mM
Triton Xt oo 1%
Protease inhibitors, according to manufactures instructions (Complete Mini from Roche)
SDS gel loading buffer 
Tris pH 6.8 
Glycerol 
SDS
Bromo phenol Blue 
Beta mercaptoethanol
Nissl stain
Cresyl violet acetate (Fluka) 0.5% in dH20
Solution was passed through filter paper prior to use to remove any precipitate.
0.1 M 
20% 
4% 
0.02% 
0.2M
50m M 
750mM 
1%
to manufactures instructions (Complete Mini from Roche)
3.3mM 
7.0mM 
60 mM
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PCR Buffer (10x)
KCI
Tris pH 9.0
MgCI2
Triton-X10o
Phosphate buffered saline: Dulbecco A (pH 7.3±0.2) 
Supplied by Oxoid:
NaCI
KCI
Sodium Phosphate dibasic 
Potassium phosphate monobasic
Potassium hydroxide
Potassium hydroxide 
80% Ethanol
Quench solution
Hydrogen peroxide 
Methanol
RIPA Buffer 
NaCI
Tris HCI pH 8.0
EDTA
NP40
Sodium deoxycholate 
SDS
Sodium citrate buffer (pH 6.0)
Sodium citrate tribasic salt dihydrate 
dH20
pH adjusted to 6.0 using HCI
0.5M 
0.1 M 
15mM 
1%
0.1 M 
2.6mM 
6.5mM 
1.2mM
0.2%
3%
150 mM 
50 mM 
5 mM 
1% 
0.5% 
0 .1%
10mM
Sorenson’s phosphate buffer (0.1M)
Solution A
Sodium Phosphate dibasic 0.2M
Solution B
Potassium phosphate monobasic 0.2M
For 100ml 0.1 M Sorensons phosphate buffer (0.1 M, pH 7.4)
Solution A 81.8ml
Solution B 18.2ml
TAE
For one litre of 50x stock solution.
Tris
EDTA 0.5M (pH 8.0)
Glacial acetic acid 
dH20
For working concentration dilute TAE stock 1:50 dH20
Toluidine blue
Toluidine blue 
Borax 
dH20
Tris buffered saline (pH 8.0)
Supplied by Sigma-Aldrich 
Tris 
NaCI 
KCI
TBS-T
Tris buffered saline (pH 8.0) containing 0 .1% Tween20
0.5M
138mM
2.7mM
1%
1%
2.0M
100ml
57.1ml
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2.9. Antibodies
2.9.1. Primary antibodies
Alpha-synuclein: Mouse monoclonal, clone 42, BD Transduction Laboratories 
Alpha-tubulin: Mouse monoclonal, clone DM 1A, Sigma 
Beta-synuclein: Mouse monoclonal, clone 8 , BD Transduction Laboratories 
GAPDH: Mouse monoclonal, clone 6C5, Santa Cruz Biotechnology 
Gamma-synuclein (anti-mouse): Rabbit polyclonal SK23, affinity purified 
Gamma-synuclein (anti-human): Rabbit polyclonal SK109, affinity purified 
Gamma-synuclein (anti-human): Goat polyclonal E20, Santa Cruz Biotechnology 
GFAP: Rabbit polyclonal, Sigma-Aldrich
Myelin basic protein: Mouse monoclonal, clone MAB387, Chemicon
Neurofilament-L: Mouse monoclonal, clone DA2, Cell Signaling
Neurofilament-M: Mouse monoclonal, clone NN18, Sigma
Neurofilament-H: Rabbit polyclonal, Sigma
NeuN: Mouse monoclonal, clone A60, Chemicon
Peripherin: Rabbit polyclonal, clone Ubi-1, Chemicon
Ubiquitin: Mouse monoclonal, clone Ubi-1, Zymed Laboratories Inc.
RCA biotinylated lectins: Vector
2.9.2. Secondary antibodies
Biotinylated secondary antibodies 1:1000 (Vector)
Alexa Fluor-conjugated secondary antibodies 1:1000 (Invitrogen)
HRP conjugated secondary antibodies 1:3000 (Amersham)
3. Gamma-synuclein overexpression in the murine nervous 
system: Behaviour, ceil bodies and aggregation
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3.1. Overview
For over a decade the accumulation and aggregation of alpha-synuclein has been associated with the 
synucleinopathy family of neurodegenerative disorders (Spillantipi et al. 1997), substantiated by the 
identification of several autosomal recessive point mutations (Kruger et al. 1998; Polymeropoulos et al. 
1997; Zarranz et al. 2004), duplication (Chartier-Harlin et al. 2004; Ibanez et al. 2004), triplication 
(Singleton et al. 2004) of the SNCA gene in Parkinsonian syndromes and its identification as a risk 
factor in several genome wide association studies (Edwards et al. 2010; Pankratz et al. 2009; Satake 
et al. 2009; Simon-Sanchez et al. 2009). The link between alpha-synuclein aggregation and 
neurodegeneration has been further demonstrated in numerous transgenic animal models with 
aberrant alpha-synuclein expression and inclusion formation (see section 1.7.). In contrast beta- 
synuclein has an extremely low propensity to aggregate in vitro (Fan et al. 2006; Park and Lansbury
2003) and is able to ameliorate the degeneration induced by alpha-synuclein overexpression in mice 
(Hashimoto et al. 2001).
Though the primary structure of gamma-synuclein is diverse compared that of the other synucleins 
(Sung and Eliezer 2007) it has nevertheless been demonstrated to share characteristics with both 
other family members. For example gamma-synuclein is able to form stable oligomeric structures in 
solution (as alpha-synuclein) (Park and Lansbury 2003) but also capable of disrupting alpha-synuclein 
aggregation (as beta-synuclein) (Uversky et al. 2002). The expression profile and intracellular 
localisation of gamma-synuclein are unique in the family; whereas alpha- and beta-synuclein 
predominantly compartmentalise to the presynaptic terminals of CNS neurons, gamma-synuclein is 
found diffusely throughout select pools of neurons in CNS and PNS (Abeliovich et al. 2000; Buchman 
et al. 1998b; Li et al. 2002; Surgucheva et al. 2002).
To investigate whether gamma-synuclein shares the ability of alpha-synuclein to induce substantial 
degeneration when overexpressed, or follows the benign scenario of beta-synuclein overexpression, 
we have produced a line of mice expressing high levels of murine gamma-synuclein throughout their 
nervous system. This chapter concerns the assessment of motor performance, sensory perception 
and characterisation of various populations of neuronal cell bodies within the CNS of these mice.
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3.2. Results: Phenotype and behaviour
3.2.1. Phenotype
ThylmySN mice are viable and during the first 3-5 months of life are indistinguishable from wild type 
controls. From 5 months onwards however, homozygous ThylmySN mice begin to develop 
characteristics typical of motor neurodegeneration. Clinical signs were found to progressively worsen 
with age. Many homozygous Thylm  ySN mice had to be culled at approximately 12-months due to 
substantial motor dysfunction and physical weakness, due in part to reduced ability to feed. Typical 
signs of ill health including a hunched posture and piloerection were frequently observed (Fig. 3b). 
Hemizygous mice also developed substantial motor dysfunction, however at an older age than 
homozygous mice, generally becoming manifest from 12-months onwards, suggesting a correlation 
between transgene dose and disease severity. The most pronounced of sign of early motor 
deterioration was the dystonic clasping of limbs against the abdomen (Fig. 3a.). This symptom began 
with clenching of the hind paw digits, with the whole leg rapidly becoming affected. Through hind limbs 
symptoms became detectable earliest in disease progression, the phenotype eventually encompassed 
all limbs. This loss of motor function had much consequence on the general behaviour of the 
T/jylmySN mice. Assessment of gait, achieved by painting the paws of the mice and allowing them to 
run over paper, revealed a marked deficit in foot placing (Fig. 3c). In contrast to the orderly foot placing 
of wild type control mice, nine-month old homozygous Thy1 mySN mice were found to misplace or 
drag their paws, with the phenotype worsening with disease progression (see Fig. 3c). Righting reflex 
was found to be decreased in Thylm  ySN mice, in particular the homozygous cohort (Fig. 3d.). When 
placed on their back a healthy mouse will instantaneously right itself onto its feet. At later stages of 
disease many homozygous Thy1 mySN mice performed very poorly at this test. Subsequently failure to 
right after one minute was deemed an experimental end point and the animal sacrificed.
3.2.2. Survival
Gamma-synuclein overexpression, and the subsequent motor deficits induced, had a pronounced 
effect upon the survival of mice (Fig. 3e). Wild type mice normally live for approximately 2.5 years. The 
survival of our control cohort was assessed during the first 2 years, with modest loss of 20% recorded. 
Both hemi- and homozygous Thylm  ySN mice had a significantly reduced life span. At the age of 2- 
years just over 40% of the hemizygous cohort had perished. The survival of homozygous Thy1 mySN 
mice was substantially diminished. Half of the colony had perished by 11-months, with no animals 
surviving past 14-months.
To assess the onset and progression of the motor deficits observed in the Thy1 mySN cohort, a battery 
of motor tests were carried out upon the animals.
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Fig. 3. Physical manifestation of Thy 1 my SN phenotype and effect on survival. Twelve-month old 
/?omozygous Thy1 mySN mice at the advanced stage of disease progression show dystonic clasping 
of all limbs against their abdomen (a). Neuromuscular dysfunction subsequently leads to a decreased 
righting reflex in mice with highly advance phenotype (d). Typical signs of ill health, including hunched 
posture and piloerection are frequently seen in symptomatic animals (b). The footprint pattern of 
Thylm ySN mice shows clear abnormalities in foot placing (c), shown at 9 and 12 months. Kaplan- 
Meier plot of wild type (squares, n=49), hemizygous Thy1 mySN (triangles, n=87) and homozygous 
Thy1 mySN (circles, n=74) mice survival over the 26 months period (e). Adapted from Ninkina et al. 
2009.
Hemi
Homo
360 450 540 630 7200 180 27090
days
homohomo
12 month old
68
3.2.3. Rotarod
Motor and balance skills were tested on a constant speed rotarod (24rpm for 4 minutes) (Fig. 4a.). 
Wild-type animals performed well at the test throughout their lifetimes, with near universal completion 
of the test. Hemizygous Thylm ySN mice show a significant deficit in performance when the test was 
performed at both the 18 and 24 months of age (p<0.01, Students t-test). In concurrence with the 
observed phenotype, the performance of homozygous Thy1 mySN mice declined at a substantially 
younger age, with significance reached already at the age of four months (p<0.01, Students t-test). 
Performance then progressively diminished with aging. The more sensitive accelerating mode rotarod 
test (4 - 40 rpm over 5 minutes) was used to further assess subtle changes in motor performance (Fig. 
4b.). That of wild type mice declined slightly between 2-6 months, however the level remained 
consistent for the remainder of age points. Hemizygous mouse performance followed a similar 
pattern, but again with a significant decline in performance from 18 months (p<0 .01, Students t-test). 
The diminished performance of homozygous Thy1 mySN mice seen in the constant speed test was 
again repeated. The accelerating test was however able to detect significant deficits in performance 
from as early as two months (p<0.01, Students t-test).
Due to the earlier developing and more severe phenotype, the majority of subsequent motor tests 
were carried out on homozygous Thy7mySN mice.
3.2.4. Inverted grid test
The inverted grid test was utilised to assess the strength and coordination of the mouse cohorts. The 
performance of homozygous Thy1 mySN mice were tested at various time points and compared to the 
performance of 18-month old wild type mice (Fig. 5.). The wild type control animals had a mean 
latency to fall of 57.4 seconds, with over 80% of animals completing the test. The latency to fall of 
homozygous Thy1 mySN mice was found to consistently decrease with age. From the age of four 
months a significant decline in performance was recorded (p<0.05 Mann-Whitney U-test), with highly 
significant deficit seen at all subsequent time points (P<0.001 Mann-Whitney U-test). At twelve-months 
of age no animals were able to complete the test, with a mean latency to fall of 7.5 seconds.
3.2.5. Acoustic startle test
The acoustic startle test was initially used as an assessment of prepulse inhibition (PPI), a complex 
motor phenomenon whereby startle response is muted by exposure to an auditory prepulse, played 
fractions of a second prior to the startle stimuli. Surprisingly PPI could not be accurately recorded in 
24-week old Thy1 mySN mice due to a substantially reduced startle response, found to be less than 
20% that of age matched wild type controls (Fig. 6b.). An obvious possibility was that the ThylmySM 
mice were deaf, however homozygous mice of various age were observed to be responsive to noise 
made in the vicinity of their home cage. Dysfunction was initially attributed to the significant motor 
deficits recorded in the older Thy1 mySN mice, and thus further attempts to record PPI were carried 
out in younger animals. Strikingly startle response was found to be reduced by over 80% in 6-week
69
(data not shown) and 3-week old Thy1 mySN mice (Fig. 6a.), the latter being the youngest age feasible 
for testing. Hemizygous mice also showed a 68% decrease in response to the loudest startle stimuli 
(Fig. 6a).
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Fig. 4. Age related decline in performance of homozygous ThylmySN mice on rotarod. Performance 
of wild type (diamonds), hemizygous (squares) and homozygous (triangles) Thy1 mySN mice on 
constant speed (a) and accelerating speed (b) rotarod tests (mean±SEM, * = p<0.01 Students t-test). 
Constant speed rotarod n-values for 2m, 4m, 6m, 9m, 12m, 18m and 24m respectively: Wild type -  
11, 28, 35, 34, 23, 17, 16; Hemizygous ThylmySN -  12, 27, 40, 36, 26, 21, 19; Homozygous 
ThylmySN -  13, 21, 23, 23, 14, 0, 0. Accelerating speed rotarod n-values for 2m, 4m, 6m, 9m, 12m, 
18m and 24m respectively: Wild type -  11, 14, 34, 32, 24, 17, 16; Hemizygous ThylmySN -  12, 19, 
40, 36, 26, 22, 15; Homozygous ThylmySN -  13, 18, 22, 23, 15, 0, 0. Adapted from Ninkina et al. 
2009.
70
60 
^  50 
40
0)
■o
I 30
r -c5
- j
10
* * *
92% 65% 50%
I
0% 84%
J >  <S>° <?° ,< ?  <?° <$? J >
<V *b  N  «> <& »JV  ^  <<>
*?>
Fig. 5. Age related deficit in performance of homozygous ThylmySN on the inverted grid. Inverted grid 
test of 18-month wild type and various age Thy 7mySNTG/TG mice (grey columns, mean±SEM * p<0.05, 
*** p<0.001 Mann-Whitney U-test). The ability of ThylmySN mice to hang from an inverted grid 
diminishes substantial with age. Inset number denotes percentage of animals able to remain on test
for the full 60 seconds test period. ThylmySN 
12m = 22. WTn; 18m = 32.
TG/TG n; 2m = 25; 3m = 17; 4m = 10; 6m = 22; 9m = 9;
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Fig. 6. Diminished response of ThylmYSN mice to acoustic startle stimulation. Response of wild type, 
hemizygous and homozygous ThylmySN mice to 105 and 120dB acoustic startle stimuli at 3 weeks 
(a) and wild type and homozygous ThylmySN mice at 24 weeks (b) (mean±SEM, * pcO.05, *** 
p<0.001 Mann-Whitney U-test). 3 week n; wild type = 6; hemizygous ThylmySN = 6; homozygous 
ThylmySN = 8. 24 weeks n; wild type = 6; homozygous ThylmySN = 10.
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3.2.6. Withdrawal threshold following tactile stimulation
To assess whether the sensory system was affected by gamma-synuclein overexpression we used 
the Von Frey hair system for measurement of withdrawal threshold following tactile stimulation. 
Sensory tests in animals unfortunately almost always require some degree of motor involvement. The 
Von Frey hair system requires the animal to lift their foot in response to sensory stimulation by the 
application of nylon filaments of increasing thickness and force to the plantar surface. Due to the 
likelihood of motor dysfunction interfering with the test in the most severely affected animals, we 
additionally recorded a more subtle response to stimulation, the fanning of the digits on the tested foot. 
This response was often seen in both sets of animals when the finest thickness filament was used. 
The hind paws were chosen for testing due to their trend to become symptomatic earliest in disease 
progression and their large plantar surface making testing more accurate.
Homozygous ThylmySN and wild type control mice aged between 6-week and 8-months were tested 
(Fig. 6.). No differences were detected in the response of 6-week old mice (Fig. 6a). Homozygous 
ThylmySN were found to have a trend towards a lower rate of response to plantar tactile stimulation 
of 0.6g at 4-months (Fig. 6b.). At 8-months significant differences were detected following tactile 
stimulation of 0.34, 0.6 and 0.88g to the plantar surface (p= 0.0369, 0.0182 and 0.0267 respectively, 
Mann-Whitney U-test) (Fig. 6c.). These differences were not however attributed to reductions in the 
response of homozygous ThylmySN mice, but to increased responses made by the wild type mice. 
Comparison of the homozygous ThylmySN data alone found no significant differences in performance 
between 6-weeks and 8-months (Fig. 6d.). It thus appears that in contrast to the age correlated motor 
dysfunction observed, sensory deficits in homozygous ThylmySN mice were limited and non­
progressive.
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Fig. 7. Paw withdrawal threshold following sensory stimuli. Paw withdrawal response following sensory stimuli of wild type and ThylmySN mice at 6 weeks 
(a), 4 months (b) and 8 months (c) (mean±SEM, Mann-Whitney U-test, * p<0.05). No progressive deficit in performance was detected in the response of 
ThylmySN mice to sensory stimulation (d). The response of wild type mice however appears to improve with age, resulting in significant differences to the 
ThylmySN response at 8-months. WT n; 6w = 6; 4m = 6; 8m = 6. Homozygous ThylmySN n; 6w = 9; 4m = 8; 8m = 10.
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3.3. Results: Spinal cord pathology
The phenotype induced by gamma-synuclein overexpression has characteristics typical to those seen 
in many animal models with compromised motor systems (Allen et al. 2002; Bruijn et al. 1998; van der 
Putten et al. 2000; Wegorzewska et al. 2009). Damage in these animals is often found to be most 
substantial in the spinal cord, with the ventral horn population of motor neurons often found to be 
highly vulnerable. To determine if the gamma-synuclein overexpression phenotype led to similar 
damage of spinal motor neurons, spinal cord samples from two- and twelve-month old homozygous 
ThylmySN and wild type mice were studied.
3.3.1. Gamma-synuclein aggregation in the spinal cord
Transverse sections of spinal cord were immuno-stained with antibodies raised against murine 
gamma-synuclein (rabbit anti-mouse gamma-synuclein SK23 affinity purified antibody (Buchman et al. 
1998)) (Figs. 8a, 9a). Concurrent with previously reported data (Ninkina et al. 2003) low levels of 
endogenous gamma-synuclein were detected in motor neurons and neuropil of both two- and twelve­
month old wild type control spinal cords (Figs. 8a, 9a). The spinal cords of homozygous ThylmySN 
mice displayed high levels of gamma-synuclein throughout both the grey and white matter. In two- 
month old animals motor neuron cell bodies and neuropil were intensely stained, though inclusion 
structures were rarely observed (Fig. 8a). In twelve-month old symptomatic ThylmySN mice however, 
high levels of gamma-synuclein were detected in widespread aggregate structures throughout the 
spinal cord (Fig. 9a, b). In the grey matter, these inclusion bodies took the form of perikaryal and 
axonal spheroids, ballooned neurites and Lewy-neurite-like structures densely stained for gamma- 
synuclein (Fig. 9a). Spheroid-like structures containing gamma-synuclein were also detected 
throughout the descending/ascending axon tracts of the white matter (Fig. 9b). H&E staining showed 
that in a manner typical of the Lewy bodies seen in human PD, a small proportion of the intracellular 
spheroids were highly eosinophilic (Fig. 9a).
In contrast to the highly soluble endogenous form of gamma-synuclein, a large proportion of the 
protein found in the spinal cords of twelve-month old homozygous ThylmySN mice was insoluble in 
non-ionic detergent containing high salt buffer (Fig 9c). Moreover, a substantial proportion of gamma- 
synuclein remained in fractions of proteins insoluble in ionic detergent containing buffers, including an 
SDS insoluble fraction. Immuno-TEM analysis of the SDS insoluble fraction revealed long straight 
gamma-synuclein positive fibrils typical for amyloid depositions found in various neurodegenerative 
conditions (data not show).
Typically the proteins contained within inclusion bodies in both human disease and animal models are 
ubiquitinated. To assess whether the gamma-synuclein containing structures seen in aged 
homozygous ThylmySN mice were similarly ubiquitinated, we fluorescently immunostained transverse 
sections of spinal cord with antibodies against both gamma-synuclein and ubiquitin (Fig. 9d). Though 
structures containing both proteins were observed, many were found to exclusively contain either
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gamma-synuclein or ubiquitin. It thus appears that ubiquitination of gamma-synuclein is not an 
essential event in the development of ThylmySN pathology.
3.3.2. Amyloid containing inclusion quantification
Congo red staining revealed that amyloid containing structures were present in the spinal cords of 
twelve-month old homozygous ThylmySN mice (Fig. 10). The simplicity and relatively low cost of 
Congo red staining made it a practical high throughput method for the quantification of amyoid 
inclusion presence in the experimental cohorts. Four groups of twelve-month old animals were 
analysed; wild-type controls, hemizygous ThylmySN mice, homozygous ThylmySN with mild 
symptoms and homozygous ThylmySN mice with advanced penetrance of the neurological 
phenotype. The number of amyloid positive structures was counted within a 0.1 mm2 field of the ventral 
horn in randomly selected transverse sections from the cervical, thoracic and lumbar regions of the 
spinal cord. Quantification revealed amyloid positive structures were occurred at a negligible 
frequency in control spinal cords (Fig. 10e). In contrast a significant number of such structures were 
observed in all three transgenic groups (p<0.0001, Kruskal Wallis, Fischer’s a priori). The presence of 
amyoid bodies was most pronounced in homozygous mice with advanced pathology, with an average 
of 27.8 observed per 0.1mm2 field. Though significant, the number of amyloid structures in the 
hemizygous and mildly symptomatic homozygous ThylmySN mice was lower than in the advanced 
stage animals with an average of 14.5 and 8.8 per 0.1mm2 field respectively. Results following a 
similar pattern to the mean values were obtained from cervical, thoracic and lumbar levels of spinal 
cord (see appendix 1).
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a  Wild type Homozygous ThylmySN
Fig. 8. Gamma-synuclein in the spinal cord of 2-month old homozygous ThylmySN mice. 
Representative transverse sections of thoracic spinal cord collected from two-month old wild type (left 
panels) and homozygous ThylmySN mice (right panels) immunostained with antibodies raised 
against gamma-synuclein (SK23, 1:100) (a) and GFAP (1:400) (b). Arrows = activated astrocytes. 
Scale bars = 50pm
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Fig. 9. Inclusions containing gamma-synuclein and ubiquitin both exclusively and in combination are 
found in the spinal cords of homozygous ThylmySN mice.
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Fig. 9 -  previous page. Inclusions containing ubiquitin and insoluble forms of gamma-synuclein both 
exclusively and in combination are found in the spinal cords of homozygous ThylmySN mice. 
Transverse sections of spinal cord ventral horn from twelve-month old wild type (left) and homozygous 
ThylmySN mice (right) immunostained with antibodies raised against gamma-synuclein (SK23 1:100)
(a). Staining detected gamma-synuclein-positive cytoplasmic inclusions (left inset) (small 
arrowheads), spheroids (large arrowheads), dystrophic neurites (small arrows) and ballooned neurites 
(large arrows). Haematoxylin and eosin staining of homozygous ThylmySN spinal cords also revealed 
occasional eosinophilic cytoplasmic inclusion (right insert). Abnormally intense staining for gamma- 
synuclein is detected in descending axons (red arrowheads) in lateral columns of the homozygous 
ThylmySN spinal cords (b). Western blot analysis of spinal cord gamma-synuclein levels in high salt 
(HS), HS/Triton-X10o (HS/T), RIPA- and SDS-soluble fractions collected from wild type, hemi- and 
homozygous ThylmySN mice (c). Double immunofluorescent staining with antibodies against ubiquitin 
(1:100) (green) and gamma-synuclein (SK23 1:100) (red) of severely affected homozygous Thy1 mySN 
mouse spinal cord sections (d). Dystrophic neurites and spheroids positive only for gamma-synuclein 
are marked with arrowheads, positive only for ubiquitin with small arrows and positive for both proteins 
with large arrows. Scale bars a=50/ym, insert=20/vm; b, c = 50 pm. Adapted from Ninkina et al. 2009.
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Fig. 10. Amyloid positive aggregates are present in the spinal cords of symptomatic homozygous 
ThylmySN mice. Representative Congo red staining of the spinal cords of wild type (a), hemizygous
(b), mildly (c) and severely (d) affected homozygous ThylmySN mice. Amyloid positive aggregates 
appear as bright red dots. Mean numbers of aggregates counted per 0.1mm2 region of 12-month old 
spinal cord analyzed (e) (Mean ± SEM, Kruscal-Wallis, Fisher’s a priori test *** p<0.001). Scale bars a- 
d Insert = 160/;m, main panel = 40/ym. Number of animals: wild type, homozygous (severe) and 
hemizygous = 5, homozygous (mild) = 4. Number of sections sampled: wild type = 104, mildly affected 
homozygous ThylmySN 72, severely affected homozygous ThylmySN 93, hemizygous ThylmySN 
121. Adapted from Ninkina et al. 2009.
3.3.3. Spinal motor neuron population quantification
The presence of gamma-synuclein positive inclusion bodies and widespread gliosis within the spinal 
cord of homozygous Thylm ySN mice, combined with the profound motor deficits they develop 
suggested the likelihood of damage to spinal motor neurons. Nissl staining allowed us to quantify this 
population of cells in the same twelve-month old sample groups used for the assessment of amyloid 
deposition (Fig. 11a-d). Quantification revealed significant numbers of spinal motor neurons were lost 
throughout the spinal cord in all transgenic groups (One-way ANOVA, Fisher’s a priori test, p<0.001) 
(Fig. 11e). The loss of spinal motor neurons correlated with the presence of amyloid positive 
structures. Accordingly the greatest cell loss occurred in the advanced stage homozygous ThylmySN 
mice, with a mean loss of 62.7%. Both the mildly affect homozygous ThylmySN and hemizygous 
ThylmySN mice also had highly significant motor neurons losses of 52.5 and 35.6% respectively. 
Similar results to mean values were obtained from cervical, thoracic and lumbar levels of spinal cord 
(see appendix 2).
3.3.4. Spinal cord gliosis
A common response to the neurodegeneration of the CNS is the recruitment and activation of 
neuroglia, in particular activated astrocytes and microglia. We immuno-labelled transverse sections of 
spinal cord from two- and twelve-month old wild type and homozygous Thy 7mySN mice with 
antibodies raised against GFAP to detect activated astrocytes (Fig. 8b, 12a). For detection of activated 
microglia, samples were stained with biotinylated Ricinus Communis Agglutinin 1 (RCA), a lectin that 
bind to the glycoproteins specifically expressed by microglia (Mannoji et al. 1986) (Fig. 12b). In 
concurrence with the full cohort of motor neurons and the absence of inclusion bodies, neither 
activated astrocytes nor microglia were frequently observed within wild type spinal cords at either age 
sampled. At the age of two months a limited number of astrocytes were detected within the spinal 
cords of homozygous ThylmySN mice (Fig. 8b). Activated glia were substantially more abundant in 
the spinal cords of ThylmySN mice at the advanced stage of pathology. Large numbers of both micro- 
and astroglia were observed, with particularly high numbers present in the spinal grey matter (Fig 12a, 
b).
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Fig. 11. Spinal motor neurons are lost in ThylmySN mice. Representative Nissl staining of the ventral 
horn region of spinal cords from twelve-month old wild type (a), hemizygous (b), mildly affected (c) and 
severely affected homozygous ThylmySN mice (d). Number of motor neurons counted within the 
ventral horn region of the twelve-month old spinal cord sections analyzed (e) (Mean±SEM expressed 
as percentage of mean number from wild type, One-way ANOVA, Fisher’s a priori test *** p<0.001). 
Scale bar a-d = 50pm. Number of animals: wild type, homozygous (severe) and hemizygous = 5, 
homozygous (mild) = 4. Number of sections sampled wild type = 160, mildly affected homozygous 
ThylmySN 149, severely affected homozygous ThylmySN 195, hemizygous ThylmySN 285. 
Adapted from Ninkina et al. 2009.
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a Wild type Homozygous ThylmySN
Fig. 12. Gliosis in the spinal cord of twelve-month old ThylmySN mice. Representative transverse 
section of thoracic spinal cord from twelve-month old symptomatic homozygous ThylmySN and wild 
type control mice immunostained with antibodies against GFAP (1:400) (a) or biotinylated lectin RCA 
(1:100) (b). Neither activated astrocytes nor microglia were detected in spinal cord of wild type 
animals, however large numbers of both were detected in those of the homozygous ThylmySN mice. 
Scale bars = 50pm.
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3.3.5. Spinal cord chaperone distribution
Loss of spinal cord motor neurons has previously been attributed to dysfunction of chaperone proteins 
that facilitate the correct protein folding. The levels of HSP70 and HSP27/HSPB1, both common 
neuronal chaperones, were assessed by Western blotting, with increase levels of the latter detected in 
the spinal cords of symptomatic homozygous ThylmySN mice (data not shown). Immunostaining of 
transverse sections of spinal cord with antibodies against HSP27/HSPB1 revealed that this increase 
was not attributed to increased neuronal expression, which unexpectedly was considerably lower than 
that seen in wild type controls, but to high levels within the surrounding activated astrocytes (Fig. 13a).
3.3.6. Spinal cord neurofilaments
To assess whether changes in cytoskeleton composition were involved in the neuronal dystrophy 
observed, transverse spinal cord sections from twelve-month old homozygous ThylmySN at 
advanced stages of disease and age-matching wild type mice were labeled with antibodies against the 
neuron specific intermediate filaments NF-L, NF-M and NF-H (Fig. 13b). Though differences in NF-M 
and NF-H distribution between both groups were limited, pronounced changes were detected in NF-L. 
In wild type animals intense staining was seen in cell bodies and neurites, the latter being well defined 
morphologically. In aged homozygous ThylmySN mice NF-L staining was notably reduced in the cell 
bodies and virtually absent from emerging neurites. Though the presence of neurofilaments within 
inclusion bodies has been previously reported in synucleinopathies no such structures were found in 
experimental animals.
3.3.7. Interaction between gamma-synuclein and neurofilament-L
Gamma-synuclein overexpression has previously been reported to increase the susceptibility of 
neurofilament networks in cultured neurons to degradation by calcium dependent proteases through 
an unclear mechanism. To investigate whether the damage presented in ThylmySN mice was 
associated with direct interaction between the two proteins we immunoprecipitated soluble NF-L from 
the spinal cords of twelve-month old wild type and Thy1 mySN mice (Fig. 13c). Immunoprecipitation of 
NF-L was followed by analysis of levels of co-immunoprecipitated gamma-synuclein. We found high 
levels of gamma-synuclein co-precipitated with NF-L in all Thy7mySN groups and was not detected in 
wild type tissues. Interestingly the highest levels were detected in ThylmySN mice with only mildly 
affected by pathology at the age of twelve-months, suggesting that the association between gamma- 
synuclein and soluble NF-L may be a contributing factor in pathogenesis. Furthermore the association 
between gamma-synuclein and NF-L most likely occurs in intact or partially intact neurons, where at 
the later stages of disease neurons are either highly degenerate or lost entirely.
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Fig. 13. Changes in levels of spinal neurofilaments are linked to the binding of gamma-synuclein with 
soluble neurofilament-L. Representative double immunofluorescent staining of spinal cord sections 
from matching mice with antibodies against neurofilament-L (1:200, green) and HSPB1 (1:20, red) (a). 
Immunostaining against NF-L (1:250), NF-M (1:250) and NF-H (1:250) in transverse section of the 
ventral horn region of spinal cords from twelve-month old wild type and severely affected homozygous 
ThylmySN mice (b). Co-immunoprecipitation of gamma-synuclein and NF-L from cytosolic fractions of 
twelve month old spinal cord from wild type and ThylmySN mice (c). Scale bars a, b = 20pm. Adapted 
from Ninkina et al. 2009.
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3.4. Results: Brain pathology
We have previously confirmed levels of gamma-synuclein protein to be high in the brain of ThylmySN 
mice (Fig. 2). To further characterise the anatomical distribution of Thy1-driven expression of gamma- 
synuclein in the brain, we immunostained sagittal brain sections of severely symptomatic twelve­
month old homozygous Thylm  ySN mice with affinity purified SK23 antibodies raised against the 
protein. Brain sections of age matched wild type mice were stained for control.
3.4.1. Gamma-synuclein in the cerebellum
In the wild type cerebellum low levels of gamma-synuclein were restricted to the Purkinje cell layer 
(Fig. 14c), with no staining detected in either the molecular or granular layers (Fig. 14b, c). Low levels 
of gamma-synuclein were also detected within the white matter tracts. In homozygous Thy1 mySN 
cerebellum comparable levels of staining were detected in the Purkinje cell layer (Fig. 14f), but axonal 
staining within the white matter region (Fig. 14e) and granular layers (Fig. 14f) was substantial. 
Beaded neurites and axonal spheroid were frequent throughout both structures. Without quantification 
of neuron survival, the consequence of such high levels of gamma-synuclein in the cerebellum is 
unclear.
3.4.2. Gamma-synuclein in the hippocampus
Gamma-synuclein was restricted to the dentate gyrus of the wild type hippocampus (Fig. 15a). Axons 
within the granular layer were gamma-synuclein positive, as were infrequent neurons within the hilus 
(Fig. 15d). No staining was observed within either the CA1 (Fig. 15b) or CA3 (Fig. 15c) regions. 
Similar cells within the dentate gyrus hilus were found to be stained in homozygous Thy1 mySN mice 
(Fig. 15h). However granular cells axon staining was substantially more pronounced and accompanied 
by perikaryal staining in granular cells (Fig. 15h). Furthermore diffuse neuropil staining was seen in 
CA1 (Fig. 15f) and CA3 (Fig. 15g) regions, in addition to high levels of staining within the perikaryal 
cytoplasm of pyramidal neurons. Abnormal inclusion bodies were not observed in any neurons of the 
homozygous Thy1 mySN hippocampus. Quantification of hippocampal neuron population survival and 
analysis of hippocampal dependent functions, for example memory, are required to further assess the 
effects of gamma-synuclein expression in the hippocampus. Unfortunately these experiments are 
beyond the scope of this project.
3.4.3. Gamma-synuclein in the olfactory tubercle
In wild type mice low-level endogenous gamma-synuclein was detected in the perikaryal cytoplasm of 
olfactory tubercle mitral cells (Fig. 16b). No further staining was detected. In homozygous Thy1 mySN 
mice, diffuse neuropil staining was observed throughout the olfactory tubercle (Fig. 16c). Furthermore 
both the cell bodies and processes of mitral neurons were densely stained for gamma-synuclein (Fig. 
16d), though intracellular inclusion bodies were not detected. Punctate staining was detected 
throughout the granular layer (Fig. 16d).
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Fig. 14. Gamma-synuclein distribution in the cerebellum. Representative images showing gamma-synuclein immunostained (SK23, 1:100) sagittal sections 
(lateral 1.44mm) of cerebellum from twelve-month old wild type (a-c) and homozygous Thy1 mySN (d-f) mice. High magnification images of the 6th cerebellar 
lobule white matter (b, e), Purkinje and granular layers (c, f). Arrows = Purkinje cell layer. Scale bars a, d = 250pm, b, c, e, f = 25pm.
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Fig. 15. Gamma-synuclein distribution in the hippocampus. Representative images showing gamma- 
synuclein immunostained (SK23, 1:100) sagittal sections of twelve-month old wild type (a-d) and 
homozygous Thy1 mySN (e-h) hippocampal regions CA1 (b, f), CA3 (c, g) and the dentate gyrus (d, h). 
Scale bars a, e = 250/vm, b-d, f-h = 50pm.
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Fig. 16. Gamma-synuclein distribution in the olfactory tubercle. Representative images showing 
gamma-synuclein immunostained (SK23, 1:100) sagittal sections (lateral 1.44mm) of twelve-month old 
wild type (a) and homozygous Thy1 mySN (c) olfactory bulbs. High magnification images (c, d) 
showing mitral cell bodies (black arrows) and punctate staining (white arrows). Scale bars a, c = 
100pm, b, d, f, h = 25pm, e, g = 250pm.
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3.4.4. Gamma-synuclein in the nigra-striatal system
The nigra-striatal system, composed of the substantia nigra pars compacts (SNpc) and its projections 
into the striatum, is the focus of much attention in synucleinopathy and PD research. In both familial 
and idiopathic forms of PD alpha-synuclein has been found in cytoplasmic Lewy bodies within 
dopaminergic neurons of the SNpc. Furthermore the SNpc dopaminergic population becomes 
substantially depleted during the course of PD progression, resulting in the movement deficits typical 
of the disease. We aimed to assess if similar dystrophic characteristics were present in twelve-month 
old homozygous Thylm  ySN mice.
For morphological analysis, the striatum and SNpc were identified in sagittal brain sections by 
immunostaining with antibodies against tyrosine hydroxylase, an enzyme essential for the synthesis of 
dopamine specific to dopaminergic neurons. The striatum consists of a “matrix” region of medium 
spiny neurons striated by “white matter tracts” containing bundles of axons. The SNpc contains a 
discrete cluster of DA neurons located within the midbrain. Tyrosine hydroxylase immunostaining 
revealed no gross changes in the morphology of either structure in twelve-month old homozygous 
Thylm ySN mice (Fig. 17d, j) in comparison to control animals (Fig. 17a, g).
Assessment of inclusion body formation was carried out through immuno-staining with affinity-purified 
antibodies against gamma-synuclein. In control wild type brains staining was found to be absent from 
matrix regions and white matter tracts of the striatum (Fig. 17b, c), with only very low levels detected in 
the dopaminergic cells of the SNpc (Fig. 17h, i). In age matched homozygous Thylm  ySN tissue, 
diffuse neuropil staining accompanied by widespread punctate staining was seen throughout both 
structures, including the striatal matrix. The striatal white matter tracts contained axons densely 
stained for gamma-synuclein, many with an abnormal, disordered morphology (Fig. 17f). Though 
some densely stained cells were observed, gamma-synuclein staining was largely absent from the 
dopaminergic cells of the SNpc (Fig. 17k), most likely due to the weak expression of the Thy1 
promotor within this cell type (van der Putten et al. 2000). Abnormal axonal inclusion structures were 
observed throughout the SNpc, with beaded neurites and spheroids widespread (Fig. 171).
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Fig. 17. Gamma-synuclein expression in the nigra-striatal system.
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3.4.5. Dopaminergic neuron survival and function
To assess whether gamma-synuclein was affecting the survival of dopaminergic neurons we 
stereotactically quantified the population of tyrosine hydroxylase positive cells in the SNpc (Fig. 18c) 
and VTA (Fig. 18d, appendix 3) of a small group of homozygous Thy1 mySN and wild type mice. A 
sample group of coronal serial sections were counted, with an estimation of total number calculated by 
Aberchrombie correction. No significant differences were found in either the SNpc (p=0.2491, Mann- 
Whitney U-test) or the VTA (p=0.4712, Mann-Whitney U-test).
Though a full complement of dopaminergic neurons projecting into the striatum were present in the 
homozygous Thy1 mySN mice, the function of these cells may have been compromised. To investigate 
whether the release and metabolic turnover of dopamine was normal we dissected the dorsal striatum 
from twelve-month old animals for analysis of neurochemicals by HPLC (Fig. 19). No significant 
differences were detected in the levels of dopamine (p=0.2556, and its metabolites 3,4- 
dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) (p=0.4168 & p=0.2556 respectively, 
Mann-Whitney U-test), or those of the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) 
(p=0.8710, Mann-Whitney U-test) and norepinephrine (p=0.6162, Mann-Whitney U-test) (Fig. 19a, 
appendix 4). The level of dopamine metabolic turnover can be estimated from the ratio of dopamine to 
its metabolites HVA and DOPAC (Fig. 19b, c). Again no significant differences were detected in either 
ratio between wild type and homozygous Thy1 mySN mice (p=0.4168 & p=0.6261 respectively, Mann- 
Whitney U-test).
* * ★
Fig. 17 - previous page. Gamma-synuclein expression in the nigra-striatal system. Representative 
tyrosine hydroxylase immunostained (1:1000) sagittal sections (lateral 1.44mm) of twelve-month old 
wild type and homozygous Thy1 mySN striatum (a,d) and substantia nigra pars compacts (g, j). 
Corresponding section immunostained with antibodies against gamma-synuclein (SK23, 1:100) show 
tracts of axons within the striatum of transgenic mice (e), some being dystrophic (f), which were not 
visible in the wild type animals (b, c). Staining of the ThylmySN striatal matrix is low, though higher 
than the endogenous level seen in wild types. Gamma-synuclein labelling is absent from the 
dopaminergic cell bodies of the substantia nigra pars compacts of both wild type (h, i) and 
homozygous Thy1 mySN (k, I) mice, though spheroids and tracts of axons are present in the latter. 
Arrows = dystrophic axons, arrowheads = axonal spheroids, scale bars a, b, d, e = 250/vm; g, h, j, k = 
100/vm; c, f, i, I = 25pm.
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Fig. 18. No loss of dopaminergic neurons from the SNpc or VTA of homozygous ThylmySN mice. 
Representative images of transverse sections of brain from twelve-month old wild type (a) and 
homozygous ThylmySN mice (b) immunostained with antibodies against tyrosine hydroxylase 
(1:100). Quantification of dopaminergic neuron populations from the SNpc (c) or VTA (d) of the above 
mice (mean±SEM). Insert number denotes number of respective regions quantified, derived from three 
animals in each group.
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Fig. 19. Striatal neurotransmitter levels and dopamine turnover are unaffected in homozygous 
ThylmySN mice, (a) Striatal levels of dopamine, DOPAC, HVA, 5-HIAA and norepinephrine in twelve­
month old wild type and homozygous ThylmySN mice. Ratio of striatal dopamine to metabolites (b) 
DOPAC and (c) HVA. All bars show mean±SEM. WT n = 5, homozygous Thy1 mySN n = 7.
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3.4.6. Gamma-synuclein in the cerebral cortex
The cerebral cortex is the largest structures in the mammalian brain comprising of two lobes, one on 
each hemisphere. The cortex carries out a vast number of functions involved in the processing of 
information, learning and perception. The mouse cortex comprises of three main regions; the motor 
region, which contains upper motor neurons, initiates and controls movement, the somatosensory 
region that receives and processes sensory information and the visual cortex, which processes visual 
information.
Endogenous gamma-synuclein immuno-labelling was weak in all regions of the cortex of twelve-month 
old wild type control mice (Fig. 20aj). In contrast high levels were seen in the homozygous Thy1 mySN 
cortex (Fig. 20ajj). Diffuse neuropil and punctate staining was found throughout the cortex, with a large 
proportion of neuron in layers 3 and 5 containing dense staining for gamma-synuclein. Intracellular 
inclusions, dystrophic neurites and extracellular axonal spheroids were detected throughout the cortex, 
however their frequency appeared to be in a rostral-caudal gradient (Fig 21 a^, being more in motor 
regions (Fig. 21a) than somatosensory (Fig. 21b) and visual regions.
The above data suggested a difference in the ability of overexpressed gamma-synuclein to produce 
pathological changes, e.g. inclusion bodies, in different populations of neurons, with cortical motor 
areas been more vulnerable than sensory. To further investigate this hypothesis we investigated the 
solubility of gamma-synuclein in the motor and somatosensory cortex regions of twelve-month old 
homozygous ThylmySN mice (Fig. 21 d). As with spinal cord (see above), a proportion of gamma- 
synuclein was found to be insoluble in high salt, ionic detergent containing buffer in both cortices. This 
insoluble gamma-synuclein was however more abundant in motor regions of the cortex than 
somatosensory regions.
3.4.7. Gliosis in the cerebral cortex
Few astro- or microglial cells were detected in the cortex of healthy, 12-month old wild type mice (Fig. 
21 bj, Cj). In the cortex of symptomatic homozygous ThylmySN mice the pattern of gliosis followed the 
same caudal-rostral gradient as the pattern of insoluble gamma-synuclein inclusions (Fig. 20bii-Cii, 
21b-c). Antibodies raised against GFAP detected a large population of activated astrocytes within 
motor regions of the cortex (Fig. 21 bj). Immunostaining with biotinylated RCA detected an additional 
large population of microglia in the same region (Fig. 21 Cj). In contrast both populations were found to 
be fewer in number in somatosensory and visual regions of the cortex (Fig. 21 bn, Fig c,,).
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Fig. 20. Gamma-synuclein expression and gliosis in the cortex. Representative sagittal sections of cortex from twelve-month old wild type (aj, bj, Cj) and 
homozygous ThylmySN mice (an, bn, Cn) immuno-stained with antibodies raised against gamma-synuclein (SK23, 1:100) (a), GFAP (1:400) (b) and 
biotinylated lectin RCA (1:100) (c). Arrows = astroglia, arrowheads = microglia. Scale bars = 1mm.
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Fig. 21. Gamma-synuclein accumulation and gliosis in the ThylmySN cortex. Representative gamma- 
synuclein (SK23, 1:100) (a), GFAP (1:400) (b) and RCA (1:100) (c) immunostained sagittal sections 
(lateral 1.44mm) of twelve-month old ThylmySN motor cortex (aj, bj, q) and somatosensory cortex (an, 
biit Ch). Western blot analysis of gamma-synuclein in high salt (HS), HS/Triton X-100 (HS/T), RIPA- and 
SDS-soluble fractions of motor and somatosensory cortices (d). The distribution of gamma-synuclein 
is consistent in both motor (aj) and somatosensory (an) regions of the cortex, however abnormal 
perikaryal and axonal inclusions (insert aj) and insoluble forms of the protein (d) are most prominent in 
the former. Levels of astrogliosis (b) and microgliosis (c) were distinctly higher in the ThylmySN motor 
cortex (bj and Cj respectively) than the somatosensory cortex (bjj and Cn respectively). Arrow = axonal 
spheroid, arrowhead = perikaryal accumulation. Scale bars = 50^m.
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3.4.8. Survival of cranial motor neuron populations
Substantial losses were detected in the spinal cord population of lower motor neurons in severely 
symptomatic twelve-month old homozygous Thy7mySN mice (see above). We aimed to further 
assess the survival of lower motor neurons in discrete nuclei of the mouse hindbrain. We 
stereologically counted the motor neurons in the abducens (Fig. 22a,b), facial (Fig. 22c,d) and 
trigeminal motor nuclei (Fig. 22e,f) on Nissl stained sections (also see appendix 5). Total number of 
neurons in each population was estimated using the fractionator technique. Unexpectedly we found 
that vulnerability of neurons to gamma-synuclein overexpression was not universal across these 
populations. Over a third of neurons were lost from the trigeminal motor nucleus (p=0.0013, Mann- 
Whitney U-test), comparable to the depletion seen in spinal cord populations (Fig. 22i). In contrast a 
full complement of neurons were found in both the abducens (p=0.9645, Mann-Whitney U-test) and 
facial nuclei (p=0.824, Mann-Whitney U-test) (Fig. 22g,h).
3.4.9. Gliosis in the proximity of cranial motor neurons
The pattern of differential lower motor neuron vulnerability observed was paralleled by the activation of 
the glia. Co-immunofluorescence with the neuron specific NeuN antibody and other raised against 
GFAP revealed a more numerous population of activated astrocytes in the vicinity of the vulnerable 
motor trigeminal nucleus (Fig. 23d) compared to the tolerant facial nucleus (Fig. 23b). Biotinylated 
RCA staining revealed a matching pattern of microglia activation, the cells being more frequent within 
the (Fig. 23f, h).
3.4.10. Neurofilament-L distribution in cranial motor neurons
Due to the relatively small size of cranial motor neuron nuclei accurate dissection is unfeasible. Thus 
quantitative Western blotting could not be used to accurately assess levels of cytoskeletal components 
and other techniques had to be used to observe any changes. Fluorescent immunostaining revealed 
no substantial loss of NF-L in either the tolerant facial nucleus (Fig. 24a,b) or vulnerable motor 
trigeminal nucleus (Fig. 24c,d). In both nuclei however infrequent neurons were found to contain 
accumulated perikaryal and axonal NF-L, though no typical inclusion bodies were detected (Fig. 
24b,d). Accumulation of NF-L was not seen in any of the wild type tissue (Fig. 24a,c).
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Fig. 22. Differential vulnerability of cranial motor neuron pools was seen in homozygous ThylmySN 
mice. Representative images of Nissl stained abducens (a, b), facial (c, d) and trigeminal motor (e, f) 
nuclei of wild type (a, c, e) and homozygous ThylmySN mice (b, d, f). Quantification of motor neuron 
population in the abducens (g), facial (h) and trigeminal motor nucleus (i). (mean±SEM, Mann-Whitney 
U-test ** p<0.001). Scale bar a-f = 25nm. Each group contained five animals, the insert number 
denoting the total number of nuclei counted.
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Fig. 23. Differential activation of gliosis in cranial motor neuron populations. Representative transverse 
sections of facial (a, b, e, f) and trigeminal motor nuclei (c, d, g, h) from twelve-month old wild type and 
homozygous ThylmySN mice stained with antibodies raised against NeuN (1:100) (green) and GFAP 
(1:400) (red) (a-d) or biotinylated lectin RCA (1:100) (e-h). Scale bars = 50(xm.
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Fig. 24. Accumulation of neurofilaments in cranial lower motor neurons. Representative images of NF- 
L (1:250, green) and GFAP (1:400, red) fluorescent immunostaining in the facial (a, b) and trigeminal 
motor (c, d) nuclei of wild type (a, c) and homozygous ThylmySN mice (b, d). Arrows = cells 
containing excessive neurofilament-L staining. Scale bar = 20/vm
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3.5. Results: Dorsal root ganglion pathology
Gamma-synuclein overexpression results in the loss of select populations of lower motor neurons. 
Furthermore morphological analysis of the cortex suggests that effect upon motor and sensory neuron 
populations in this brain region is also selective, with sensory neurons appearing resistant to damage. 
To further test this hypothesis, we assessed the survival and morphology of the discrete pool of 
sensory neurons contained within dorsal root ganglia.
3.5.1. Gamma-synuclein expression in dorsal root ganglia
Expression of gamma-synuclein in wild type adult dorsal root ganglia (DRGs) has been reported 
previously (Buchman et al. 1998b). Furthermore we have found that in ThylmySN transgenic mice, 
gamma-synuclein mRNA expression in the DRG was seven-fold that of the wild type levels and 
comparable to the level of in expression their spinal cord (Fig. 2c). Through immuno-staining we 
confirmed the presence of gamma-synuclein protein in L4/5 DRGs collected from twelve-month old 
wild type mice (Fig. 25a), with diffuse cytoplasmic staining in all neuron cell bodies. DRGs collected 
from age matched, severely affected, homozygous ThylmySN contained a higher level of cytoplasmic 
staining (Fig. 25b). In contrast to motor neurons however all sensory neurons examined were free of 
both intra- and extracellular gamma-synuclein positive inclusion structures.
3.5.2. Amyloid staining in dorsal root ganglia
Thioflavin-S staining unexpectedly revealed the presence of granular amyloid structures, that 
appeared to be extracellular or possibly intra-axonal, and also fibrous amyloid material within the 
cytoplasm of a small fraction of cells (Fig. 26b, d). Such structures were not found in wild type tissue 
(Fig. 26a, c). Though gamma-synuclein positive inclusion bodies were not detected in sensory 
neurons, it was feasible that other protein may form such structures, for example such as the ubiquitin 
positive gamma-synuclein negative structure that were found in the spinal cord (see above). 
Immunostaining against neurofilaments (Fig. 25d) and ubiquitin (Fig. 25f) however did not reveal any 
structures. Thus the composition of the sensory amyloid structures remains unclear.
3.5.3. Assessment of gliosis in dorsal root ganglia
Neuroinflamation was investigated by immunostaining of DRGs from twelve-month old wild type and 
severely symptomatic homozygous ThylmySN mice with antibodies raised against GFAP for 
astrogliosis (Fig. 27a,b) and biotinylated RCA for assessment of microgliosis (Fig. 27c,d). Neither cell 
type was found activated in the DRGs of homozygous ThylmySN mice (Fig. 27b, d).
3.5.4. Dorsal root ganglion sensory neuron population quantification
Though gliosis was not detected, the presence of amyloid structures suggested possible damage to 
sensory neurons. Thus we carried out Nissl staining to quantify the population of sensory neurons 
contained within the L4/5 DRGs of 12-month old wild type and homozygous ThylmySN mice (Fig. 28, 
appendix 5). For each mouse all four ganglia were serial sectioned, a sample portion stereologically
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counted and total population estimated using the fractionator technique. Significant difference was not 
detected between the mean total population of wild type and homozygous Thy1 mySN mice (p=0.441, 
Mann-Whitney U-test).
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Fig. 25. Dorsal root ganglia of homozygous ThylmySN mice do not contain inclusions positive for 
gamma-synuclein, NF-M or ubiquitin. Representative images of lumbar DRGs immuno-stained for 
gamma-synuclein (1:100) (a,b), NF-M (1:250) (c, d) and ubiquitin (1:250) (e, f) from wild type (a, c, e) 
and homozygous ThylmySN (b, d, f) mice. Scale bars a-f = 25pim.
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Fig. 26. Dorsal root ganglia of ThylmySN mice contain amyloid-like structures. Representative 
thioflavin-S staining of L4/5 DRG of twelve-month old wild type (a, c) and homozygous ThylmySN 
mice (b, d). Arrows = intracellular fibrous amyloid positive material. Arrowheads = granular structures. 
Scale bar a, b = 200um, scale bar c, d = 25p,m.
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Fig. 27. Neither astrocytes nor microglia are activated in the dorsal root ganglia of homozygous 
ThylmySN mice. Representative section of L4/5 DRG from twelve-month old wild type and 
homozygous ThylmySN mice immunostained with antibodies against GFAP (1:400) (a, b) and 
biotinylated lectin RCA (1:100) (c, d). Scale bars = 25jaiti.
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Fig. 28. The population of sensory neurons in lumbar dorsal root ganglia is unchanged in ThylmySN 
mice. Quantification revealed no loss in the population of neurons found within L4/5 dorsal root 
ganglion (mean±SEM, Mann-Whitney U-test). Insert number denotes the total number of ganglia 
quantified, with each group containing eight animals.
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3.6. Summary of results and discussion
The overexpression of both wild type and mutant forms of alpha-synuclein in the murine nervous 
system has been robustly linked to its degeneration (see section 1.3.). In contrast, the overexpression 
of wild type beta-synuclein has no impact on the nervous system (Hashimoto et al. 2001), though a 
mutant form has recently been shown to induce toxicity (Fujita et al. 2010). To test whether gamma- 
synuclein overexpression was able to induce degeneration in a similar manner to alpha-synuclein, a 
line of C57BI/6J mice expressing high levels of murine gamma-synuclein within the nervous system 
was generated. A Thy1 expression cassette was chosen for generation of transgenic mice, as the 
promoter is strongly and selectively expressed in neurons and thus has previously been utilized in the 
production of several model systems of neurodegeneration (for example van der Putten et al. 2000). 
Secondly the Thy1 expression cassette in not expressed until P4-10 (Aigner et al. 1995), and therefore 
any neurological effects could be attributed to postnatal transgene expression and not developmental 
defects.
Gamma-synuclein overexpression was found to have a devastating effect upon the nervous system of 
ThylmySN mice, inducing an age- and dose-dependent neurological phenotype characterised by 
deficits in motor function and a significantly reduced lifespan (Fig. 3). This motor function deficiency 
clearly not caused by damage or dysfunction of the nigra-striatal system, with neither dopaminergic 
cell number or striatal neurotransmitter concentration diminished (Fig. 18, 19). Similar to mice with 
Thy1 controlled alpha-synuclein overexpression (van der Putten et al. 2000), motor dysfunction in 
ThylmySN mice was attributed to the gradually developing damage of spinal cord motor neurons and 
their axons. Widespread depletion of spinal motor neurons was accompanied by deposition of 
gamma-synuclein in perikaryal and axonal inclusion bodies, in addition to substantial gliosis (Fig. 8 , 9, 
12). Similar inclusion formation and gliosis was observed in the brain of homozygous ThylmySN mice, 
though the extent varied between regions (Fig. 14-17, 20). Surprisingly both inclusion bodies and 
gliosis were absent from the DRGs of affected animals (Fig. 25-27).
3.6.1. Effects of gamma-synuclein overexpression are dose dependent
Gamma-synuclein overexpression in the ThylmySN line induced toxicity in a dose dependent manner. 
A preliminary line of mice generated alongside the ThylmySN line carried a low gamma-synuclein 
transgene copy number and did not develop a detectable phenotype (see section 1.8.). Homozygous 
ThylmySN mice, in which transgene copy number was substantially greater than that of the low copy 
number line, developed visible signs of neurodegeneration such as hind-limb clasping from five- 
months of age, with symptoms leading to death from approximately eight months (Fig. 3). The onset of 
visible clinical signs in hemizygous ThylmySN mice (where copy number was half that of homozygous 
ThylmySN mice) occurred much later in life, from twelve-months of age onwards, with death generally 
occurring between 18- and 24-months. This dose-dependent development of symptoms was 
confirmed by analysis of motor function by rotarod. In both constant and accelerating test modes 
homozygous ThylmySN mice were found to develop significant differences at least fourteen-months
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prior to the onset of deficits in hemizygous ThyfmySN mice (Fig. 4). This positive correlation between 
transgene copy number and onset of clinical signs was expected. What is less clear is why such a 
high level of ThylmySN transgene expression is necessary to induce neurodegeneration. A similar 
situation is presented by alpha-synuclein. In familial cases of human PD both duplication and 
triplication of SNCA are sufficient to induce the symptoms of disease (Chartier-Harlin et al. 2004; 
Ibanez et al. 2004; Singleton et al. 2004) Mouse models of alpha-synucleinopathy however require 
substantially higher levels of transgene overexpression to induce neuronal dystrophy (for examples 
see section 1.7.). Why high levels of expression are required is unclear, but is most likely due to an 
increased load of protein toxicity being required to induce neurodegeneration during the relatively short 
lifespan of the mouse.
A striking feature of the gamma-synuclein overexpression induced pathology observed in the 
ThylmySN line was its selective nature. This selectivity was found to occur not only between motor 
and sensory neurons, but also between different populations of motor neurons.
3.6.2. Tolerance of sensory neurons to gamma-synuclein overexpression
Peripheral and central sensory neurons were found to be either resistant, or substantially less 
vulnerable to ThylmySN transgene induced toxicity than motor neuron populations. This bias towards 
motor dysfunction was detected in both the behaviour of the transgenic mice and following histological 
analysis of neuron populations. Where motor performance analysis robustly demonstrated deficits that 
progressed with age (Figs. 4-6), studies of withdrawal response to tactile stimulation indicated that 
changes in sensory function were not progressive, though older homozygous ThylmySN mice did 
have a lower response than age-matched control animals (Fig. 7). This deficit in the oldest animal is 
likely to be due to significant motor deficits impeding their response to tactile stimulation. Analysis of 
homozygous ThylmySN data alone showed no significant change in performance (Fig. 7d), 
contrasting wild type mice in which an improvement in tactile sensitivity was observed (Fig 7a-c). 
Thus any effects of gamma-synuclein overexpression upon tactile sensitivity are limited. In spite of 
comparable levels of ThylmySN mRNA expression (Fig. 2), sensory neuron cells bodies of the dorsal 
root ganglia and sensory regions of the cortex appeared significantly less vulnerable to the pathology 
that compromised the motor system. The DRG sensory neuron population was undiminished, and 
neither gamma-synuclein positive inclusion bodies nor activated glia were detected (Figs. 26-28). With 
regard to sensory regions of the cortex, gamma-synuclein positive inclusions, concentration of 
insoluble forms of gamma-synuclein and numbers of activated glia were all lower than in adjacent 
motor regions (Fig. 20-21).
The potential involvement of gamma-synuclein in sensory neuropathies is not without precedent, 
having been identified in mouse models of two neurodegenerative disorders affecting sensory 
neurons. In DBA/2J mice, a line that spontaneously develop glaucoma, spheroids containing gamma- 
synuclein have been identified in the axons of retinal ganglion cells, a population of sensory fibres that
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form the optic nerve (Nguyen et al. 2011). Furthermore, accumulation of gamma-synuclein within 
astrocytes has been identified in mouse models of glaucoma and in the optic nerves of humans 
suffering from the disease (Nguyen et al. 2011; Surgucheva et al. 2002). The development of gracile 
axonal dystrophy in UCH-L1 null mice is accompanied by the formation of spheroid inclusion 
structures containing gamma-synuclein (Wang et al. 2004). In both these examples however, gamma- 
synuclein predominantly is found in axonal inclusion bodies, and not found to accumulate in perikaryal 
cytoplasm of sensory neurons. It thus is necessary to access the condition of sensory axons in 
Thy1 mySN mice prior to making conclusions with regard to the resistance of sensory neurons to 
gamma-synuclein overexpression. This analysis shall be detailed in the following chapter.
3.6.3. Differential vulnerability of motor neuron populations
In contrast to sensory neurons, motor neurons were vulnerable to gamma-synuclein overexpression 
induced degeneration, however the loss of the cells appeared to be highly selective. Those of the 
spinal cord were universally sensitive, with significant deficits found at all spinal cord levels (Fig. 11). 
Cranial lower motor neuron populations however showed a profile of differential 
vulnerability/resistance (Fig. 22). Comparable with the spinal pool, depletion of over 30% was 
recorded within the motor trigeminal nucleus that innervates masticatory muscle. In contrast both the 
orofacial-innervating facial nucleus and the occulomotor-innervating abducens nucleus contained a full 
complement of motor neurons. Further evidence of selective neuronal dystrophy was suggested by 
uneven distribution of the population of activated glia in the brains of homozygous ThylmySN mice. 
Numbers of activated micro- and astroglial cells within the facial and abducens nuclei were 
comparable to those in the surrounding tissue. In the degenerating motor trigeminal nuclei however, 
numbers of both activated mico- and astroglial cells were notably higher than surrounding tissues, 
suggesting their increased infiltration in response to neurodegeneration (Fig. 23). Increased numbers 
of activated glial cells was also a prominent feature of motor regions of the cortex of ThylmySN mice 
(Fig. 20).
Degeneration of spinal cord neuron populations has been previously observed in models of alpha- 
synucleinopathies. Loss of spinal motor neurons has been reported in numerous lines of transgenic 
mice overexpressing alpha-synuclein (Giasson et al. 2002; Lee et al. 2002; van der Putten et al. 
2000). There is however no published evidence of either the selective loss/survival of cranial motor 
neurons or the discrete dystrophy of cortical motor regions in these mice. A similar pattern of motor 
loss does however occur in amyotrophic lateral sclerosis (ALS), a common form of motor neuron 
disease. More so, this pattern has been well recapitulated in transgenic mouse models of the disease. 
The familial and sporadic ALS are characterised by substantial loss of motor function through the 
selective loss of both upper motor neuron pools in the motor regions of the cortex, and lower motor 
neuron pools in the brainstem and spinal cord (Wijesekera and Leigh 2009), though it should be noted 
that mild changes in sensory function have been also been reported (Hammad et al. 2007; Isaacs et 
al. 2007; Pugdahl et al. 2007). The selective loss of motor neurons in cranial nuclei described in
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Thy1 mySN mice is also a frequently observed characteristic of ALS. Moreover, observed mouse 
pathology shares the selectivity pattern with the human disease. Generally motor neurons innervating 
orofacial muscles degenerate during the course of ALS progression, contributing in symptoms 
including dysphagia and dysarthria. These vulnerable populations include the facial muscle- 
innervating facial nucleus, the motor trigeminal nucleus that stimulates muscles involved in mastication 
and the tongue-innervating hypoglossal nucleus (Kiernan and Hudson 1991). In contrast motor 
neurons located in nuclei that innervate targets in the occulomotor system appear to resist 
degeneration. Both the abducens and occulomotor nuclei have been found to remain intact late into 
disease, allowing some ALS patients to retain some degree of eye movement (Wijesekera and Leigh 
2009).
The pattern of motor neuron loss observed in human cases of ALS is recapitulated in transgenic 
mouse models of the disease. Spinal motor neurons are lost from all levels of the spinal cords during 
the progression of ALS pathology. The spinal cord motor neuron population of end-stage SOD1G93A 
mice is reduced by 50-60% (Chiu et al. 1995; Kanning et al. 2010; Kong and Xu 1998). The largest 
volume motor neurons appear most vulnerable to degeneration, being diminished by over 90% in end- 
stage mice (Kong and Xu 1998). A significant increase in the populations of activated astrocytes 
(Gould et al. 2006) and microglia (Saxena et al. 2009) has also been found to correlate with the 
progression of motor neuron loss in the spinal cords of SOD1G93A mice. In the more recently 
developed TDP-43 transgenic mouse lines, spinal motor neurons have been found more modestly 
depleted by 20-25% (Shan et al. 2010; Wegorzewska et al. 2009; Wils et al. 2010). In addition to loss 
of spinal cord motor neurons, brainstem populations are also selectively diminished in mutant SOD1 
transgenic mice. Several groups have carried out detailed quantification of brainstem motor neuron 
populations in mutant SOD1 transgenic mouse lines, where a relatively consistent pattern is observed 
(Ferrucci et al. 2010; Haenggeli and Kato 2002; Nimchinsky et al. 2000; Zang et al. 2004). Motor 
neurons pools innervating oromotor targets, including the hypoglossal nucleus, dorsal vagus nucleus, 
motor trigeminal nucleus and facial nucleus are found to be significantly susceptible to SOD1G93A and 
SOD1G86R induced degeneration. In 120 day old, end-stage SOD1 mutant mice, losses of up to 70% 
have been reported in the tongue innervating hypoglossal nucleus (Ferrucci et al. 2010) and up to 
50% in the facial muscle-innervating facial nucleus (Nimchinsky et al. 2000; Zang et al. 2004) and 
mastication controlling motor trigeminal nucleus (Ferrucci et al. 2010). Furthermore, progressive motor 
neuropathy (pmn) and “wobbler” mice, that develop a spontaneous ALS-like motor neuron disease, 
both recapitulate these losses (Haenggeli and Kato 2002). In contrast to the consistent loss of 
oromotor motor neuron populations, those innervating occulomotor targets appear to be spared from 
degeneration. Pools of motor neurons within the eye muscle innervating occulomotor nucleus and 
abducens nucleus are found to be unaffected in both end-stage SOD1G93A and SOD1G86R transgenic 
mice (Ferrucci et al. 2010; Haenggeli and Kato 2002; Nimchinsky et al. 2000; Zang et al. 2004) and 
also spared in end stage wobbler mice (Haenggeli and Kato 2002). Inconsistency has however been 
noted in pmn mice, which were found to develop a highly significant loss of approximately 36% in the
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occulomotor nuclei (Haenggeli and Kato 2002). Currently there are no reports of quantification of 
brainstem motor neuron populations in TDP-43 transgenic mice.
Symptomatic homozygous ThylmySN mice partially recapitulated this typical ALS associated pattern 
of selective brainstem motor neuron degeneration. The 30% loss of motor trigeminal nucleus motor 
neurons and survival of those within the abducens nucleus was comparable to the reported findings in 
mutant SOD1 lines. The survival of facial nucleus does however present an inconsistency, as this 
population degenerates in both models of ALS and human cases of the disease. This discrepancy 
may be due to several factors. The level of Thy1 mySN transgene expression has been demonstrated 
in the above data, with hemizygous transgenic mice developing a delayed phenotype compared to that 
of homozygous mice. The lack of degeneration in the facial nucleus and abducens nucleus might be 
the result of transgene expression being below the level necessary to induce degeneration. The 
expression pattern of gamma-synuclein within cranial motor neurons of wild type mice might also 
suggest a factor in the survival of the facial nucleus. In contrast to all other cranial motor neuron 
populations where perikaryal gamma-synuclein translocates to the axon, the facial nucleus partially 
retains gamma-synuclein in the cytoplasm of the cell body (Ninkina et al. 2003). Thus as gamma- 
synuclein is normally present within the cell bodies of this populations, they might carry some degree 
of tolerance to the high levels expressed in homozygous mice. Finally, ALS is a diverse disorder, with 
familial cases associated with numerous genetic risk factors and sporadic disease with little evidence 
of causative factors. It therefore seems feasible that the pattern of neuronal degeneration seen in 
mutant SOD1 associated ALS might vary from that induced by gamma-synuclein overexpression. A 
more detailed assessment of motor neuron loss in spinal cord and cranial populations could be 
achieved by immunostaining against apoptotic markers, for example cleaved caspase-3, or the 
TUNEL staining technique. Both processes could be carried out at different time points during the 
development of pathology in transgenic mice, and might give us a more clear idea of the dynamics 
and time course of motor neuron loss in these populations.
In summary, the above data shows that the pan-neuronal overexpression of gamma-synuclein triggers 
an age- and dose-dependent neuronal dystrophy in mice with substantial loss of motor function. 
Affected animals develop dramatic motor deficits, whilst only subtle changes occur in tactile sensitivity. 
The phenotype is characterised by widespread loss of spinal motor neurons, selective loss of cranial 
motor neurons and dystrophy in motor regions of the cortex. In contrast sensory neurons of the dorsal 
root ganglion are not lost and dystrophy within sensory regions of the cortex is less pronounced than 
that seen in motor regions. The phenotype suggests that gamma-synuclein overexpression induces a 
process of selective degeneration comparable to that seen in ALS.
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4. Gamma-synuclein overexpression in the murine nervous 
system: The effect of gamma-synuclein upon motor and
sensory neu rites
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4.1. Overview
The previous chapter described the ability of gamma-synuclein to induce a selective neuronal 
dystrophy when overexpressed. Discrete populations of motor neuron cell bodies were lost from the 
spinal cord and brains of twelve-month old homozygous ThylmySN with severe clinical signs of 
neurodegeneration. In contrast the sensory neuron pool contained within dorsal root ganglia of these 
mice was complete, with only limited evidence of dystrophy. Furthermore behavioural analysis 
revealed a progressive loss of motor function in the homozygous ThylmySN mice that was not seen 
in sensory perception.
These data suggest it is feasible that gamma-synuclein might play a role in human disease that has 
yet to be fully elucidated. There is a small body of evidence in favour of this possibility. Gamma- 
synuclein has been detected in rare, atypical inclusion bodies, all of which are found in axonal lesions. 
Axonal spheroids have been reported in the hippocampal dentate molecular region in cases PD and 
dementia with Lewy bodies (Galvin et al. 2000) and also in the cingulate and midfrontal cortices in 
Hallervorden-Spatz sufferers (Galvin et al. 2000). Gamma-synuclein positive inclusions have also 
been reported in the sensory gracile and dorsal spinocerebellar tracts of gracile axonal dystrophy 
(gad) mice, a strain which develop a sensory ataxia (Wang et al. 2004). Furthermore atypical gamma- 
synuclein positive structures have been isolated in both human cases and animals of glaucoma 
(Buckingham et al. 2008; Nguyen et al. 2011; Soto et al. 2008; Surgucheva et al. 2002). The intra­
neuronal localization of gamma-synuclein, which differs substantially from the other members of the 
synuclein family, appears to be a factor in the formation of these structures. Whereas alpha- and beta- 
synuclein are restricted to presynaptic terminal within the brain, gamma-synuclein is found diffusely 
throughout the soma, neurites and synapses of select populations of CNS and PNS neurons 
(Buchman et al. 1998b).
In this chapter we shall assess the effect of gamma-synuclein overexpression upon discrete pools of 
motor and sensory axons in the sciatic nerve and its spinal nerve roots. In particular we shall focus on 
whether any degeneration seen is selective in nature, or affects all fibre types equally. Furthermore we 
shall assess the morphology of sensory fibres in optic nerve and the retinal ganglion cells from which 
they originate to determine whether gamma-synuclein overexpression can induce glaucoma-like 
symptoms.
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4.2. Results: Sciatic nerve
To investigate the effects of gamma-synuclein overexpression on neurites we investigated the 
morphology of the sciatic nerve. Composed of motor and sensory fibres emerging from dorsal and 
ventral lumbar spinal nerve roots, the sciatic nerve is the primary sensory-motor nerve in the hind 
limbs of mammals. The sciatic nerve was chosen over the equivalent forelimb medial nerve due to the 
earlier onset of motor deficits in the hind limbs.
Fluorescent gamma-synuclein immunostaining of longitudinal sections of sciatic nerve collected from 
twelve-month old wild type confirmed the expression and localization of the protein in the axonal 
cytoplasm (Fig. 29aj). Diffuse staining was found throughout the sciatic nerve, with some regions of 
punctate staining. Similar staining of age matched tissue from severely affected homozygous 
ThylmySN mice revealed dense staining throughout the sciatic nerve (Fig. 29aji). Many neurites were 
found to containing dense strands of gamma-synuclein positive material along the length of the axon, 
with others found to contain dense clusters of aggregated protein.
4.2.1. Neurofilament-L distribution in the sciatic nerve
Immunostaining revealed that gamma-synuclein overexpression results in a visible depletion of 
neurofilaments from axons and cell bodies within the spinal cord. To investigate if similar damage 
occurred in the sciatic nerve we immunostained longitudinal sections from twelve-month old 
symptomatic homozygous Thylm  ySN and wild type mice with antibodies raised against NF-L. In 
control sciatic nerves, NF-L was found uniformly localised throughout the length of the axons (Fig. 
29bi). In concurrence with the spinal cord, the level of NF-L was substantially diminished in the sciatic 
nerves of transgenic mice (Fig. 29bn). Though a portion of axons were normal in appearance, many 
axons were found to be totally absent of NF-L, whereas other contained regions of sparse staining.
4.2.2. Cytoskeletal proteins in the sciatic nerve
The reduction of sciatic nerve NF-L content observed in the above immunostaining experiment was 
confirmed through semi-quantitative western blotting (Fig 29c, Appendix. 6). In addition to NF-L, we 
measured the levels of several major axonal cytoskeletal proteins in the sciatic nerves of severely 
affected twelve-month old Thy1 mySN mice with severe motor phenotype, and also those with milder 
developing symptoms. In mildly affected homozygous ThylmySN mice significant reductions were not 
seen in neurofilaments-L, -M or -H , peripherin, alpha-tubulin or actin. Reductions of approximately 
39% and 66% were however respectively detected in the 21kDa and 18kDa isoforms of myelin basic 
protein, a major component of the axonal myelin sheath. In the severely affected group of 
homozygous ThylmySN mice reductions of over 50% were recorded for all neurofilaments, alpha- 
tubulin and both the 18kDa and 21kDa isoforms of myelin basic protein. Levels of peripherin and beta- 
actin were unaffected.
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Fig. 29. Gamma-synuclein disrupts neurofilament distribution in the sciatic nerve. Representative transverse sections of sciatic nerve from twelve-month old 
wild type (as, bj) and homozygous ThylmySN (a*, bjj) immunostained with antibodies against gamma synuclein (SK23, 1:100) (a) and neurofilament-L (1:250)
(b). Increased levels of gamma-synuclein were present in the axons of homozygous ThylmySN mice, including spheroid inclusion bodies (white arrows) 
accompanied by substantial reductions of NF-L. Representative Western blot showing levels of several neuronal structural proteins in the sciatic nerves of 
twelve-month old, severely symptomatic homozygous ThylmySN and healthy control mice (c). Adapted from Ninkina et al. 2009.
Neurofilament-L
115
4.2.3. Ultrastructure analysis of the sciatic nerve
The substantial losses of axonal and myelin cytoskeletal component in the nerves of severely affected 
homozygous ThylmySN mice suggested substantial alteration to the structure of the fibres composing 
the nerve. To further investigate the morphology of the axonal ultrastructure we prepared samples of 
sciatic nerve from twelve month old, severely affected homozygous ThylmySN and age-matched 
control mice for analysis by transmission electron microscopy (TEM). The wild type sciatic nerve 
contains two type of fibre (Fig. 30a). A-fibres are composed of a single axon enveloped by a Schwann 
cell, and vary in size depending on their velocity of transmission and neuron type. The sciatic nerve 
contains both afferent sensory and efferent motor A-fibres. C-fibres are a smaller class of 
unmyelinated axons, normally found packaged into bundles that were tightly enveloped by a single 
Schwann cell. All C-fibres in the sciatic nerve are derived from sensory neurons. Both fibre classes 
making up the control sciatic nerve were found to be turgid and densely packed into the nerve in an 
orderly fashion, with little space remaining between fibres. Nuclei of Schwann cell nuclei were visible 
and sparsely distributed across the transverse section. No other cell types were detected.
Analysis of the sciatic nerves of severely affected homozygous Thy1 mySN mice revealed a notably 
sparser distribution of fibres (Fig. 30b, 31, 32b, d). Deterioration of A-fibres was clear with a large 
number found to have a highly abnormal morphology. The myelin sheaths of many cells contained 
abnormal structures (Fig. 32bj) or debris between layers of myelin (Fig. 32bji). The origin of this debris 
is unclear, with both the axon and Schwann cell possible sources. Many axons were found to contain 
vacuole or swollen mitochondria (Fig. 32biii), or be in a highly degenerate state (Fig. 32biv). Many 
fibres were found to be totally absent of axon, with only a multilamellar, Schwann cell derived structure 
remaining (Fig. 32bv, vi). Further abnormally was detected in the bundling of C-fibres, with many cluster 
found to be loosely bundled or totally absent of the enveloping Schwann cell (Fig. 32d). Unbound 
Schwann cell processes were also occasionally observed (Fig. 30b). In addition to fibre degeneration, 
infiltration by microglia (Fig. 31a), and large phagocytic cells, believed to be macrophages (Fig. 31b) 
was widespread, signifying Wallerian-like degeneration of the nerve was likely.
To further assess the extent of pathology, we quantified both the number of healthy and unhealthy A- 
fibres and the number of normal and atypically bundled C-fibres (Fig. 32a, c, appendix 7). In mildly 
affected homozygous Thy1 mySN mice a full complement of both A- and C-fibres was present, though 
a small but statistically significant portion of A-fibres was damaged (Mann-Whitney U-test, p=0.0493). 
A more prominent significant reduction of 24.9% was detected in the total population of sciatic nerves 
A-fibres in severely symptomatic homozygous ThylmySN mice (p=0.0005, Mann-Whitney U-test). 
When these were grouped by condition a loss of 38.6% of healthy fibres (Mann-Whitney U-test, 
p<0.0001) was found, accompanied by an approximate 8 times increase in population of damaged 
fibres. The total population of unmyelinated sensory C-fibres was undiminished in the symptomatic 
homozygous ThylmySN sciatic nerve, however a significant proportion, over 40%, of these fibres 
were found within atypical bundles (Mann-Whitney U-test, p<0.0001).
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Fig. 30. Severe damage of nerve fibres in the sciatic nerves of mice overexpressing gamma-synuclein. 
Representative electron micrographs of transverse sections of the sciatic nerve from twelve-month old 
healthy wild type (a) and severely affected homozygous ThylmySN (b). A -  healthy myelinated A- 
fibre, C -  healthy bundle of C-fibres, M -  healthy mitochondria, S -  A-fibre with visible Schwann cell 
nucleus, n -  Schwann cell nucleus, ML -  abnormal multilamellar A-fibre remnant, SP -  unbound 
Schwann cell processes, Ph -  phagocyte, AM -  abnormal mitochondria. Scale bar a-b=3^im.
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Fig. 31. Non-neuronal cell types in the sciatic nerve of homozygous ThylmySN mice. Representative 
transverse sections of sciatic nerve from twelve-month old severely affected homozygous ThylmySN 
mice (a, b). n -  nucleus of microglial cell (a) or phagocyte (b), black arrowheads -  phagocytes, black 
arrows -  microglia, white arrows -  mast cell. Scale bar = 10pm.
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Fig. 32. Loss of normal fibre morphology and population in the ThylmySN sciatic nerve. Quantification 
of total, healthy and damaged A-fibres (a) and total, normally and atypical encapsulated C-fibres (c) in 
the sciatic nerve of twelve month old wild type, mildly and severely affected homozygous ThylmySN 
mice (Mean±SEM, *** p<0.001, Mann-Whitney U-test). High magnification electron-micrographs of 
various degenerating A-fibres (brbvi,). A healthy bundle of C-fibres from wild type sciatic nerves, 
enveloped by a single Schwann cell sheath (d). An atypically enveloped bundle of C-fibres from 
severely affected homozygous ThylmySN sciatic nerve (e). Insert number denotes the number of 
nerves assessed, each collected from a separate animal.
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4.3. Results: Spinal nerve roots
Investigation of the sciatic nerves of severely affected homozygous ThylmySN mice showed that 
dystrophy induced by gamma-synuclein overexpression was not restricted to cell bodies. In the 
previous chapter we showed that cell bodies dystrophy differed between neuron type, with pools of 
motor neurons lost from the spinal cord and brain, but sensory neurons of the dorsal root ganglion 
appearing resistant. A similar pattern of selective dystrophy was also found between motor and 
sensory regions of the cortex. We aimed to determine whether a similar scenario occurred in axon 
populations. The sciatic nerve contains both efferent motor and afferent sensory fibres, however it is 
impossible to determine whether the damage that occurred was restricted to a particular group/type of 
fibre. At its point of entry into the lumbar spinal cord vertebrae, the sciatic nerve separates into several 
spinal root nerves. These nerves can be separated into two types, dorsal and ventral nerve roots. The 
dorsal nerve roots are composed of dorsal root ganglion-derived, small to medium size myelinated A- 
fibres and bundles of unmyelinated C-fibres. The ventral nerve roots are composed of spinal motor 
neuron-derived, small to large myelinated A-fibres only. By careful dissection of the vertebral column 
the motor and sensory nerve roots were collected for assessment of these pure populations.
4.3.1. Gamma-synuclein distribution in the spinal nerve roots
Immunostaining with affinity purified antibodies against gamma-synuclein revealed its presence in 
both dorsal and ventral nerve root axons of twelve-month old wild type control animals (Fig. 33a). 
Staining was diffuse and even throughout the axons, though the intensity of staining varied between 
axons. High levels of gamma-synuclein expression were detected throughout both class of spinal 
nerve root in severely affected homozygous ThylmySN mice, though were more frequent in the 
ventral nerve root. Both staining-free regions of neurite ballooning and regions of dense gamma- 
synuclein accumulation within collapsed, strand-like neurites were detected. Immuno-staining against 
NF-M displayed similar ballooned structures in the nerve roots of ThylmySN mice (Fig. 33bjjj,jV).
4.3.2. Semi-thin ultrastructure analysis of the spinal nerve roots
To gain deeper insight into the pathological process within the spinal nerve roots, which accompany 
phenotypical changes in ThylmySN mice, we stained with toluidine blue semi-thin transverse sections 
of roots dissected from twelve-month old mice. In dorsal nerve roots various size of healthy myelinated 
A-fibres were present, with C-fibres bundles interspersed between (Fig. 34 -  top left). Non-neuronal 
cell types were rarely observed. Age matched tissue from symptomatic homozygous ThylmySN mice 
displayed tightly packed fibres, however a portion of fibres were appeared to have an abnormal 
morphology, including both dense and severely bloated fibres (Fig. 34 -  top right). Infiltration by non­
neuronal cell types was also apparent. The ventral nerve roots of wild type mice contained tightly 
packed large and small myelinated A-fibres of normal appearance (Fig. 34 -  bottom left). As with the 
wild type dorsal nerve root, non-neuronal cell types were infrequent in number. The ventral nerve roots 
of severely affected homozygous ThylmySN mice presented striking pathology (Fig. 34 -  bottom
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right). Significant loss of myelinated A-fibres was clear, with non-neuronal cell types occupying space 
between fibres. A-fibres of abnormal morphology were widespread.
4.3.3. Ultra-thin ultrastructure analysis of the spinal nerve roots
TEM was utilised to carry out detailed assessment of spinal nerve root morphology. Dystrophic axons 
containing vacuoles and swollen mitochondria (Fig. 35d) and multilamellar structures void of axons 
(Fig. 35e) similar to those described in the sciatic nerve (see above) were found in both dorsal and 
ventral nerve roots, however were substantially more frequent in the latter. Quantification revealed that 
myelinated A-fibres were significantly fewer in number and more likely to be dystrophic in the motor 
ventral nerve root than the sensory dorsal nerve root (Fig. 35a,b, appendix 8). Though a small fraction 
of myelinated A-fibres were found to be damaged in the dorsal nerve roots of twelve-month old, 
symptomatic, homozygous ThylmySN mice (6.1%, p<0.001 Mann-Whitney U-test), no total loss of 
fibres was detected. In contrast we found an 18% decrease in total A-fibre population in the ventral 
nerve roots of twelve-month old symptomatic homozygous ThylmySN mice (Mann-Whitney U-test, 
p=0.0005). Within the remaining population we found a 33.9% decrease in the number of healthy 
fibres (Mann-Whitney U-test, p<0.0001). The number of damaged fibres was 10.8 times higher than 
the level seen in control ventral nerve roots (Mann-Whitney U-test, p<0.001 for all). Statistically 
significant numbers of phagocytes containing swirls of digested myelin (Fig. 36) were seen in both 
dorsal (Mann-Whitney U-test, p=0.0002) and ventral nerve roots (Mann-Whitney U-test, p=0.0001), 
though the number per 100pm2 was higher in ventral nerve roots.
The above data suggested that, in a pattern similar to neuronal cell bodies, the motor axons were 
more susceptible to gamma-synuclein overexpression induced dystrophy than sensory axons. We 
found that within the cranial motor neuron population, vulnerability was selective. As the caliber of an 
axon denotes its class of neuron, we measured the area of myelinated A-fibres within the nerve roots 
to assess whether a similar selectivity occurred within the populations of motor and sensory axons. 
The combined area of the axon and myelin sheath was measured using Image-J software, and 
calculated the mean area and size distribution of A-fibres (Fig. 37). Striking differences were detected 
in the ventral nerve roots of twelve-month old homozygous ThylmySN mice (Fig. 37a), with a 49.5% 
decrease in mean fibre area. Plotting of A-fibre size distribution revealed a substantial loss of the 
largest caliber axons. In contrast no difference in either the mean size or distribution of A-fibres was 
detected between the wild type or homozygous ThylmySN dorsal nerve roots (Fig. 37b).
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Fig. 33. Gamma-synuclein accumulates in spinal nerve root axons of aged ThylmySN mice and 
disrupts neurofilament-H distribution. Representative longitudinal sections of dorsal (a*) and ventral (an, 
ajjj) nerve roots from twelve-month old ThylmySN mice immunostained with antibodies raised against 
gamma-synuclein (SK23, 1:100). Dorsal and ventral nerve roots from twelve-month old wild type (bj 
and bin respectively) and ThylmySN mice (bn and biv respectively) immunostained with antibodies 
raised against neurofilament-H (1:250). Two signs of damage were generally found, ballooning 
(arrows) and dense intra-neuronal accumulation (arrowheads). Scale bars: a = 25nm; b, c = 50nm.
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Wild type Homozygous Thy1 mySN
Fig. 34. Substantial degeneration in the ventral nerve roots of ThylmySN mice. Representative 
toluidine blue stained transverse semi-thin sections through ventral and dorsal nerve roots of twelve­
month old wild type and symptomatic homozygous ThylmySN mice. Scale bar = 50pm.
123
Q  Dorsal nerve root
300
Ventral nerve root
1 0 0
<D
o- 150 
</>
<D
£ 100
O)
(0
E
CO
Q□
>»
CO
a>
I□
Fig. 35. The population of motor fibres entering the sciatic nerve are both damaged and diminished in 
ThylmySN mice. Quantification of total, healthy and damaged myelinated fibres in L4-L5 ventral (a) 
and dorsal (b) nerve roots of twelve-month old wild type and symptomatic homozygous ThylmySN 
mice (mean±SEM, *** p<0.001 Mann-Whitney U-test). High magnification electron-micrographs 
showing the normal myelinated A-fibres of wild type ventral nerve roots (c), in contrast to those of 
homozygous ThylmySN mice, where abnormal axons containing vacuoles and enlarged mitochondria 
(d), and multi-lamellar structure without axons (e) are found throughout. Scale bars c-e = 3|nm. The 
insert number denotes the number of nerves assessed, each collected from a separate animal.
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Fig. 36. Pronounced phagocyte infiltration occurs in the nerve roots of ThylmySN mice. The number 
of phagocytes (n=7, mean±SEM, ***p<0.001, Mann-Whitney U-test) found to have infiltrated the 
sensory and motor nerve roots of Thy1 mySN mice (a) and the EM image of infiltrating phagocyte in 
the motor nerve root (b). Arrows indicate phagocytosed myelin, ‘n’ indicates the nucleus. Scale bar = 
3nm. WT n = 9, homozygous Thy1 mySN n = 10.
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Fig. 37. The largest motor fibres of ThylmySN mice are most sensitive to gamma-synuclein 
overexpression induced degeneration. The size distribution of motor nerve fibres is significantly 
smaller in the ventral nerve root of twelve-month old ThylmySN than age-matched wild type mice due 
to a distinct shift towards smaller classes of fibre surviving (a). The mean area and size distribution of 
sensory fibres do not differ between genotypes (b). The number of animals analysed and total number 
of fibres measured (in brackets) are shown (mean±SEM, *** pcO.001, Mann-Whitney U-test).
126
4.4. Results: Retinal ganglion cells and the optic nerve
4.4.1. Confirmation of gamma-synuclein expression
Sections of eye from twelve-month old wild type and homozygous ThyfmySN mouse were immuno­
stained with antibodies raised against gamma-synuclein (Fig. 38a, b). In confirmation of previous 
reports gamma-synuclein staining was restricted to inner layers of the retina (Surgucheva et al. 2002). 
Perikaryal staining for gamma-synuclein was seen in neurons of the retinal ganglion cell layer of wild 
type mice, with less defined staining also observed in the inner plexiform layer (Fig. 38a). In the 
homozygous ThylmySN retina, staining was again restricted to outer layers of the retina. Denser 
cytosolic staining was observed in the RGC layer than that seen in wild type animals, with widespread 
punctate staining in the inner plexiform layer (Fig. 38b). No further differences between control and 
ThylmySN groups were detected in the level of staining in other retinal layers.
4.4.2. Assessment of RGC dendritic tree complexity
In an effort to determine whether gamma-synuclein overexpression was affecting the morphology of 
RGCs, we assessed the integrity of the neurons complex network of dendritic processes using the 
DiOlistic staining technique (Gan et al. 2000). This analysis was carried out in collaboration with the 
laboratory of Prof. James Morgan, Cardiff University School of Optometry. Whole mounted retina 
collected from wild type and homozygous ThylmySN mice were impregnated with a fluorescent 
lipophilic dye, staining both the soma and neurites of RGCs (Fig. 38c-f). Due to the limited penetration 
range of the dye-coated beads, bar infrequent retinal amacrine interneurons non-RGC cell types were 
not stained.
RGCs with large dendritic trees and defined axons were dispersed throughout the retina of both wild 
type (Fig. 38c, d) and homozygous ThylmySN mice (Fig. 38e, f). Signs of overt damage such as total 
loss of the dendritic tree or disruption of the axon were not observed in homozygous ThylmySN 
retina. Observation alone however was insufficient to accurately measure any subtle differences that 
may have occurred. Thus we measured dendritic complexity using Scholl analysis, an analytical 
technique that plots the number of dendrite bifurcation/intersections and their distance from the soma. 
Scholl analysis detected no differences between control and homozygous ThylmySN mice in either 
the number of dendritic intersections or in their distance from the soma (Fig. 38g).
4.4.3. Ultra-thin ultrastructure analysis of the optic nerve
Optic nerves were collected from twelve-month old wild type and severely affected homozygous 
ThylmySN mice and prepared for analysis by transmission electron microscopy (Fig. 39, appendix 9). 
The optic nerves of both control and experimental mice were composed of densely packed, small- 
caliber A-fibres, interspersed with infrequent astrocytes and microglia. Damaged A-fibres were rarely 
observed in either group, though swollen mitochondria and small vacuoles were common in both 
groups. Quantification (Fig. 39b) revealed neither significant loss of fibres (Mann-Whitney U-test,
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p=0.0750) nor changes in fibre size (Mann-Whitney U-test, p=0.9398). In addition to population and 
fibre size, we additionally measured the ratio between axon area to fibre area, termed the g-ratio, 
substantial changes in which indicate axonal dystrophy. No significant difference was detected 
between mean g-ratio values (Two-sample t-test, p=0.262).
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F/g. 38. Overexpression of gamma-synuclein does not affect the dendrites of retinal ganglion cells. 
Representative images of retina collected from wild type (a) and homozygous ThylmySN (b) mice 
immunostaining with antibodies against gamma-synuclein (SK23, 1:100). Representative images of 
diOlistically labeled retina ganglion cells from wild type (c, d) and homozygous ThylmySN mice (e, f), 
axons marked by arrows. Scholl analysis (e) revealed no differences in dendritic complexity between 
wild type and ThylmySN mice (mean±SEM). Wild type n=23 cells from 6 retina. ThylmySN n=17 
cells from 5 retina. Scale bars a-b = 25^171, d-f = 100nm.
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Fig. 39. No differences were found in the number or condition of fibres in the optic nerves of 
homozygous Thy 1 mySN mice. Representative images of optic nerves collected from twelve-month old 
wild type (a) and homozygous ThylmySN mice (b). Quantification of total number of myelinated fibres
(c), mean fibres area (d) or g-ratio (e) of fibres composing the optic nerves of twelve-month old wild 
type and homozygous ThylmySN mice (mean±SEM, Mann-Whitney U-test). Within each bar the 
number = number of fibres assessed, and (number) = number of nerves sampled.
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4.5. Summary of results and discussion
Gamma-synuclein has been identified in axonal inclusion bodies in several human diseases including 
PD, Hallervorden-Spatz syndrome, DLB and glaucoma (Galvin et al. 1999). (Galvin et al. 2000; 
Surgucheva et al. 2002). Furthermore the protein has been detected in similar structures in UCH-L1 
null GAD mice (Wang et al. 2004) and rodent models of glaucoma (Nguyen et al. 2011). It is unclear 
whether gamma-synuclein plays an active role in the neurodegeneration that occurs in the above 
examples, or its accumulation is a passive secondary event. In the previous chapter we noted the 
presence of axonal spheroid inclusion bodies in the brain and spinal cord of aged homozygous 
ThylmySN mice, suggesting that gamma-synuclein was impacting upon the normal morphology and 
function of CNS axons. To test this hypothesis we assessed the morphology and survival of pools of 
axons within the sciatic nerves, lumbar spinal nerve roots and optic nerves of control and homozygous 
ThylmySN mice.
Gamma-synuclein overexpression was found to induce substantial damage to axons of the sciatic 
nerves of symptomatic homozygous ThylmySN mice, with dense accumulation of gamma-synuclein 
protein detected within the neurites of the sciatic nerve (Fig. 29). Levels of several neuronal 
cytoskeletal proteins were substantially reduced in the sciatic nerves of these animals. Similar to the 
spinal cord of ThylmySN mice, neurofilament-L was depleted from the sciatic nerve neurites, many of 
which having a highly dystrophic morphology (Fig. 29). Infiltration by phagocytes, microglia and mast 
cells indicated active degeneration of the sciatic nerve (Fig. 31). Quantification by TEM revealed a loss 
of 25% of A-fibres from the sciatic nerves of the most severely affected homozygous ThylmySN mice, 
with almost 20% of remaining A-fibres in a state of dystrophy (Fig. 32). Loss of C-fibres was not 
observed, though changes in bundle encapsulation did occur in a proportion of fibres (Fig. 32). Neither 
form of dystrophy was found to occur in the sciatic nerves of twelve-month old homozygous 
ThylmySN mice displaying only mild symptoms, suggesting that axonal degeneration is a key event in 
gamma-synucleinopathy pathogenesis. Quantification of the lumbar spinal nerve roots that 
emerge/enter the sciatic nerve showed that the lost fibres were almost exclusively motor fibres of the 
ventral nerve root, with the largest A-fibres appearing most vulnerable (Fig. 35). In contrast, damage to 
the efferent sensory neurons of the dorsal nerve root was limited, with no fibre loss recorded, though a 
small proportion of fibres were damaged (Fig. 35). Neither loss of optic nerve efferent sensory axons 
nor abnormalities in the complexity of the dendritic tree of RGCs were detected in symptomatic 
homozygous ThylmySN mice (Figs. 38, 39).
The previous chapter drew comparison between the pattern of neuronal cell body loss detected in 
ThylmySN mice and that seen in both human ALS and in mouse models of the disease. The above 
axonal morphology data is concurrent with this resemblance, describing a pattern of axonal damage 
typical of both human and modeled ALS.
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4.5.1. Differential vulnerability between motor axon types
Analysis of axon number and morphology in the spinal nerve roots of ThylmySN mice further 
demonstrates the selective nature of the gamma-synucleinopathy. Over a third of myelinated motor 
fibres were either lost or damaged in the ventral spinal nerve roots of twelve-month old homozygous 
ThylmySN mice, with the largest appearing most vulnerable (Fig. 35, 37). In patients affected by ALS, 
selectivity is seen in the vulnerability of motor neurons and their axons. Examination of lumbar ventral 
nerve roots and spinal cord descending motor columns shows that the largest caliber fibres are 
disproportionately lost (Kawamura et al. 1981). Measurement of deep peroneal nerve conduction 
velocities has confirmed that the slowing of conduction velocity, concurrent with the selective loss of 
fast firing motor fibres, occurs with the progression of ALS (Theys et al. 1999). Our ability to assess 
factors contributing to this selective loss in human tissues in more detail is confounded by that fact that 
much of the available human ALS tissue is derived from patients at the late stages of disease 
progression, and is thus insufficient to accurately determine the dynamics of motor neuron 
degeneration. Fortunately the recapitulation of ALS in animal models of the disease have allowed us 
to achieve this, with selective motor neuron loss particularly well characterised in mutant SOD1 mouse 
lines (reviewed in (Kanning et al. 2010).
The earliest detectable changes in SOD1G93A mice are found in the innervation of neuromuscular 
junctions (NMJs). From approximately P50 partial denervation of NMJs in the medial gastrocnemius, 
soleus, and tibialis anterior muscles has been observed (Fischer et al. 2004), soon followed by the 
selective degeneration of fast-firing fatigable neuromuscular junctions (Frey et al. 2000; Gordon et al. 
2010; Hegedus et al. 2008; Pun et al. 2006). Denervation of fast-fatigue-resistant and slow 
neuromuscular junctions occurs significantly later in disease progression (Frey et al. 2000; Pun et al. 
2006). This pattern of loss has also been observed in pmn and mnd mice (Frey et al. 2000). The 
disproportionate loss of fast-firing motor units has led to the suggestion that the increased metabolic 
load of the fastest firing fibres is a factor in selective degeneration.
The caliber of an axon is proportional to its conduction velocity, with large fibres firing at the greatest 
velocity. This allows researchers to identify which class of motor neuron degenerate during the 
progression of ALS. Complementary to the early degeneration of their neuromuscular junctions, the 
large axons of fast-firing fatigable motor neurons type are consistently found to become dystrophic 
early in disease progression in mice expressing mutant SOD1 with significant loss of the largest 
caliber fibres detectable from as early as P20 (Bruijn et al. 1998; Fischer et al. 2005; Fischer et al. 
2004; Kong and Xu 1998). As motor deficits develop, a shift towards a higher proportion of small 
caliber fibres occurs. This shift has been attributed to both the loss of large fibres and to the partial 
regeneration of dystrophic fibres, generally resulting in a smaller axon caliber (Fischer et al. 2004; 
Kanning et al. 2010). At the stage of paralysis the largest axons are almost entirely lost (Kong and Xu 
1998). Matching findings have been reported in the SOD1G85R line, where 70% of the largest ventral 
root axons were lost with no loss of the smallest fibres (Bruijn et al. 1998). Thy1-hTDP-43 transgenic
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mice also develop a similar phenotype, with significant losses detected in largest caliber of ventral 
nerve axons from as early as 3 weeks of age (Shan et al. 2010). Thus the selective loss of large 
caliber motor axons in gamma-synuclein transgenic mice appears to be a common feature of ALS and 
previously produced mouse models of this disease.
4.5.2. Tolerance of sensory neurites to gamma-synuclein overexpression
In contrast to the motor axon damage seen in the ventral spinal nerve roots of ThylmySN mice, 
sensory axons of dorsal nerve roots were found to survive. Only a small fraction of fibres showed 
signs of damage (Fig. 35), consistent with the condition of sensory neurons in lumbar DRG of these 
animals where only limited abnormalities were detected (see section 3.5.). Furthermore encapsulation 
of sensory C-fibre was found to be abnormal in the sciatic nerves of the most severely affected twelve­
month old ThylmySN mice, though no fibres were lost (Fig. 32c). Though not considered a 
widespread symptom of ALS, sensory neuropathy has been reported in human cases. Patients are 
often reported to experience feelings of burning (Andersen et al. 1996) or numbness in the extremities 
(Dyck et al. 1975; Kawata et al. 1997). Moderate slowing of sensory neuron conduction velocity and/or 
action potentials have been reported in various sensory nerve of ALS patients (Hammad et al. 2007; 
Isaacs et al. 2007; Pugdahl et al. 2007; Theys et al. 1999). It has been noted that sensory deficits are 
more common in familial ALS compared to the sporadic form of disease (Li et al. 1988), with sensory 
neuropathy reported in SOD1G93S (Kawata et al. 1997) and SOD1D90A pedigrees of ALS (Andersen et 
al. 1996). Such functional abnormalities have been attributed to degeneration and loss of sensory 
axons. Remyelination, a sign of axonal stress followed by regeneration, has been reported in sural 
nerve biopsy tissue (Hammad et al. 2007; Heads et al. 1991). More so, substantial loss of myelinated 
A-fibres has been reported in the sural nerve (Bradley et al. 1983; Hammad et al. 2007; Heads et al. 
1991), superifical peroneal nerve (Dyck et al. 1975) and ascending spinal cord sensory columns 
(Kawamura et al. 1981) of ALS patients. Similar to the pattern seen in motor axons, these losses have 
been noted to affect the largest caliber of sensory fibre (Hammad et al. 2007; Heads et al. 1991; 
Kawamura et al. 1981).
In contrast to the detailed examination of motor axon degeneration, remarkably little work has been 
carried out to assess the extent of sensory damage seen in mouse models of ALS. Quantification of 
sensory A-fibres in the dorsal nerve roots of the SOD1G93A line of mice found losses varying from 
modest and non-progressive (Dal Canto and Gurney 1995; Sun et al. 2002) to decreases of over 50% 
(Fischer et al. 2005; Guo et al. 2009). Assessment of the femoral nerve of end-stage mice expressing 
prion promoter driven TDP43A315T however failed to detect any loss of sensory fibres (Wegorzewska et 
al. 2009), demonstrating the variable nature of ALS pathology.
The mechanisms governing the selective vulnerability of motor fibres and relative resistance of 
sensory fibres are currently under much scrutiny. As the pathologies seen in the motor and sensory 
cell bodies of ThylmySN were also found to follow the same pattern, factors that might determine their
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vulnerability and how they might relate to gamma-synucleinopathy shall be discussed in the final 
chapter as a whole (see below).
4.5.3. Gamma-synuclein and glaucoma
Glaucoma appears to be the most likely neurodegenerative disease in which gamma-synuclein might 
play a role. The pathogenesis of this disease is unclear, with degeneration of RGCs and their 
processes within the optic nerve head linked to an increase in IOP. Involvement of gamma-synuclein 
in this degeneration has been suggested by several studies. Changes in the expression of gamma- 
synuclein have been linked to both normal RGC development (Mu et al. 2004) and to the development 
of glaucoma (Soto et al. 2008). The role of gamma-synuclein in glaucoma is yet to be elucidated. The 
protein has been found within atypical inclusion bodies in both the axons of the optic nerve and in a 
subset of optic nerve astrocytes of both human patients and animal models of the disease (Nguyen et 
al. 2011; Surgucheva et al. 2002). The issue has been further complicated by the recent findings by 
Nguyen et al, in which the authors suggest that gamma-synuclein might even play a protective role in 
glaucoma, activating phagocytic activity in a subgroup of astrocytes within the myelination transition 
zone of the optic nerve (Nguyen et al. 2011).
We found no evidence that gamma-synuclein overexpression is a causative factor in the degeneration 
of either the optic nerve or the RGC dendritic tree of symptomatic homozygous ThylmySN mice (Figs. 
38, 39). Additional unpublished results obtained in collaboration with laboratory of Dr. Nicholas Marsh- 
Armstrong in John Hopkins University School of Medicine, Baltimore support this finding. Automated 
quantification of retinal ganglion cell bodies in whole mounted retinas found a full complement in the 
retina of the most symptomatic homozygous ThylmySN mice despite very high level of transgene 
expression in these cells (Nicholas Marsh-Armstrong, personal communication). Neuronal gamma- 
synuclein overexpression alone is thus insufficient to induce RGC degeneration. We speculate that the 
reported accumulation of gamma-synuclein into atypical inclusion structures in both axons and glia 
most likely represents a secondary process occurring during RGC degeneration. It is feasible however 
that the reported appearance of gamma-synuclein within activated optic nerve astrocytes of glaucoma 
patients play a role in RGC degeneration (Surgucheva et al. 2002), explaining the lack of glaucoma­
like degeneration in ThylmySN mice. This hypothesis may be relatively easily tested, through the 
development of transgenic mice with astrocyte targeted overexpression gamma-synuclein, for 
example utilising a GFAP-promoter (Brenner et al. 1994).
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5. Influence of endogenous gamma-synuclein upon the 
phenotype induced by the Thy1 mySN transgene
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5.1. Overview
Cabin et al (2005) described the apparent ability of endogenous murine alpha-synuclein to confer a 
degree of resistance to the toxicity induced by overexpression of prion-promoter driven human alpha- 
synuclein transgene. Mice null for the endogenous alpha-synuclein gene were found to present a more 
pronounced transgene-induced phenotype in comparison to those whom have developed with the 
endogenous gene (Cabin et al. 2005). To test whether a similar scenario is true with regards to 
gamma-synuclein, we bred a previously generated line of C57BI6/J mice null for the endogenous 
SNCG gene (Ninkina 2003) with the ThylmySN line. We subsequently generated a cohort of 
endogenous SNCG null mice homozygously expressing the ThylmySN transgene (SA/CG'7' 
Thy1mySNTG7TG). A cohort of homozygous ThylmySN mice (Thy1 mySNTG/TG) were used as control 
animals.
5.2. Results: Behaviour and survival
5.2.1. Survival
The lifespan of SNCG'1' Thy1 mySNTG7TG was compared against that of Thy1 mySNTG7TG mice (Fig. 40). 
Any animals sacrificed due to unrelated health problems were disqualified from the study. 17 
Thy1 mySNTG/TG mice and 28 SNCG'1' Thy1 mySNTG/TG deaths were recorded. No significant difference 
was found between the survival of SNCG'1' Thy1 mySNTG/TG and Thy1 mySNTG/TG mice (log rank test for 
equality of survival p=0.1532, generalized Wilcoxon test for equality of survival, p=0.2285).
Though the survival of SNCG'' Thy1 mySNTG7TG mice was comparable to that of Thy1mySNTG/TG, 
differences in the onset and severity of disease were feasible. Thus behavioural tests were carried out 
to analyse the motor performance of these mice;
5.2.2. Rotarod
Mice were tested on both constant and accelerating rotarod modes. At each time point between 21 
and 63 mice we tested. No significant differences in performance were detected on the constant speed 
mode (Kruskal-Wallis, Mann-Whitney U-test, all p>0.05) (Fig. 41a). The more sensitive accelerating 
mode detected a significant difference in performance at 2-months (Kruskal-Wallis, Mann-Whitney U- 
test p=0.0045) (Fig. 41b), where the SNCG'1' Thy1mySNTG/TG cohort performed 20.4% worse than the 
control Thy1 mySNTG7rG group (Mann-Whitney U-test, p=0.0045). No further differences in performance 
were detected (Kruskal-Wallis, Mann-Whitney U-test, all p>0.05).
5.2.3. Beam test
The ability of SNCG'1' Thy1 mySNTG/TG and Thy1 mySNTG/TG cohorts to complete an 180° turn (Fig. 42a) 
and traverse the length of a 500mm length and 20mm diameter wooden beam was assessed (Fig. 
42b). At each time point between 26 and 63 mice were tested. At the 2-, 4- and 6-month test points the 
completion rate of the turn phase was equal in both groups. An improved turn performance was seen
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in 9-month old SNCG1' Thy1 mySNTG/TG mice, completing 21.0% more turns than the Thy1 mYSNTG/TG 
cohort (x2 value 4.777, critical value 3.841), however at twelve-months this difference had diminished 
to an insignificant 12.5%. No differences were detected in the ability of either group to complete the 
traverse phase.
5.2.4. Inverted grid test
The strength and coordination of both cohorts was assessed at 6-, 9- and 12-months upon an inverted 
mesh grid for a 60-second test period (Fig. 43). A trend towards an improved performance was 
observed in the 12-month trial by the S N C G Thy1mySNTG/TG group. In spite of this trend, no 
significant differences were detected at any time points (p=4398, 0.3038, 0.1857 for 6-, 9- and 12- 
months respectively, Mann-Whitney U-test).
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Fig. 40. The survival of SNCG'' Thy1 mYSNTG/TG mice. Kaplan-Meier plot showing survival of SNCG1' 
Thy1 mySNTG/TG (red) and Thy1 mySNTG/TG mice (blue). No significant difference was detected by log 
rank test for equality of survival (p=0.1532) nor by generalized Wilcoxon test for equality of survival 
(p=0.2285). n-values; SNCG1' Thy1 mySNTG/TG = 28, Thy1 mySNTG/TG = 17.
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Fig. 41. Age related motor function decline in SNCGA ThylmySNTG/TG mice measured by rotarod. 
Mice were tested on both constant (a) and accelerating (b) rotarod modes. (mean±SEM ** = p<0.01 
Mann-Whitney U-test). Thy1 it iy S N tg / tg n; 2m = 9; 4m = 11; 6m = 11; 9m = 12; 12m = 7. SNCG'1' 
Thy1 mySNTG/rG n; 2m = 10; 4m = 20; 6m = 19; 9m = 21; 12m = 16.
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Fig. 42. Age related motor function decline in SNCG'''ThytmySNrQ/rG
The ability of mice to turn on (a) and traverse (b) a suspended beam were recorded over a one minute 
test period. The results are presented as the percentage of the cohort able to complete the test in the 
set period. * = x2 value greater than critical value at p=0.05. Thy1 mySNTG/rG n; 2m = 9; 4m = 11; 6m = 
11; 9m = 12; 12m = 9. SNCG1' Thy1 mySNTG/TG n; 2m = 10; 4m = 20; 6m = 19; 9m = 21; 12m = 16.
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Fig. 43. Age related motor function decline in SNCG'' Thy1mySNTGnG mice measured by inverted grid 
test. The ability of mice to stay on an inverted grid for a 60-second test period (mean±SEM). No 
significant differences were detected (Mann-Whitney U-test). Insert number = number of mice tested.
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5.3. Results: Histopathology
Cabin et al (2005) observed an increased protein accumulation in the CNS of endogenous SNCA null 
mice expressing transgenic alpha-synuclein in comparison to those carrying the wild type locus. To 
assess whether the absence of endogenous SNCG might lead to similarly exacerbated accumulation 
of gamma-synuclein, samples of several regions of CNS were collected from twelve month old SNCG' 
'' Thy1 mYSNTGm3 mice for histological analysis and comparison against Thy1 mySNTG/TG control tissue.
5.3.1. Spinal cord
Transverse sections of thoracic spinal cord immuno-stained with affinity purified antibodies raised 
against gamma-synuclein revealed a pattern of protein accumulation matching that seen in age 
matched Thy1 it iy S N TG/TG mice (Fig. 44, see section 3 .3 . ) .  High levels of gamma-synuclein were found 
throughout both the grey and white matter of the spinal cord. Cell bodies, neurites and neuropil all 
contained intense staining for gamma-synuclein. Typical inclusion bodies seen in Thy1 i t iy S N t g /tg  
spinal cord were also detected in SNCG'1' Thy1 mySNTG/TG tissue, most prominently Lewy neurites and 
axonal spheroids which were widespread (Fig. 44a -  white arrows).
Concurrent with the clinical signs of neurodegeneration presented, immunostaining against GFAP 
revealed widespread infiltration of activated astrocytes in the spinal cord of twelve-month old SNCG'1' 
Thy1 i t iy S N t g / tg mice at a level comparable with that observed in ThylmySN10710 control animals (Fig. 
44b, see section 3.3). Furthermore staining with the biotinylated lectin RCA revealed infiltration of 
activated microglia occurring in parallel to astrogliosis (Fig. 44c).
5.3.2. Sciatic nerve
Overexpression of gamma-synuclein in the sciatic nerves of SNCG'1' Thy1 mySNTG/TG mice resulted in 
matching signs of pathology as seen in the ThylmySN10770 (Fig. 44d, also see section 4.2). In the 
sciatic nerves of twelve-month old SNCG'1' Thy1 it iy S N t g /tg  mice gamma-synuclein was found to be 
distributed unevenly, suggesting the loss of unstained fibres. Furthermore typical signs of 
degeneration previously observed in the ThylmySN10716 nerves were also detected. Abnormal intra- 
axonal structures, including spheroid-like structures were detected, as were regions of neurite 
ballooning (Fig. 44d).
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Fig. 44. Gamma-synuclein aggregation and gliosis in the central nervous system of SNCG'/' 
Thy1 mySNTG/rG mice. Representative transverse sections of thoracic spinal cord collected from 
twelve-month old SNCG'' Thy1 mySNTG/TG immunostained with antibodies raised against gamma- 
synuclein (SK23, 1:100) (a), GFAP (1:400) (b) and biotinylated lectin RCA (1:100) (c). Representative 
longitudial section of SNCG1 Thy1mySNTG/TG sciatic nerve immuno-stained with antibodies raised 
against gamma-synuclein. White arrows = Lewy neurites, white arrowheads = axonal spheroids, black 
arrows = intra-axonal structures, black arrowheads = ballooned neurites. Scale bars = 50pm.
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5.3.3. Brain
Immuno-staining of sagittal brain sections with affinity purified antibodies raised against gamma- 
synuclein revealed widespread expression and accumulation of the protein in the brains of twelve­
month old SNCG'1' Thy1 mySNTG/TG (Fig. 45-47), consistent with the pattern seen in ThylmySN16™3 
mice (see section 3.4).
Nigra-striatal system
Dopaminergic regions were located using antibodies raised against tyrosine hydroxylase (Fig. 45a, c). 
TH immunostaining revealed no gross changes in the morphology of these structures in SNCG''' 
Thy1 mySNTG/TG mice when compared to age matched wild type tissue (Fig. 45b, d). Gamma-synuclein 
immunostaining in the striatal matrix was comparable to the diffuse neuropil staining seen throughout 
the brain (Fig. 45b). Striatal white matter tracts were densely stained for gamma-synuclein with 
numerous dystrophic axons observed (Fig. 45b). Consistent with the low level expression of Thy1 
promoter in dopaminergic neurons, little gamma-synuclein staining was detected in the cell bodies of 
the SNpc, though axonal spheroids were detected in the surrounding tissue (Fig. 45d).
Hippocampus
Gamma-synuclein was found throughout the SNCG1' ThylmySN10™3 hippocampus (Fig. 46). 
Perikarya! cytoplasm staining within pyramidal neurons and diffuse staining of the surrounding neuropil 
was detected in both the CA1 (Fig. 46b) and CA3 (Fig. 46c) regions. Gamma-synuclein positive 
staining was detected in axons of the dentate gyrus granular layer and infrequent neurons within the 
hilus (Fig. 46d). Abnormal intracellular inclusion bodies were not observed in neurons of the SNCG'1' 
ThylmySN16™3 hippocampus.
Cerebellum
High levels of staining were detected within both the white matter region (Fig. 47b) and the granular 
layer (Fig. 47c) of the SNCG'1' Thy1 mySNTG/TG cerebellum. Substantial accumulation of gamma- 
synuclein within dystrophic neuritis was revealed, with spheroid inclusions frequently observed. 
Cytoplasmic staining of neurons within the Purkinje cell layer was also detected (Fig. 47c). As with 
ThylmySN mice, this was comparable to the endogenous levels seen in wild type mice (Fig. 14).
Cortex
Neuropil gamma-synuclein staining was observed throughout the cortex of SNCG'1’ Thy1 mySNTG/TG, 
with high levels detected in perikaryal and axonal cytoplasm in both the external (Fig. 47e) and internal 
(Fig. 47f) pyramidal cell layers. Granular layer staining was comparable to the widespread neuropil 
staining. Axonal spheroids and dystrophic axons were detected throughout the cortex, with a similar 
motor-sensory region gradient as described for the cortex of homozygous ThylmySN mice (see 
above).
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Fig. 45. Gamma-synuclein expression in the nigra-striatal system of SNCGThy1  mySNTG/TG mice. 
Representative tyrosine hydroxylase (1:1000) immunostained sagittal sections (lateral 1.44mm) of 
twelve-month old SNCG'1' Thy1mySNTG^ G (a) striatum and substantia nigra pars compacta (b). 
Corresponding sections immunostained with antibodies against gamma-synuclein (SK23, 1:100) show 
tracts of axons within the striatum of SNCG'7' Thy1 mySNTG/TG mice (b) and little staining in the SNpc 
(d). Scale bars a, b = 250/vm; c, d = 100pm.
TH Gamma synuclein
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Fig. 46. Gamma-synuclein expression in the hippocampus system of SNCG'/' Thy1 mySNTG/TG mice. 
Representative gamma-synuclein immunostained (SK23, 1:100) sagittal sections of twelve-month old 
SNCG'1' ThylmySN16™3 (a-d) hippocampal regions CA1 (b), CA3 (c) and the dentate gyrus (d). Scale 
bars a = 250/; m; b-d = 50pm.
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Fig. 47. Gamma-synuclein expression in the cerebellum and cortex ofSNCG'A Thy1 mySNTG/TG mice. Representative gamma-synuclein immunostained (SK23, 
1:100) sagittal sections (lateral 1.44mm) of cerebellum (a-c) and cortex (d-f) from twelve-month old SNCG1' Thy1 mYSNTG/TG mice. Gamma-synuclein ia seen 
in the neurites of the white matter (b) and granular layer (c) of the 6th cerebellar lobule, and within cell bodies of the Purkinje cell layer (black arrows) (c). 
Gamma-synuclein positive cell bodies are seen in both the external (e) and internal (f) pyramidal cell layers of the S1 somatosensory region of cortex (d). 
Scale bars a = 250/vm; d = 100/vm; b, c, e, f, = 25pm.
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5.4. Summary of results and discussion
Increases in the expression of alpha-synuclein have been robustly demonstrated to induce substantial 
neurodegeneration, both in human synucleinopathies (Chartier-Harlin et al. 2004; Edwards et al. 2010; 
Ibanez et al. 2004; Kruger et al. 1998; Pankratz et al. 2009; Polymeropoulos et al. 1997; Satake et al. 
2009; Simon-Sanchez et al. 2009; Singleton et al. 2004; Zarranz et al. 2004) and animal models 
(reviewed in Buchman and Ninkina 2008). One such animal line, in which the mutant A53T form of 
alpha-synuclein was overexpressed on an alpha-synuclein null background, developed an 
exacerbated phenotype compared to that seen in control alpha-synuclein overexpressing mice on a 
wild type alpha-synuclein background (Cabin et al. 2005). The above chapters demonstrated the 
progressive neurodegeneration caused by gamma-synuclein overexpression in mice carrying the 
endogenous gamma-synuclein allele. To test whether endogenous gamma-synuclein confers any 
resistance to the pathology induced by overexpression of gamma-synuclein transgene, or conversely if 
developmental absence of endogenous gamma-synuclein causes an exacerbation of 
neurodegeneration, we developed a line of Thy1 mySNTG/TG mice on a pure C57BI/6J and null for 
endogenous gamma-synuclein (SNCG'7' Thy1mySNTG7TG).
The animals developed a phenotype indistinguishable from that of the Thy1 mySNTG7TG line, 
characterised by identical motor abnormalities and an equally shortened lifespan (Fig. 40). Differences 
in motor behaviour were limited and inconsistent (Fig. 41-43). The most substantial difference was 
detected in the accelerating rotarod test, where significant impairment in S N C G Thy1 mySNTG7TG 
performance was detected at two months (Fig. 41b). No further differences were seen at any other 
accelerating rotarod time-point and, furthermore, constant speed rotarod performance matched that of 
the Thy1 mySNTG7TG cohort (Fig. 41a). Converse to the early age deficit detected by the accelerating 
rotarod, twelve-month old SNCG'1' Thy1 mySNTG/TG mice outperformed control Thy1 mySNTG/TG on the 
inverted grid test (Fig. 43). A similar trend was also detected in the ability of the mice to turn on the 
beam test, with 9- and 12-month old SNCG'1' Thy1 mySNTG/TG mice completing the test more frequently 
than the Thy1 mySNTG/TG cohort (Fig. 42). Consistent with the similarity seen in motor activity, 
histological analysis of the CNS of twelve-month old SNCG’1' Thy1 mySNTG/TG mice revealed a pattern 
of gamma-synuclein expression matching that seen in the Thy1 mySNTG/TG cohort (Fig. 44-47). 
Abnormal gamma-synuclein inclusion bodies matching those seen in Thy1mySNTG7TG mice were found 
in the brain, spinal cord and sciatic nerves of SNCG'1' Thy1 mySNTG/TG mice. It can thus be concluded 
from the lack of a consistent deficit in motor performance and similarity of CNS dystrophy that the 
presence of endogenous gamma-synuclein during murine CNS development has no influence upon 
the pathology induced by overexpression of the Thy1 mySN transgene.
Cabin et al. make several hypotheses for the exacerbated phenotype seen in the alpha-synuclein null 
mice expressing the mutant A53T human form of alpha-synuclein under a prion-promoter (-/-/A53T). 
The -/-/A53T mice were generated on a mixed FVB/129 background, whereas control mice expressing 
both endogenous alpha-synuclein and the A53T transgene (+/+/A53T) were a FVB/N stain. The
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authors suggest that the introduction of unspecified FVB/129 alleles may sensitize the mice to alpha- 
synuclein overexpression. They suggest that interaction between the murine endogenous alpha- 
synuclein and the human transgene in +/+/A53T mice limits disease severity. However this possibility 
was dismissed, due to the mouse protein being more fibrillogenic than the human (Rochet et al. 2000). 
Though the autosomal dominant mutation of alanine to threonine at residue-53 is a known cause of 
PD in humans, threonine is the wild type residue-53 in mice. It is suggested that this, or one of the 
other six residual differences between mouse and human synuclein, confers some degree of 
developmental tolerence to the human synuclein protein. Furthermore, endogenous alpha-synuclein 
expression in the spinal cord is normally restricted to dorsal horn however the damage seen in 
+/+/A53T mice, where transgene expression is pan neuronal, occurs predominantly within motor 
neurons of the ventral horn (Cabin et al. 2005), again suggesting an innate protective role.
From the SNCG7' Thy1 mySNTG/TG data it seems likely that the exacerbated phenotype seen by Cabin 
et al is most likely due to differences in either the genetic background of the animal lines used or that 
the endogenous murine SNCA confers protection against human SNCA. Our experimental design 
removed these two factors from the experiment. Both the gamma-synuclein null and Thy1 mySNTG/TG 
lines were produced on pure C57BI/6J backgrounds, limiting the influence of any stain differences 
upon the experiment. Secondly both the endogenous and transgenic SNCG genes used in the 
Thy1mySNTGm3 line are the murine form and thus neither differences in fibrillation propensity nor 
tolerance conferred by residual heterogeneity should be factors in pathogenesis. Thus as no 
substantial change in disease onset or severity was observed in the SNCG'1' Thy1 mySNTGyTG cohort, 
and it appears that the presence of endogenous gamma-synuclein plays no significant role in the 
neuropathy seen in Thy1 mySNTG/TG mice. In future it may be interesting to closer replicate the 
experiments of Cabin et al by using mice transgenic for the fibrillogenic human SNCG (Park and 
Lansbury 2003) and, if degeneration is induced, test whether the ablation of the murine endogenous 
SNCG would exacerbate the pathology.
It can thus be concluded that the presence of endogenous gamma-synuclein during development does 
not significantly protect mice against the toxicity induced by its postnatal overexpression. Furthermore, 
with regards to the findings of Cabin et al. 2005, the above suggests that the increased severity found 
in -/-/A53T mice is due to stain differences in the genetic background of the mice and/or the forms of 
SNCA expressed.
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6. The impact of gamma-synuclein overexpression upon
the CSPa-null phenotype
149
6.1. Overview
The deletion of cysteine string protein alpha (CSPa), a co-chaperone associated with SNARE complex 
assembly, induces a progressive neurodegenerative phenotype in mice (Chandra et al. 2005; 
Fernandez-Chacon et al. 2004). Degeneration is caused by the immature development of synaptic 
junctions, attributed to reductions in SNARE-complex assembly, specifically through a 30-50% 
reduction in levels of SNAP-25 (Burre et al. 2010; Chandra et al. 2005). Remarkably overexpression of 
both human and mouse wild type alpha-synuclein rescues CSPa-null mice from the 
neurodegenerative phenotype (Chandra et al. 2005). Conversely ablation of both alpha- and beta- 
synuclein induces a more pronounced phenotype (Chandra et al. 2005). Current data suggests that 
alpha-synuclein rescues the CSPa-null phenotype by promoting the assembly of SNARE complexes 
through direct interaction with synaptic phospholipid membranes and with the SNARE component 
synaptobrevin-2 (Burre et al. 2010).
To investigate whether the overexpression of gamma-synuclein is similarly able to rescue the 
phenotype seen in CSPa-null mice, we produced a line of C57BI/6J mice null for CSPa and 
overexpressing high levels of the ThylmySN transgene.
6.2. Results
6.2.1. Phenotype of CSPa-null mice
We generated a line of CSPa'7' mice on a pure C57BI/6J background. The survival of these animals 
was assessed to ensure a phenotype comparable to those previously reported was presented 
(Chandra et al. 2005; Fernandez-Chacon et al. 2004). CSPa'7' mice were indistinguishable from their 
wild type and CSPa+7' littermates during the first two weeks of their life. Similar to the previously 
reported observations of CSPa'7' mice on a mixed genetic background, the CSPa'7' mice on C57BI/6J 
background stopped gaining weight after P14 and started to show signs of lethargy. From P22 
emaciated pups began to die, with 50% of the cohort not surviving beyond P34 (Fig. 48b). No mice in 
the CSPa'7' cohort survived past P52 (Fig. 48b). No control wild-type littermates died during this period 
(data not shown).
6.2.2. Phenotype of CSPa'A Thy1 mySN mice
To test the hypothesis that gamma-synuclein overexpression would rescue mice from the CSPa'7' 
phenotype we generated cohorts of CSPa'7' expressing the ThylmySN transgene either homo- or 
hemizygously. In neither case did the overexpression of the ThylmySN transgene increase either the 
survival of CSPa'7' mice or reduce the severity of their neurodegeneration. Thus for further analysis of 
lifespan, data for CSP-null hemi- and homozygous ThylmySN mice were combined (herein CSPa'7' 
ThylmySN). During the first two weeks CSPa'7' and CSPa'7' ThylmySN pups were indistinguishable. 
Beyond this point the growth of both groups was retarded (Fig. 48a). Lethargy was apparent, though 
mice were able to move when prompted. Similar to the CSPa'7' line, the majority of the CSPa'7'
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ThylmySN cohort had died at approximately P34. An insignificant fraction of the CSPa'7 ThylmySN 
cohort survived past P60. No significant difference was detected between the survival of CSPa7 and 
CSPa'7' ThylmySN mice by either log rank (p=0.5284) or generalised Wilcoxon’s tests for equality of 
survival (p=0.4109) (Fig. 48b).
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Fig. 48. Gamma-synuclein overexpression does not rescue the CSPa null phenotype, (a) Four-week 
old CSPa+/+rhy7mYSN (left) are indistinguishable from wild type mice, where as CSPa'7'ThyfmySN 
(right) are visibly smaller and indistinguishable from CSPa-null mice. Log rank and generalized 
Wilcoxon tests for equality of survival (b) found no significant difference (p=0.5284 and 0.4109 
respectively) between CSPa'7' 7T7y 7mYSN'7' mice (red) and either CSPa'7T /7y 7mYSN cohorts (blue), n- 
values: CSPa'7 "T/?y7mYSN'7' =16; CSPa'7' ThylmySN = 26.
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6.3. Summary of results and discussion
To assess whether gamma-synuclein is able to functionally replace alpha-synuclein in its capacity to 
rescue neurons from neurodegeneration induced by the ablation of CSPa, we produced a line of 
CSPa-null mice overexpressing the Thy1 mySN transgene on a pure C57BI/6J background, with a 
control group of CSPa-null mice also generated on a matching background. Prior to assessment of the 
experimental cohort, we confirmed control animals developed a phenotype similar to that previously 
reported for the ablation of CSPa in mice. Our CSPa-null mice showed retarded growth following the 
second postnatal week, followed by premature death within the second month. Both of the above are 
observed in existing CSPa-null lines (Burre et al. 2010; Chandra et al. 2005; Fernandez-Chacon et al. 
2004), however the lifespan of our line was substantially shorter (Fig. 48b). Though factors such as 
environment or diet may affect penetrance of phenotype, the difference is most likely due to the 
background stains the CSPa-null genotypes were developed on. Our CSPa-null cohort was produced 
on a pure C57BI/6J strain, whereas previously reported work was carried out on a mixed 
Ola129xC57BI/6J background (Burre et al. 2010; Chandra et al. 2005; Fernandez-Chacon et al. 2004). 
CSPa-null mice on the latter background appear to develop a slightly less pronounced phenotype, with 
numerous mice living past P60, with some living as long as P100 (Chandra et al. 2005). It thus 
appears that unspecified genetic differences between the backgrounds of mice may play a role in the 
development of neurodegeneration triggered by CSPa ablation.
Overexpression of gamma-synuclein resulted in no significant improvement in the health of CSPa'7' 
mice. CSPa^T/iylmySN16719 and CSPa'T/iylmySN16776 mice were indistinguishable from both wild 
type and CSPa'7' mice for the first two weeks of life, after which their growth became retarded and 
motor abnormalities apparent (Fig. 48a). Unfortunately, due to the rapid nature of neurodegeneration it 
was not possible to carry out any quantitative behavioural tests, however the CSPa'7T /7y 7mYSNTG7TG 
were not observed to show any substantial behavioural differences to the CSPa'7' cohort. 
Approximately 90% of the CSPa'7T /7y 7mySNTG7TG cohort was deceased by P50, with the remaining 
fraction dying by P80 (Fig. 48b). No significant difference was detected between the survival of either 
CSPa'7' or CSPa'7'T/iy7mySNTG7TG.
It thus appears unlikely that the role of gamma-synuclein within the neuron overlaps with the 
downstream neuroprotective function that alpha-synuclein possesses. The ability of the latter to inhibit 
synaptic degeneration in CSPa-null mice has been linked to the proteins function in promoting SNARE 
complex formation in pre-synaptic terminals (Burre et al. 2010). Though the mechanism by which this 
is facilitated is unclear, alpha-synuclein directly interacts with vesicle phospholipid membranes through 
its N-terminal lipid-binding domain and with synaptobrevin-2 through its C-terminus (Burre et al. 2010; 
Perrin et al. 2000). There are data to suggest that crucial structural differences between alpha- and 
gamma-synuclein account for this functional disparity. The A30P mutant form of alpha-synuclein, the 
lipid-binding domain of which is disrupted by the polymorphism (Perrin et al. 2000), is unable to
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facilitate the rescue of CSPa-null mice (Chandra et al. 2005). As gamma-synuclein has a lower 
propensity to bind phospholipid membranes, due to it having a less alpha-helical structure than alpha- 
synuclein (Sung and Eliezer 2007), it is feasible that it is less able or entirely unable to carry out the 
function of alpha-synuclein. The interaction between the C-terminus of alpha-synuclein and 
synaptobrevin-2 also appears essential for SNARE complex assembly. Defective SNARE complex 
assembly seen in triple synuclein null neurons is rescued by the expression of wild type alpha- 
synuclein, but not when a C-terminus truncated form of alpha-synuclein was expressed (Burre et al. 
2010). The C-terminus of gamma-synuclein is significantly diverse compared to that of alpha- and 
beta-synuclein, being shorter and less ordered (Sung and Eliezer 2007). As with lipid-binding 
variability it is feasible that such variations in C-terminus sequence determine functional interaction 
between synuclein proteins and synaptobrevin-2 .
Further investigation of the synaptic role of gamma-synuclein through replication of experiments 
carried out by Burre et al may allow some insight into its function. Alpha-synuclein was found to co- 
immunoprecipitate with SNAP-25, synapsin 1 and synaptobrevin in brain homogenate of wild type 
mice. Secondly, viral mediated overexpression of alpha-synuclein is able to rescue SNARE complex 
assembly deficits in cultured hippocampal neurons of triple synuclein null mice. Similar co- 
immunoprecipitation experiments would determine if the protein is capable of direct interaction with the 
synaptic vesicle fusion components. Absence of interaction may explain the inability of gamma- 
synuclein to rescue the CSPa-null phenotype. If gamma-synuclein were able to interact with such 
proteins, transfection of triple synuclein null hippocampal neurons with viral expressed gamma- 
synuclein would determine whether the protein is able to increase SNARE complex assembly. 
Ineffective promotion of such complexes may again explain the inability of gamma-synuclein to rescue 
mice from the effects of CSPa ablation.
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7. Gamma-synuclein in human amyotrophic lateral 
sclerosis and frontotemporal lobar degeneration
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7.1. Introduction
The previous chapters of this thesis have demonstrated that gamma-synuclein is capable of inducing 
widespread neurodegeneration when overexpressed in the murine nervous system. A pattern of 
damage is induced that recapitulates several features of human ALS, most notable the 
disproportionate vulnerability of motor neurons to degeneration. There is currently no evidence to 
suggest gamma-synuclein might be involved in human cases of the disorder, though research in the 
field is limited. A small study of 92 cases of familial and sporadic cases of ALS failed to detect any 
polymorphisms associated with increased risk of the disease (Flowers et al. 1999). The involvement of 
gamma-synuclein in neurodegeneration is not however unfeasible. The protein has been identified as 
a component of rare, atypical inclusion bodies in several human neurodegenerative disorders, 
including PD, Lewy body dementia (Galvin et al. 1999), Hallervorden-Spatz syndrome (Galvin et al. 
2000) as well as glaucoma (Surgucheva et al. 2002). Furthermore the degeneration seen in animal 
models of both glaucoma and gracile axonal dystrophy has been associated with accumulation of 
gamma-synuclein (Nguyen et al. 2011; Wang et al. 2004).
In collaboration with Dr Tibor Hortobagyi and the MRC London Brain Bank for Neurodegenerative 
Diseases, King’s College, London, we have studied expression and distribution of gamma-synuclein in 
the human spinal cord and frontal lobe using a set of histological samples from neurologically healthy 
individuals and patients with several types of neurological disorders. This allowed us to begin 
characterising the normal distribution of gamma-synuclein in the human CNS, and gave an invaluable 
opportunity to look for evidence of gamma-synucleinopathy in human disease. We were given access 
to tissues collected from patients with sporadic ALS, FUS/TLS or SOD1 associated familial ALS, 
frontotemporal lobar degeneration with motor neuron disease and TDP43-proteinopathy associated 
frontotemporal lobar degeneration.
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7.2. Results: Healthy and ALS spinal cord samples
Transverse sections of cervical or thoracic spinal cord were assessed from samples group including 
healthy control individuals, patients with sporadic ALS (sALS) and familial SOD1 or FUS associated 
ALS (fALS) (appendix 10). Age of death varied from 35 to 79 years of age, with post-mortem 
dissection (PDM) of tissues generally carried out within 72 hours of death. Staining was carried out 
with two sets of antibodies raised against gamma-synuclein. Affinity purified rabbit anti-human 
gamma-synuclein polyclonal antibodies (SK109) were produced by ourselves (Ninkina et al. 1998) and 
following optimization were used at a working concentration of 1:250. For confirmation of results 
staining was then repeated using a commercially available goat anti-human gamma-synuclein 
polyclonal antibody (E20) produced by Santa Cruz Biotechnology Inc, used at a concentration of 
1:100. No notable differences were detected between the patterns of staining produced by both 
antibodies. As such the findings obtained from each round of staining are discussed in unison.
7.2.1. Healthy control tissue samples
Immunostaining of healthy control tissue revealed a pattern of gamma-synuclein distribution 
comparable with that seen in wild type mice. The perikaryal cytoplasm of ventral horn motor neurons 
stained positive for the protein (Fig. 49a, b). No evidence of abnormally high levels or uneven 
distribution of gamma-synuclein within motor neuron cell bodies was detected. The surrounding 
neuropil was also weakly stained for the protein, with widespread punctate staining. The staining was 
observed in axons in both the grey and white matter (Fig. 49a-d). Transversely cut axons appeared as 
a small intensely stained central structure (~5^,m) surrounded by a gamma-synuclein negative myelin 
sheath (Fig. 49c, d). Longitudinally cut axons were stained for gamma-synuclein in an even manner, 
with no evidence of ballooned neurites or axonal spheroids (Fig. 49c). A similar pattern of gamma- 
synuclein distribution was also detected within the axons of the dorsal and ventral spinal nerve roots 
(Fig. 49e, f). Levels of gamma-synuclein appeared comparable between the motor and sensory axon 
populations.
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Fig. 49. Healthy spinal cord immunostained with antibodies against gamma-synuclein. Ventral horn 
motor neurons of healthy control tissue A049/03 immunostained with SK109 (a) and E20 (b) polyclonal 
antibodies. White matter region axons were not found to contain inclusion bodies following staining 
with SK109 antibodies, with gamma-synuclein distributed evenly (c). No abnormal structures were 
detected in the corticospinal tracts of either control case (d). Dorsal (e) and ventral (f) spinal nerve 
roots of healthy control tissue A130/09 immunostained with SK109 polyclonal antibody. Scale bars = 
50 p ir n .
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7.2.2. Amyotrophic lateral sclerosis tissue samples
Immunostaining of tissues donated by patients with sporadic or familial forms of ALS revealed a 
pattern of staining that initially appeared similar to that seen in healthy control tissue, however detailed 
examination revealed the presence of abnormal gamma-synuclein positive structures in several of the 
tissue samples. A large portion of ventral horn motor neurons were clearly lost from the sporadic and 
familial ALS patients’ spinal cords. Analysis of all remaining motor neurons in the tissue revealed a 
pattern of gamma-synuclein distribution that consistently matched that seen in the control samples, 
with an even distribution of protein throughout the perikaryal cytoplasm (Figs. 50, 51, 53). The typical 
intracellular inclusion structures normally associated with ALS, such as Bunina and skein-like bodies, 
were not detected by gamma-synuclein immunostaining in any of the samples studied (Fig. 53). 
Furthermore abnormal axonal structures, such as the ballooned neurites and axonal spheroids that 
were frequently detected in the spinal cords of gamma-synuclein overexpressing mice, were not 
detected in the grey matter of any of the human tissue samples assessed (Figs. 50, 51, 53).
Unexpectedly, assessment of white matter of several tissue samples did reveal structures intensely 
stained for gamma-synuclein that were not seen in control tissues. These appeared to fall into two 
classes, one prominent within the lateral corticospinal tracts, and a less defined class of structure in 
the peripheral dorsal and dorsolateral tissue. The lateral corticospinal tract structures were detected in 
four sets of sample tissue, being three cases of sporadic ALS, samples A251/09 (Fig. 50), A098/09 
(Fig. 53), and A038/01 (not shown) and a single case of SOD-1 associated fALS, sample A348/08 
(Fig. 51). The morphology of these structures was consistent across the tissues and samples, 
generally spherical, with a diameter of approximately 10-20|xm, and granular in composition. The 
presence of these structures does not appear to be a prerequisite to ALS, as they were absent or 
highly infrequent in the corticospinal tracts of other ALS sample tissues (Fig. 52). Similar ubiquitin 
positive structures were not detected within the corticospinal tracts of tissue containing the gamma- 
synuclein structures, suggesting the accumulated gamma-synuclein is not ubiquitinated and that 
ubiquitin and other ubiquitinated proteins are not components of these structures (Fig. 53).
The second class of structure was detected in the peripheral regions of dorsal and dorsolateral white 
matter in sALS cases A190/06 and A038/01, in SOD1-fALS case A348/08 and in FUS-fALS case 
A018/93 (representative images shown in Fig. 54). The structures appear to be distinct from those 
seen in the corticospinal tract. Gamma-synuclein immunostaining of these was notably weaker than 
those of the corticospinal tract, though variation in tissue processing cannot be ruled out as a cause of 
this difference. Though of comparable size to the corticospinal tract structures (10-20n,m width), the 
morphology of these structures was less regular and the shape was generally more angular. The 
occasional presence of nuclei within these structures suggests that they are most likely glial or a small 
class of neuronal cells (Fig. 54c, f).
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SK109 E20
Fig. 50. Gamma-synuclein immunostained spinal cord tissue from sALS sample A251/09. Low 
magnification images of the lateral region of cervical spinal cord stained using antibodies SK109 (a, c, 
e) and E20 (b, d, f). The blue line denotes the corticospinal tract region (CS) containing unidentified 
structures intensely stained for gamma-synuclein. Of all tissues assessed these structures were most 
prominently detected in the lateral corticospinal tract of sample A251/09, and were generally spherical 
and of granular composition (c, d). Neither set of antibodies detected inclusion bodies within ventral 
horn motor neurons (e, f). Scale bars: a, b = 500|j,m, c-f = 50n.m.
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SK109 E20
Fig. 51. Gamma-synuclein immunostained spinal cord tissue from SOD1-fALS sample A348/08. Low 
magnification images of the lateral corticospinal tract region (CS) of thoracic spinal cord stained using 
polyclonal antibodies SK109 (a, c, e) and E20 (b, d, f). Both sets of antibodies detected abnormal 
structures positive for gamma-synuclein (arrows) within this region (c, d). Gamma-synuclein positive 
inclusion bodies were not detected within the cytoplasm of ventral horn motor neurons (e, f). Scale 
bars: a, b = 500nm, c-f = 50jxm.
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Fig. 52. Abnormal gamma-synuclein positive structures were not common to all ALS tissues. Low 
magnification images of gamma-synuclein immunostained lateral corticospinal tract (CS) region of 
spinal cord tissue samples from patients with sporadic ALS (A190/06 & A195/04), FUS associated 
fALS (A086/02) and SOD1 associated fALS (A101/96). Tissues were stained with antibodies SK109 
(a, b) and E20 (c, d). Detailed assessment found abnormal gamma-synuclein positive structures to be 
absent (a, c, d) or highly infrequent (b) from the CS tracts of many of the ALS cases assessed. Scale 
bars: main panel = 50nm, insert = 50[xm.
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Gamma-synuclein (SK109) Ubiquitin
Fig. 53. Gamma-synuclein and ubiquitin immunostained spinal cord tissue from sALS sample 
A098/09. Lateral corticospinal tract region (a, b) and ventral horn motor neurons (c, d) of thoracic 
spinal cord stained using antibodies raised against gamma-synuclein (SK109, a, c) and ubiquitin (b, 
d). Abnormal structures in the corticospinal tract intensively stained for gamma-synuclein (a - arrows) 
were not detected with anti-ubiquitin antibody (b). In contrast intracellular, ubiquitin-positive, skein-like 
bodies (arrowhead, d) were not found to contain gamma-synuclein (c). Scale bars = 50nm.
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DorsalDorsolateral (left)
Fig. 54. Gamma-synuclein immunostained spinal cord tissue from FUS-fALS sample A018/93. 
Gamma-synuclein positive structures were detected in the peripheral dorsolateral (DL) (a, c, e) and 
dorsal (D) (b, d, f) spinal cord tissue of several samples. These structures (black arrows) stained 
positive for gamma-synuclein following incubation both with SK109 (c, e) and E20 (d, f) polyclonal 
antibodies. Red arrows indicate apparent nuclei seen in several of the structures. Scale bars: a, b = 
500nm, c-f = 50^m.
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7.3. Results: Frontotemportal lobar degeneration samples
Using the SK109 polyclonal antibody, we assessed the localization of gamma-synuclein in frontal 
lobes of five cases of sporadic FTLD-MND and two cases of FTLD with TDP-43 proteinopathy. 
Regrettably control tissue was unavailable for analysis. Immunostaining revealed the presence of 
gamma-synuclein in axons and neuron cell bodies of all frontal lobes analysed. A portion of neuron 
cell bodies in the inner and outer pyramidal cell layers stained for gamma-synuclein (Fig. 55a-d). 
Generally these neurons appeared healthy, with no obvious sign of degenerations. No intracellular 
inclusion bodies were detected in any of the tissue samples analysed. Widespread punctate staining 
was seen throughout the neuropil, signifying the presence of gamma-synuclein in transversely 
sectioned axons. Uniform distribution of gamma-synuclein was observed in longitudinally sectioned 
neurons, with no evidence of axonal spheroids (Fig. 55e). Axonal inclusions were not detected in any 
of the tissues assessed, but ballooned neurites containing gamma-synuclein were detected in TDP43- 
FTLD sample A409/08, though it should be noted these structures were rare (Fig. 55f, g).
Abnormal structures stained positive for gamma-synuclein were detected in the frontal lobe neuropil of 
FTLD-U/MND case A029/09 (Fig. 56). Several of the structures were detected on the periphery of cells 
null for gamma-synuclein (Fig. 56a-c). The structures were most likely not cellular; nuclei were not 
detected and the structures often had a width greater than 40|xm, too large for neurons or glia. It is 
feasible that the structures might be the remnants of degenerating neurons. Dystrophic neurites 
containing gamma-synuclein were also detected (Fig. 56d).
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Fig. 55. Gamma-synuclein immunostaining in the frontal lobe of FTLD samples. Representative gamma-synuclein positive neurons in the frontal lobe stained 
SK109 polyclonal antibodies. Gamma-synuclein positive axons from TDP43-FTLD sample A409/08 (arrows) accompanied by punctate neuropil staining were 
detected in all FTLD tissues analysed (e-g). Occasional ballooned neurites (arrowheads) containing gamma-synuclein were detected (f, g). Scale bars a-d = 
50p,m, e-g = 25p.m.
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Fig. 56. Abnormal accumulation of gamma-synuclein in FTLD-U/MND case A029/09. Rare, 
extracellular, gamma-synuclein positive structures were detected in the frontal lobe neuropil of FTLD- 
U/MND sample A029/09 (a). Several of these structures appear to be remnants of degenerate cell 
bodies (a-c). Structures resembling dystrophic axons were also detected (d). Arrow = border between 
gamma-synuclein negative cell and gamma-synuclein positive extracellular structure; arrowheads = 
dystrophic neurite-like structure positive for gamma-synuclein. Scale bars = 20^im.
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7.4. Summary of results and discussion
7.4.1. Gamma-synuclein in amyotrophic lateral sclerosis
Here we report the first evidence of an association between aberrant gamma-synuclein accumulation 
and cases of human ALS. Though gamma-synuclein was not found in the inclusions bodies typically 
present in motor neurons of ALS patients i.e. Bunina bodies or skein-like bodies, we detected 10- 
20nm spherical structures containing what appears to be granules of gamma-synuclein in three cases 
of sALS and one case of SOD1 associated fALS (Figs. 50, 51). These structures were tightly restricted 
to the lateral corticospinal tracts, areas of the spinal cord consisting of descending axons of motor 
neurons localised in cortical motor regions. Immunostaining against ubiquitin failed to detect similar 
structures within the corticospinal tract. Interestingly the gamma-synuclein positive structures were 
found in a subset of studied ALS cases, and were not detected in 10 of the 14 cases assessed (Fig. 
52, appendix 11). Retrospective analysis of the clinical histopathological notes provided by the MRC 
London Brain Bank revealed that these four cases shared two common features that were absent in 
cases lacking the structures. Firstly, loss of Betz cells from the motor cortex was more pronounced in 
these cases than the loss seen in patients without the gamma-synuclein positive structures. A similar 
pattern was seen Secondly, the spinal cord of patients with gamma-synuclein positive structures 
displayed marked demyelination in the corticospinal tract, characterised by substantial myelin pallor 
not seen in the spinal cord of other patients. These findings suggest the accumulation of gamma- 
synuclein within the corticospinal tract might represent a causative factor, or marker of, a subtype of 
ALS with substantial upper motor neuron involvement. It the future would be intriguing to assess the 
condition of lower motor neuron axons in similar patients to this subgroup, as similar axonal 
pathologcial structures might be present Unfortunately this is currently unfeasible, as peripheral nerves 
such as the sciatic nerve are not frequently collected from late stage ALS patients, and those that are 
often in highly degenerate condition.
7.4.2. Gamma-synuclein in frontotemporal lobar degeneration
In addition to analysis of spinal cord tissue, we also assessed the presence of gamma-synuclein in 
seven cases of FTLD, a form of dementia that is often accompanied by the onset of ALS. In five of 
these cases abnormal gamma-synuclein positive structures were absent. However ballooned neurites 
containing gamma-synuclein were observed in one case of TDP43 associated FTLD and possible 
remnants of degenerate neuron cell bodies in a case of FTLD-U/MND. In both cases these structures 
were very rare and few conclusions can be drawn from the data. Further assessment of histological 
samples will be required to determine whether these structures are a frequent feature of FTLD.
7.4.3. Identity of corticospinal tract gamma-synuclein structures
The identity of the gamma-synuclein positive structures in the spinal cord was unclear, their size and 
morphology suggesting several possibilities. The diameter of the structures is comparable with that of 
axonal spheroids, a common form of inclusion seen in neurodegeneration consisting of densely
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accumulated fibrillar, oligomeric protein (Galvin et al. 2000; Galvin et al. 1999; Wang et al. 2004). The 
likelihood of the structures being axonal inclusions is given further weight by the previous identification 
of gamma-synuclein as a component of axonal spheroids in several human neurodegenerative 
disorders. These include glaucoma (Surgucheva et al. 2002), PD, dementia with Lewy bodies and 
Hallervorden-Spatz syndrome (Galvin et al. 2000; Galvin et al. 1999). Similar structures have also 
been identified in mouse models of neurodegeneration. Gamma-synuclein positive axonal spheroids of 
a similar size are a feature of the progressive degeneration affecting sensory axons of the gracile tract 
of UCH-L1 deficient ‘gad’ mice (Wang et al. 2004). Furthermore comparable axonal inclusion 
structures, including spheroids and Lewy neurites, were frequently observed throughout the CNS of 
Thy1 nrvySN transgenic mice, particularly prominent in the grey and white matter of the spinal cord.
It should be noted however that the gamma-synuclein structures identified in the sALS and SOD1- 
fALS patients are more granular in appearance than typical axonal spheroids. This suggests a second, 
equally feasible possibility -  that the structures represent the intraperikaryal accumulation of gamma- 
synuclein. The absence of neuronal cell bodies within the corticospinal tracts makes the likelihood of 
the structures being intraneuronal unlikely. They may however represent the accumulation of gamma- 
synuclein within glial or phagocytic cells. This possibility should be treated with caution however, as 
the structures lack a typical features of glial morphology, such as process. The suggestion is not 
however implausible, as gamma-synuclein was detected in cells resembling glia in peripheral 
dorsal/dorsolateral regions of the spinal cords of several cases (Fig. 54). Furthermore the 
accumulation of gamma-synuclein within astrocytes has previously been reported in human cases of 
glaucoma (Surgucheva et al. 2002) and in animal models of the disease (Nguyen et al. 2011). There 
is no robust evidence to suggest that gamma-synuclein is expressed by glia, and the protein most 
likely enters the cell via endocytosis. Thus, if the gamma-synuclein positive structures seen in the 
corticospinal tracts are indeed non-neuronal, the protein contained within the cell may represent that 
phagocytosed by cells clearing debris from degenerating axons. A further, more speculative, scenario 
is also feasible. Nguyen et al. demonstrated that following the onset of glaucoma in mice, the transfer 
of gamma-synuclein from axons to a subset of astrocytes within the myelination transition zone of the 
optic nerve induces phagocytic activity not normally associated with the glia (Nguyen et al. 2011). It is 
feasible that a similar mechanism might occur in ALS, for example gamma-synuclein released by 
degenerating axons in the corticospinal tract might accumulate within glial cells and activate further 
phagocytosis of damaged axons.
The apparent involvement of gamma-synuclein in both ALS and glaucoma links it to another ALS- 
associated protein, optineurin. Autosomal dominant and recessive mutations have been identified in 
OPTN in fALS (Maruyama et al. 2010), with dominant negative mutations in the gene accounting for 
16.7% of cases of primary open angle glaucoma, the most common form of the disease (Rezaie et al. 
2002). Furthermore the protein has been identified in several different forms of inclusion body in sALS 
and fALS (Maruyama et al. 2010). Though the normal function of both proteins are unclear, it is
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tempting to speculate that optineurin and gamma-synuclein both induce degeneration through a 
similar mechanism, possibly through the formation of aberrant inclusions structures. Alternatively the 
proteins might disrupt an essential cellular function, for example protein degradation or cytoskeletal 
stability, such that a vulnerable class of neuron are lost.
In summary, we show that there is evidence of the aberrant accumulation of gamma-synuclein within 
the corticospinal tract, a mechanism that might represent a subtype of ALS in which the degeneration 
of upper motor neuron is notably pronounced. This conclusion should currently be interpreted with 
some caution, as it has been made from a small number of cases, utilising only histological samples. 
Further histological and biochemical assessment of ALS donor tissue should now be carried out to 
elucidate the role of gamma-synuclein in human ALS and fully identify the origin and composition of 
the corticospinal tract structures.
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8. Final discussion, perspectives and conclusions
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Though not currently recognised as a major contributing factor in human neurodegenerative disease, a 
growing body of evidence is beginning to suggest that under certain pathogenic conditions gamma- 
synuclein can play a role in neuronal dysfunction and degeneration. In this thesis we report that 
gamma-synuclein is potentially a contributing factor in the development of the motor neuron disease 
amyotrophic lateral sclerosis. This hypothesis is supported by evidence collected from tissue donated 
by patients affected by sporadic and familial forms of ALS and through the investigation of a novel 
mouse model of neuronal gamma-synucleinopathy.
8.1. Amyotrophic lateral sclerosis
We have identified large aberrant gamma-synuclein-positive structures in the lateral corticospinal 
tracts of the spinal cord in three cases of sALS and one case of SOD1-fALS. The presence of the 
structures correlates with myelin pallor of the lateral corticospinal tract and substantial loss of Betz 
cells from motor regions of the cortex, suggesting gamma-synuclein is associated with a subtype of 
ALS characterised by pronounced upper motor neuron involvement. Intriguingly the gamma-synuclein- 
positive structures do not match typical axonal inclusions such as spheroids, with analysis of available 
literature failing to identify similar corticospinal tract structures in ALS case studies. We therefore 
propose that these structures represent a novel form of pathological axonal inclusion associated with 
the loss of upper motor neuron populations, or alternatively represent a novel histopathological maker 
specific to cases of ALS with pronounced upper motor neuron damage. Whilst the identity of these 
structures remains unclear, both of the above possibilities are feasible.
Investigation into the role of gamma-synuclein in ALS thus requires much further research. We plan to 
continue our collaboration with Dr Tibor Hortobagyi and the MRC London Brain Bank for 
Neurodegenerative Diseases in an attempt to resolve the identity of the structures and assess their 
composition. We shall continue histological analysis of more tissue samples and additionally dissect 
lateral corticospinal tract tissue samples from donated spinal cord tissue held by the MRC Brain Bank. 
With these samples we hope to carry out sequential protein extraction experiments to determine the 
solubility of the gamma-synuclein contained within the corticospinal tract structures. Furthermore we 
currently have only had access to spinal cord tissue samples. This has allowed us to assess the 
condition of upper motor neuron axons, those within the corticospinal tract, however we have not been 
able to assess the condition of spinal cord motor neuron axons within the peripheral nerves. In future 
studies we hope to investigate the distribution of gamma-synuclein within these motor axon 
populations.
8.2. Thy1 mySN mice
Data collected from the ThylmySN transgenic mouse line further supports the hypothesis that 
gamma-synuclein is involved in ALS. The phenotype developed is remarkably similar to that 
developed in established transgenic mouse models of motor neuron disease (Bruijn et al. 1998; 
Gurney et al. 1994; Shan et al. 2010; Wegorzewska et al. 2009; Wils et al. 2010). Homozygous
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ThylmySH mice were found to develop substantial neurodegeneration throughout the CNS, 
accompanied by the deposition of gamma-synuclein in axonal and perikaryal inclusion structures, the 
activation of glia and the reduction in cytoskeletal components. Neurons of the motor system were 
most compromised, resulting in significant loss of motor function that worsened with age. Pools of 
upper and lower motor neurons were affected in a selective manner, with the largest class of motor 
axons being disproportionately sensitive to degeneration. The sensory system appears to be spared 
from degeneration, with no substantial deficits in tactile sensory function or change in the health of 
DRG or RGC populations detected.
These data collected from ThylmySN mice have several shortcomings that should be addressed, 
primarily with regard to the tolerance of the sensory system to degeneration. Variations in neuron 
survival might be in part due to fluxuations in the level of Thy1-driven transgene expression, with a 
correlation between greater expression and increased vulnerability. Thus comparable expression in 
both motor and sensory neuron populations needs to be more robustly confirmed. The samples of 
DRG collected for quantification contained an almost pure population of sensory neurons and 
transgene levels determined by qPCR are likely to be accurate. Though qPCR is a powerful technique 
for quantification of gene expression, the results collect for the spinal cord motor neurons are 
‘contaminated’ by the presence of other neuronal populations, and consequentially might not reflect 
the true level. Several techniques might be used to address this problem. More accurate dissection of 
spinal cord motor neurons is possible through use of laser capture dissection of frozen spinal cord 
samples. Unfortunately due to the number of neurons that would need to be dissected to collect 
enough DNA for analysis, this technique would be highly time consuming and is not practical. A more 
feasible option is utilising quantitative fluorescent in situ hybridization, whereby the level of 
fluorescence is proportional to transgene expression. To confirm that sensory neuron populations are 
universally less sensitive than motor populations it may be necessary to quantify further populations, 
for example neurons of the trigeminal ganglion. Finally, further behaviour test should be used to prove 
all sensory function is unaffected. Currently we have only tested tactile sensitivity, the response to 
touch. Protocols testing the response of mice to other sensations, such as heat and pain, are available 
and should be carried out upon the ThylmySN mice. Ultimately we hope to collect electrophysiological 
data of the animal’s response to differing sensory stimuli.
Further effort should also be made to track the progression of pathological changes in the CNS of 
ThylmySN mice, in particular investigating early changes in neuronal function. Significant deficits in 
the motor function of homozygous ThylmySN mice were detected by accelerating rotarod from two 
months of age (Fig. 4), with the acoustic startle test detecting a substantially reduced response from 
as early as three weeks (Fig. 6). With regard to the latter, the young mice did not appear to be deaf, 
responding to noise in their proximity similarly to wild type mice. As the Thy1 promoter only becomes 
active during p4-10 (Aigner et al. 1995), these data suggest that substantial functional changes are 
occurring early in the model of gamma-synucleinopathy. Furthermore the data suggest a dissociation
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between the expression of gamma-synuclein and the deterioration of motor function, with both hemi- 
and homozygous animals showing a substantially diminished response, suggesting that the deficits 
are due to aberrant activity of gamma-synuclein in young animals, rather than the damage its 
overexpression induces at latter stages of pathology. Precisely how gamma-synuclein is affecting 
startle response is highly unclear. Alterations in startle response have previously been reported in 
animals with motor system dysfunction, for example Huntington’s disease models R6/1 (Brooks et al. 
2011) and R6/2 (Carter et al. 1999), however these changes are only substantial at older ages where 
other motor deficits are also pronounced. The reduction of spinal cord noradrenaline concentration 
and loss of locus coeruleus dopaminergic neurons have been attributed to limited startle response in 
parkin null mice (Von Coelln et al. 2004). The concentration of noradrenaline and other spinal cord 
neurotransmitters can be assessed using the same HPLC methods used to assess striatal dopamine 
concentrations. The locus coeruleus population can also be quantified through immunostaining against 
tyrosine hydroxylase. Ultimately the acoustic startle response potential presents a novel 
endophenotype of ALS, and work should be carried out to identify if this deficit is common to other 
preexisting rodent models of ALS, for example mutant TDP-43 or SOD1 mice. There is currently no 
literature detailing such experiments in these animals. Ultimately if these animals do have a limited 
acoustic startle response, the test might have much use in the early, preclinical diagnosis of ALS in 
families where there is a risk of developing the disease. A variation on the protocol we used to assess 
ThylmySN mice is already currently used clinically to assess prepulse inhibition, deficits in which are 
a well defined endophenotype of schizophrenia, and the technique could be easily adapted for testing 
of acoustic startle response in ALS patients in the clinic,
Further electron microscopy analysis of peripheral nerves in younger ThylmySN mice should also be 
carried out, to allow us to determine whether large fibres are the most vulnerable and lost early in 
pathogenesis. Confirmation of this would confirm that the pathology seen in ThylmySN mice 
recapitulates the phenotype of other ALS models and the clinical pattern of disease progression. We 
additionally hope to characterise the morphology of neuromuscular junctions innervated by the 
peripheral nerves. There is compelling evidence to suggest the denervation of these motor end plates 
is the earliest event in the pathology affecting SOD1G93A transgenic mice (reviewed in Kanning et al. 
2010). We are currently attempting to optimize histological techniques to visualize these junctions, with 
initial data suggesting gamma-synuclein accumulates within the NMJs of eight-week old ThylmySN 
mice (see appendix 12).
8.3. Can the Thy1 mySN be considered a true model of ALS?
We have demonstrated that the gamma-synucleinopathy seen in ThylmySH mice closely parallels the 
pattern of damage seen in both human ALS and mouse models of the disease. A question does 
however remain; does the Thy1 mySN phenotype represent a clinically relevant form of ALS, or an 
experimental model in which the same neurons become damaged, but through a mechanism that has 
no precedent in nature?
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Clearly, the most compelling argument in support of the models clinical relevance is the identification 
of gamma-synuclein positive structures in the corticospinal tracts of several case of ALS. The 
presence of such structures is correlated with significant degeneration of upper motor neurons in 
motor regions of the cortex. Whether these structures are a direct causative agent in the degeneration 
of these neurons, or a secondary correlative marker is not clear. It is interesting to note that, though 
the population of upper motor neurons was not quantified in Thy1 mySN motor cortex, damage to the 
region was clear, demonstrated by the presence of substantial numbers of activated glial cells and 
deposition of ionic-detergent insoluble, gamma-synuclein positive inclusion bodies in the region. The 
presence of inclusion bodies suggests a pattern of dystrophy comparable to the formation of Betz cell 
inclusions in ALS. With regards to physiological relevance, it is essential to note that gamma-synuclein 
is normally present in upper motor neurons, though to a lesser extent than in spinal cord populations. 
Previously published data from our group demonstrated that endogenous SNCG is expressed in all 
regions of the murine adult cerebral cortex, increasing with age (Buchman et al. 1998b). Furthermore 
our studies of human motor cortex in FTLD confirmed the presence of the protein in these cortical 
regions, with data from healthy control spinal cords confirming the presence of the endogenous protein 
in corticospinal tract axons. It is therefore feasible that aberrant activity of gamma-synuclein might 
influence the health of upper motor neurons and their processes within the corticospinal tract. Further 
support for the clinical relevance of the Thy 1mySN model is provided by the formation of axonal 
inclusion bodies throughout the grey and white matter the ThylmySN mouse spinal cords, including 
the corticospinal tract regions. Identifying whether any of these structures match those detected in the 
human cases is not currently possible as the precise identity and composition of the human structures 
is unclear. They do not appear to be ubiquitinated and thus some of the gamma-synuclein- 
positive/ubiquitin-negative structures detected in the mouse spinal cord might be comparable 
structures. This speculation cannot be resolved until more is understood about the human structures, 
in particular we must identify further protein components that are specific markers of the structures. 
This will then allow us to accurately investigate the presence of comparable structures in the nervous 
system of ThylmySN mice.
With regard to treating the ThylmySN mice as an experimental model, our study of the progression of 
the ALS-like phenotype in ThylmySN mice has provided data that might help elucidate the 
mechanisms by which ALS develops in humans, several of which warrant further investigation to 
determine whether they provide therapeutic targets in the treatment of the disease. Two of these 
mechanisms shall be discussed below: the formation of intraneuronal inclusion bodies and the 
disruption of the neuronal cytoskeleton.
a. Aggregation
A common characteristic of overexpressed gamma-synuclein and the ALS associated forms of SOD1, 
TPD-43 and FUS/TLS is their heightened propensity to aggregate and produce inclusion bodies
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(Bruijn et al. 1998; Kwiatkowski et al. 2009; Neumann et al. 2009; Vance et al. 2009; Wegorzewska et 
al. 2009). The presence of inclusion bodies varied between regions of the ThylmySN CNS, in 
particular between motor and sensory cell bodies. Inclusion bodies were not detected in the sensory 
cell bodies of lumbar dorsal root ganglia, and detergent insoluble inclusions were present at a lower 
concentration in sensory regions of the cortex than in motor regions. The infrequency of inclusion 
structures suggests that some sensory neuron populations might possess innate protection against 
their formation, or conversely that some protective mechanisms are compromised in the vulnerable 
populations. The mechanism responsible for the regulation of protein folding and degradation are a 
candidate process. Interestingly levels of HSPB1, a molecular chaperones involved in the processing 
of misfolded proteins, were reduced in the cytoplasm of spinal cord motor neurons. The presence of 
ubiquitin-positive, gamma-synuclein-negative structures in the spinal cord further supports this 
hypothesis. These ubiquitinated structures may be a consequence of UPS saturation, whereby the 
system is overwhelmed with high levels of gamma-synuclein, resulting in the neglect of normal 
ubiquitinated protein degradation. It is feasible that further innate cellular mechanisms for removing 
abnormally folded or excessive proteins, might act more efficiently in the surviving neuron populations, 
for example through the up regulation of components to handle an abnormal load of toxic proteins. 
Higher efficiency would allow neurons to clear the high volume of transgenic gamma-synuclein prior to 
the onset of aggregation. This conjecture can be tested, by for example comparison of protein 
degradation systems in the spinal cord and DRGs. Up regulation or modification of UPS components 
can be assessed through qPCR and quantitative western blotting. Levels of autophagy may be 
assessed through measurement of levels of the autophagosome-associated protein LC3 (Klionsky et 
al. 2008). LC3 is found in two forms, as free cytosolic LC3-I or when bound to the autophagosomes, 
LC3-II conjugated to phosphatidylethanolamine. The ratio between these two forms may be measured 
through quantitative western blotting. Assessment of UPS function may also be carried out relatively 
simply, through commercially available kits produced by several manufacturers. Unfortunately results 
of these assays will have to be treated with caution, as they shall be affected by the heterogeneous 
composition of the spinal cord. All cell types possess protein degradation mechanisms, and thus in 
addition to motor neuron protein degradation activity, that of non-motor neuron cell types, including 
glia, will be included in the data.
b. Cytoskeleton disruption
Profound disruption of the neuronal cytoskeleton, caused by changes in distribution and decreased 
levels of components was observed in the CNS of symptomatic ThylmySN mice. Similar changes 
have also been demonstrated in ALS. Rare dominant mutations in the gene encoding NF-H have been 
detected in several cases of familial ALS (Al-Chalabi et al. 1999; Figlewicz et al. 1994; Tomkins et al.
1998). Accumulated neurofilaments are often detected within spinal cord motor neuron perikaryal 
inclusion bodies of ALS patients (Hirano et al. 1984; Ince et al. 1998; Rouleau et al. 1996). The 
question does remain as to whether this event represents a direct cause of neuronal dystrophy or an 
indirect correlate. Several lines of mice with altered expression of neuronal cytoskeleton components
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have demonstrated a clear association between the expression, assembly and homeostasis of 
neuronal intermediate filament and the development of ALS-like pathology. Selective degeneration of 
motor neurons and their axons has been reported in transgenic mice expressing mutant forms of NF-L 
(Lee et al. 1994), or overexpressing wild type NF-L (McLean et al. 2005; Xu et al. 1993), NF-M (Wong 
et al. 1995a), NF-H (Cote et al. 1993) or peripherin (Millecamps et al. 2006). Disruption of normal 
neurofilament homeostasis in these mouse lines was also linked to a prominent feature observed in 
Thy ImySN mice, the highly selective dystrophy and loss of the largest caliber motor axons in the 
peripheral nerves (Cote et al. 1993; Lee et al. 1994; McLean et al. 2005; Wong et al. 1995a; Xu et al. 
1993). Selective degeneration of large caliber motor neurons also occurs in mice null for NF-L 
(McLean et al. 2005; Zhu et al. 1997), with severe motor dysfunction and selective large fibre loss also 
being reported in a the NF-L deficient “Quiver” line of Japanese quail (Sakaguchi et al. 1993). Loss of 
large caliber fibres is also feature of SOD1 and TDP43 transgenic mice (Frey et al. 2000; Pun et al. 
2006; Shan et al. 2010) and ALS patients (Bradley et al. 1983; Kawamura et al. 1981; Theys et al. 
1999). As the supply and volume of neurofilaments determines the caliber of axons (Hoffman et al. 
1984), it may be speculated that disruption of normal neurofilament homeostasis by gamma-synuclein 
structurally destabilizes the largest caliber of axon, leaving them highly vulnerable to degradation. This 
may explain the apparent tolerance of sensory fibres, which are predominantly of the smaller fibre 
classes.
ALS-linked mutations in SOD1 have been found to directly influence the neuronal production of 
neurofilament components. The familial SOD1G93A and SODG41s mutations were found to result in a 
surprising gain-of-function in NSC34 cells (Ge et al. 2005). Both mutations conferred the ability to bind 
and destabilize NF-L mRNA through direct interaction with the 3’-UTR of the transcript (Ge et al. 
2005). Furthermore, mice expressing SOD1G93A progressively develop a selective down-regulation of 
NF-L mRNA, leading to reduced levels of NF-L subunits (Menzies et al. 2002). This hypothesis is 
given further credence by recent investigation of the ALS-associated, DNA/RNA binding protein TDP- 
43 and the finding of remarkably complementary data. The binding and stabilization of NF-L RNA was 
identified as a normal function of TDP-43 (Strong et al. 2007; Volkening et al. 2009). Strong et al 
demonstrated that TDP-43 was able to selectively interact with the 3’-UTR of NF-L mRNA in HEK293 
and Neuro2a cells. Truncated forms of TDP-43 with disrupted DNA/RNA binding motifs were unable 
carry out such stabilization (Volkening et al. 2009). This function appeared to have physiological 
relevance in humans, with both NF-L and NF-H mRNA co-immunoprecipitated with TDP-43 in 
homogenate prepared from human spinal cord (Strong et al. 2007). Even more surprisingly, TDP-43 
and SOD1 were also found to co-immunoprecipitate, along with 14-3-3 protein, suggesting that 
stabilization of neurofilament mRNA transcripts might be facilitated by a complex of the proteins. Thus 
loss-of-function mutation in TDP-43, or toxic gain-of-function mutations in SOD1 might disrupt normal 
neurofilament homeostasis by depleting the pool of free subunits through limited production.
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Data collected from ThylmySN mice in this study, and also in vitro work carried out prior to this thesis, 
strongly suggests that gamma-synuclein toxicity might also be mediated through disruption of normal 
neurofilament homeostasis. Levels of several cytoskeletal components were diminished in the sciatic 
nerves of these mice and the distribution of NF-H & NF-L were altered. Our laboratory has previously 
reported the ability of acute gamma-synuclein overexpression to increase the susceptibility of the 
neurofilament networks of cultured neurons to degradation by calcium-dependent proteases 
(Buchman et al. 1998a). It seems feasible that this latter function may also occur in vivo and 
potentially be the cause of the neurofilament disassembly seen in spine and nerves of ThylmySN 
mice. If this hypothesis were correct, the co-immunoprecipitation of gamma-synuclein with soluble NF- 
L subunits in the spinal cords of ThylmySN mice would suggest that gamma-synuclein acts directly in 
the process, possibly through recruitment of calpains to the neurofilament network. In a second, 
protease-free hypothesis, aberrant binding of gamma-synuclein to NF-L monomers may block their 
incorporation into the cytoskeleton, limiting the available functional pool of this essential subunit.
How disruption of neurofilament homeostasis results in the degeneration of neurons is currently 
unclear. A deeper understanding of this mechanism may explain why the selective nature of neuronal 
degeneration seen in ThylmySN mice recapitulates ALS pathology. Dysfunctional axonal 
transportation is emerging as a causative factor in neurodegeneration, in particular in ALS due to the 
extraordinary length of motor axons. Defective transport “strangulates” the synaptic machinery of vital 
components, resulting in a Wallerian-like dying back of the distal axon (Williamson and Cleveland
1999), and has also been associated with the accumulation of perikaryal neurofilaments often 
observed in ALS cases (Lee et al. 1994; Xu et al. 1993). Deficits in both fast and slow axonal transport 
have been reported in SOD1 mutant mice (Murakami et al. 2001; Williamson and Cleveland 1999; 
Zhang et al. 1997). Interestingly, ALS associated, autosomal dominant mutations have been identified 
in a component of the axonal transport system, the p150Glued subunits of dynactin, (Puls et al. 2003). 
Dynactin is a multi-subunit complex and an essential component of the axonal transport system, 
facilitating the binding of the transport motor unit dyenin with its cargo and the microtubule network 
upon which it translocates (Waterman-Storer et al. 1997). Rodent models have further confirmed the 
association between axonal transport disruption and motor neuron loss. Mice transgenic for a 
missense point mutation form of dynactin develop a similar phenotype, accompanied by the presence 
of SOD1 and neurofilament positive inclusion bodies (Hafezparast et al. 2003). Furthermore 
transgenic mice expressing high levels of the dynactin component dynamitin have significantly 
decreased retrograde transport caused by the dissociation of dynein and p150Glued, and develop 
neurodegeneration selective for motor neurons (LaMonte et al. 2002). Deficits in axonal transport have 
also been linked to disruption of neuronal neurofilament-network. Transgenic mouse lines expressing 
high levels of peripherin or NF-H both develop significant decreases in the speed of slow axonal 
transport (Collard et al. 1995; Marszalek et al. 1996; Millecamps et al. 2006; Xu et al. 1993).
177
Considering these findings it seems feasible that the reduced levels of cytoskeletal components 
observed in the spinal cord and sciatic nerves of ThylmySN mice are likely to cause similar disruption 
to axonal transport. The high levels of gamma-synuclein might also disrupt axonal transport through 
alternative mechanisms. The volume of the overexpressed protein targeted for translocation to the 
axon and synapse might place additional burden upon the axonal transport system, saturating the 
transport machinery, resulting in a decrease in essential components being transported to the 
synapses. A final possible mechanism by which gamma-synuclein might disrupt axonal is through the 
physical impairment. Large protein inclusions, for example axonal spheroids, are like to take up a large 
portion of the axons internal space, distorting/disrupting the neurofilament network and impeding the 
movement of cargo by axonal transport machinery. In summary, efforts should be made to assess the 
axonal transport system in ThylmySN mice, as significant disruption of the system might underlie the 
motor neuron loss developed by the animals.
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8.4. Concluding remarks
This thesis has demonstrated that gamma-synuclein overexpression is able to induce widespread, 
though selective, degeneration of the murine nervous systems that has a pronounced effect upon the 
motor system. This resulted in a phenotype that remarkably recapitulates many features seen in the 
motor neuron disease ALS and is similar to phenotype of certain other rodent models of this disease. 
These findings led us to investigate the relationship between the protein and the human disease, 
resulting in the identification of previously unseen aberrant structures in the corticospinal tract of the 
spinal cord of a subset of ALS patients. Retrospective comparison of the pathology reports for the 
donor patients suggested a correlation between the presence of the gamma-synuclein positive 
structures and the loss of cortical Betz cells and the demyelination of the spinal cord portion of their 
axons. We thus propose that these gamma-synuclein positive structures are a causative agent or 
marker of upper motor neuron damage characteristic for a subtype of ALS with substantial upper 
motor neuron involvement. As only spinal cord tissue samples were available for analysis, we are 
currently unable to ascertain whether the structures seen in the upper motor neuron derived 
corticospinal tract are also present in the axons of spinal motor neurons. Thus assessment of spinal 
motor neuron axons in the peripheral nerves is necessary to fully determine the extent of gamma- 
synuclein structure distribution. Concerted effort should now be made to clarify the identity of the 
gamma-synuclein positive structures and assess their frequency in cases of both sALS and fALS.
The ThylmySN mouse line may prove a useful tool in assessing the progression of ALS, in particular 
if an importance of gamma-synuclein pathology in the pathogenesis of certain subtypes of the disease 
is confirmed. Their accurate recapitulation of ALS suggests gamma-synuclein induces toxicity in a 
similar mechanism to SOD1, TDP43, FUS/TLS and other ALS associated proteins. The identity of this 
mechanism is unclear, however all the above proteins share characteristics, having all been shown to 
aggregate and influence the stability and production of neurofilament networks. The ThylmySN 
mouse line might have use as a tool for testing much needed new therapeutics in the treatment of 
ALS. Future analysis of the ThylmySN line might allow us to identify some of the initial changes in 
ALS pathogenesis, allowing for early intervention in the diseases progression.
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Appendix
Appendix 1. Congo red positive inclusion body quantification. Mean±SEM, (number) denotes 
number of spinal cord sections assessed. Statistics: Kruskal Wallis, Fischer’s a priori test.
Wild type Homozygous 
Thy1 mySN 
(mild)
Homozygous 
Thy1 mySN 
(severe)
Hemizygous 
Thy1 mySN
Cervical 0.5 ±0.19 7.3 ± 1.59 33.8 ±2.81 15.7 ±1.25
(30) (35) (32) (43)
Thoracic 0.1 ±0.08 10.3 ±0.89 23.2 ± 1.73 14.7 ±0.63
(55) (17) (37) (51)
Lumbar 0.7 ±0.29 10.1 ±2.48 26.0 ± 1.74 12.4 ±0.78
(19) (20) (24) (27)
Mean 0.3±0.1 8.8±1.1 27.6±1.3 14.5±0.6
(104) (72) (93) (121)
p<0.0001 p<0.0001 p<0.0001
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Appendix 2. Spinal motor neuron quantification. Mean±SEM, (number) denotes number of spinal 
cord sections assessed. Statistics: Kruskal-Wallis, Fischer’s a priori.
Wild type Homozygous 
Thy1 mySN 
(mild)
Homozygous 
Thy1 mySN 
(severe)
Hemizygous 
Thy1 mySN
Cervical 7.3 ±0.47 3.5 ± 0.53 2.3 ± 0.22 4.5 ± 0.26
(39) (29) (50) (100)
Thoracic 5.5 ± 0.28 1.7 ±0.20 2.0 ±0.17 3.4 ±0.15
(79) (60) (103) (112)
Lumbar 5.3 ± 0.37 3.8 ± 0.28 2.5 ± 0.25 3.4 ±0.16
(42) (60) (42) (73)
Mean 5.9±0.2 2.8±0.2 2.2±0.1 3.8±0.1
(160) (149) (195) (285)
p<0.0001 p<0.0001 p<0.0001
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Appendix 3. Dopaminergic neuron population quantification in the SNpc and VTA of twelve­
month old wild type and homozygous T/iyfmySN mice. Mean±SEM, (number) denotes number of 
SNpc/VTA assessed. Statistics: Mann-Whitney U-test.
SNpc VTA
Wild type 2632.7±474.7 2591.1 ±596.0
(6)
Homozygous TAiyfmySN 2244.5±502.5 2202.9±403.8
(6) p=0.2491 p=0.4712
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Appendix 4. Spinal cord HPLC data. Mean±SEM, (number) denotes number of animals assessed. 
Statistics: Mann-Whitney U-test.
Wild type 
(5)
Homozygous Thy1 mySN 
(7)
DA 52.1 ±3.92 64.0±5.72
(pmol/mg) p=0.2556
DOPAC 6.4±0.72 6.8±0.4
(pmol/mg) p=0.4168
HVA 5.2±0.49 6.6±0.79
(pmol/mg) p=0.2556
5-HIAA 2.0±0.26 2.4±0.25
(pmol/mg) p=0.8710
NA 0.9±0.16 0.8±0.19
(pmol/mg) p=0.6261
DOPAC:DA 0.12±0.01 0.10±0.01
p=0.6261
HVA:DA 0.11±0.01 0.11±0.01
p=0.4168
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Appendix 5. Motor neurons pools are selectively sensitive to gamma-synuclein toxicity 
whereas sensory neurons are resistant. For cranial nuclei, left and right nuclei were quantified 
separately in each animal. For dorsal root ganglia, left and right ganglia for both lumbar 4 and 5 were 
quantified separately. Mean±SEM, (number) denotes number of nuclei/ganglion assessed. Statistics: 
Mann-Whitney U-test.
Wild type Homozygous TTiyfmySN
Abducens nu. 265.0 ± 22.3 
(8)
248.0 ± 20.7 
(10) 
p=0.9645
Facial nu. 2180.0 ± 105.9 
(8)
2102.0 ±71.7 
(10) 
p=0.824
Motor trigeminal nu. 1010.0 ±38.7
(9)
668.0 ± 57.9 
(10) 
p=0.0012
L4/L5 dorsal 
root ganglion
4456.3 ± 150.6 
(32)
4308.2 ±117.2 
(32) 
p=0.441
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Appendix 6. Cytoskeietal components are depleted in the sciatic nerves of the most 
symptomatic homozyogus ThylmySN mice. Levels of neuronal cytoskeietal proteins in the sciatic 
nerves of twelve-month old wild type, mildly and severely affected ThylmySN mice. Mean±SEM, 
(number) denotes number of nerves assessed. Statistics: Mann-Whitney U-test.
Protein Wild type Homozygous
ThylmySN
(Mild)
Homozygous
ThylmySN
(Severe)
Neurofilament-H 1.00±0.112 0.79±0.742 0.34±0.054
( 5 ) (6) ( 5 )
Neurofilament-M 1.00±0.025 0.74±0.124 0.45±0.153
( 3 ) (2) (3 )
Neurofilament-L 1.00±0.103 0.72±0.963 0.36±0.061
( 5 ) (6) ( 5 )
Peripherin 1.00±0.238 0.87±0.224 0.76±0.176
( 3 ) (3 ) (3 )
Aipha-tubulin 1.00±0.117 0.89±0.617 0.41 ±0.145
( 3 ) (3 ) (3 )
Actin 1.00±0.190 0.94±0.330 1.05±0.505
( 3 ) (3 ) (3 )
Myelin Basic Protein 1.00±0.095 0.61±0.100 0.47±0.101
(21 kDa) ( 3 ) (3 ) (3 )
Myelin Basic Protein 1.00±0.091 0.33±0.146 0.18±0.006
(18kDa) ( 3 ) (3 ) ( 3 )
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Appendix 7. Nerve fibre counts for sciatic nerve.
Mean±SEM, (number) denotes number of nerves from individual animals assessed. 
Statistics: Mann-Whitney U-test
Sciatic Nerve Total Healthy Damaged
A-fibres A-fibres A-fibres
Wild type 
(7)
269.4 ±14.3 264.4 ±13.9 5.1 ±1.1
TTiyfmySN (mild) 275.7 ±19.2 266.4 ± 20.2 9.2 ±2.5
(3) p=0.9156 p=0.9789 p=0.0493
Thylm ySN (severe) 202.2 ± 10.3 162.8 ±10.5 39.4 ± 3.9
(7) p=0.0005 p=0.0001 p<0.0001
Sciatic Nerve Total Encapsulated Atypical
C-fibres C-fibres C-fibres
Wild type 576.0 ± 90.6 570.1 ±91.2 5.9 ±5.9
(3)
T/iyfmySN (mild) 556.0 ±138.8 553.6 ±139.2 2.5 ±2.4
(3) p=0.6458 p=0.6756 p=0.5997
Thy1 mySN (severe) 
(3)
529.7 ± 45.8 
p=0.8605
308.0 ± 54.7 
p=0.0318
221.8 ±36.5
p<0.0001
Appendix 8. A-fibre quantification of dorsal and ventral nerve roots from twelve-month old control and homozygous TAiyfmySN mice. Mean±SEM, 
(number) denotes number of nerves from individual animals assessed. Statistics: Mann-Whitney U-test.
Dorsal Nerve Root Total A-fibres 
(per 100pm2)
Healthy A-fibres 
(per 100pm2)
Damaged A-fibres 
(per 100pm2)
Phagocyte nuclei 
(per 100pm2)
Mean A-fibre area 
(Mm2)
Wild type 
(9)
262.5±10.0 258.8±9.8 3.7±0.6 0.4±0.2 25.4±1.02
Homozygous TibyfmySN 
(10)
254.6±9.7
p=0.8493
239.0±9.8
p=0.2716
15.6±1.1
p<0.0001
4.6±0.8
p=0.0002
25.0±1.08
p=0.600
Ventral Nerve Root Total A-fibres 
(per 100pm2)
Healthy A-fibres 
(per 100pm2)
Damaged A-fibres 
(per 100pm2)
Phagocyte nuclei 
(per 100pm2)
Mean A-fibre area 
(Mm2)
Wild type 
(9)
95.8 ±3.4 94.3 ± 3.3 1.5 ±0.4 0.1 ±0.1 73.4±3.05
Homozygous Thy1 mySN 
(10)
78.6 ±3.9 
p=0.0005
62.5 ±3.1
p<0.0001
16.2 ±1.9
p<0.0001
8.4 ± 1.2
p<0.0001
37.1±1.08
p<0.0001
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Appendix 9. A-fibre quantification for optic nerves of twelve-month old wild type and 
homozygous T/iyfmySN mice. Mean±SEM, (number) denotes number of nerves from individual 
animals assessed. Statistics: Total A-fibres, Mean A-fibre area: Mann-Whitney U-test; g-ratio: Two- 
sample t-test
Optic Nerve Total A-fibres 
(per 100pm2)
Mean A-fibre area 
(pm2)
g-ratio
Wild type 4307.2±138.4 1.86±0.07 0.51±0.01
(6)
Homozygous 3975.3±143.5 1.90±0.07 0.50±0.00
Thy1 mySN
(6) p=0.0750 p=0.9398 p=0.262
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Appendix 10: Summary of spinal cord tissue.
Gamma-synuclein positive structures
Sample Sex Age PMD Diagnosis Motor neuron 
Cytoplasm
Corticospinal
tract
Dorsal/Dorsolateral 
white matter
A049/03 M 79 24 Control: Mild aqinq chanqes No No No
A139/09 M 54 31 Control: Normal brain No No No
A147/08 M 61 44 Unspecified MND No No No
A175/08 M 71 58 Unspecified MND No No No
A194/04 M 55 54 sALS No No No
A195/04 F 78 69 sALS No No No
A190/06 F 57 48 sALS No No Yes
A038/01 M 68 8 sALS No Yes Yes
A251/09 M 78 2 sALS No Yes No
A098/09 M 72 26 sALS No Yes No
A101/96 F 46 5 SOD1 fALS No No No
A348/08 F 69 64 SOD1 fALS No Yes Yes
A034/06 M 46 14 SOD1 fALS No No No
A063/08 F 35 20 FUS fALS No No No
A086/01 F 35 24 FUS fALS No No No
A018/93 M 33 71 FUS fALS No No Yes
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Appendix 11. Summary of frontal lobe tissues assessed as part of this study.
Sample Sex Age PMD Diagnosis
A029/09 M 69 42 FTLD with ubiquitin inclusions and probable MND
A244/07 M 68 46 FTLD with MND
A211/05 F 67 6 FTLD with MND
A030/06 M 71 44 FTLD with MND
A174/08 F 43 69 FTLD with MND with ubiquitin & TDP-43 positive inclusion
A013/10 M 69 6 TDP43-FTLD
A409/08 M 78 N/A TDP43-FTLD
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Appendix 12. Pilot data: Gamma-synuclein accumulation within the neuromuscular junctions 
of two-month old homozygous ThylmySN mice. Immunostaining against gamma-synuclein (SK23, 
1:100) revealed high levels of the protein within the neuromuscular junctions of triceps surae muscles 
of two-month old Thy1 rrrySN mice (a). Similar immunostaining did not detect such structures in the 
muscles of wild type mice (not shown). To confirm the presence of accumulated gamma-synuclein in 
homozygous ThylmySN mouse NMJs, fluorescent immunostaining using acetylcholine receptor 
specific alexafluor-633 conjugated alpha-bungarotoxin (red) and antibodies against gamma-synuclein 
(green) was carried out on triceps surae muscles of two-month old wild type (b) and homozygous 
ThylmySN mice (c). Alpha-bungarotoxin consistently labeled NMJs of wild type mice, however 
endogenous gamma-synuclein levels were too low to detect by immunostaining (b). High levels of 
gamma-synuclein were frequently observed within the NMJs of homozygous ThylmySN muscles, 
though levels in the distal portion of motor axon were too low to detect (c). These finding suggest the 
abnormal accumlation of gamma-synuclein within the NMJs of homozygous ThylmySN mice is an 
early event in the gamma-synucleinopathy. White arrowheads = accumulation of gamma-synuclein, 
scale bar = 50p,m.
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The role of a-synuclein in pathogenesis of familial and idiopathic forms of Parkinson’s disease, and other 
human disorders known as a-synucleinopathies, is well established. In contrast, the involvement of two 
other members of the synuclein family, p-synuclein and Y-synuclein, in the development and progression 
of neurodegeneration is poorly studied. However, there is a growing body of evidence that a-synuclein 
and p-synuclein have opposite neuropathophysiological effects. Unlike a-synuclein, overexpressed (3-synu- 
clein does not cause pathological changes in the nervous system of transgenic mice and even ameliorates 
the pathology caused by overexpressed a-synuclein. To assess the consequences of excess expression 
of the third family member, Y-synuclein, on the nervous system we generated transgenic mice expressing 
high levels of mouse Y-synuclein under control of Thy-1 promoter. These animals develop severe age- and 
transgene dose-dependent neuropathology, motor deficits and die prematurely. Histopathological changes 
include aggregation of Y-synuclein, accumulation of various inclusions in neuronal cell bodies and pro­
cesses, and astrogliosis. These changes are seen throughout the nervous system but are most prominent 
in the spinal cord where they lead to loss of spinal motor neurons. Our data suggest that down-regulation 
of small heat shock protein HSPB1 and disintegration of neurofilament network play a role in motor neurons 
dysfunction and death. These findings demonstrate that Y-synuclein can be involved in neuropathophysio­
logical changes and the death of susceptible neurons suggesting the necessity of further investigations of 
the potential role of this synuclein in disease.
INTRODUCTION
The importance o f  a-synuclein in the developm ent and pro­
gression o f  the human disorders known as synucleinopathies 
is beyond doubt although the exact m echanism  o f  neurodegen­
eration induced by dysfunction o f  this protein is the subject o f 
heated debate [for recent reviews see Ref. (1)]. On the other 
hand, (3-synuclein is believed to be a neuroprotective 
factor— in several experimental in vivo systems, expression 
o f  this protein ameliorated neuronal pathology caused by over­
expression o f  a-synuclein (2 -7 ) .
Despite lim ited information, certain known properties o f 
Y-synuclein place it structurally and functionally in between 
the other two members o f  the synuclein family. For instance,
Y-synuclein adopts a free-state residual secondary structure 
similar to a-synuclein  w hereas in an extended mode its struc­
ture resembles (3-synuclein (8 ). These structural differences 
correlate w ith different propensities o f  the synucleins to aggre­
gate. A ggregation o f  a-synucle in  in vivo is believed to be a 
crucial event in pathogenesis o f  these diseases, with intermedi­
ates (i.e. soluble oligom ers) and final products (i.e. larger, 
insoluble and im m unohistochem ically detectable aggregates) 
playing different but equally im portant roles (1,9,10). Conver­
sely, a protective function o f  (3-synuclein seems to correlate 
with its negligible propensity  to aggregate and its ability to 
retard the aggregation o f  a-synuclein  in vitro (2 ,11-13). 
Y-Synuclein is able, albeit less efficiently than a-synuclein, 
to aggregate and form fibrils in vitro. However, like
*To whom correspondence should be addressed at: Cardiff University, Museum Avenue, Cardiff, CF10 3AX, UK. Tel: + 4 4  2920879068; Fax: +44 
2920874116; Email: buchmanvl@cardiff.ac.uk
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(3-synuclein, it has also been shown to inhibit the aggregation 
o f a-synuclein (11,12). In contrast to a-synuclein, acute over­
expression o f  y-synuclein does not induce death o f  cultured 
neurons but perturbs their neurofilament network by an 
unknown mechanism (14,15).
While a-synuclein is the m ajor component o f  Lewy bodies 
and other histopathological hallm arks o f synucleinopathies, 
neither (3-synuclein nor y-synuclein have been found in 
these structures. Nonetheless, changes in their expression or 
distribution (1 6 -1 8 ) and accum ulation o f  these proteins in 
unconventional histopathological lesions w ithin neurons and 
axons (Refs 19-21  and our unpublished observations) have 
been observed in several hum an neurodegenerative disorders 
as well as certain transgenic or pharm acological animal 
models o f  neurodegeneration (16 ,22-26). Therefore, it is 
tem pting to speculate that accum ulation and aggregation o f 
y-synuclein might be a causative factor in the development 
o f certain, yet to be identified, types o f  neurological disorders.
To test whether increased and/or ectopic expression o f 
mouse y-synuclein could trigger neurohistopathological 
changes and phenotypes typical for synucleinopathies, we pro­
duced transgenic mice with pan-neuronal overexpression o f 
this protein. Animals expressing high levels o f y-synuclein 
develop severe and fatal neurological disease associated with 
aggregation o f the overexpressed protein and its deposition 
in cytoplasm ic and axonal lesions.
RESULTS
Production of transgenic animals and analysis of transgene 
expression
Transgenic mice expressing elevated levels o f mouse wild- 
type y-synuclein were generated using the Thy-1 neuron- 
specific expression cassette (Fig. 1A) that we and others 
have used previously for generating lines expressing high 
levels o f  either a-synuclein (2 7 -3 0 ) or (3-synuclein (5). 
M ice from one line, T hylm yS N , expressed high levels o f 
m ouse y-synuclein throughout the nervous system and devel­
oped an age-dependent neurological phenotype. Mice o f a 
second line with lower levels o f  the transgene expression did 
not develop a noticeable phenotype and were excluded from 
this study.
Transgenic mice were produced on a pure genetic back­
ground and the colony was maintained by backcrossing hemi- 
zygous T hylm yS N  mice with C57B16 mice. These 
hemizygous animals were indistinguishable from their wild- 
type litterm ates during the first year o f  their life. Later most 
o f  these mice developed a clasping reflex, abnormal posture 
and gait, as well as other signs o f  m otor dysfunction (see 
below). In an attempt to augment the pathology we bred 
T hylm ySN  mice to homozygosity. This resulted in an 
approximate doubling o f  the transgene expression levels, 
which in dorsal root ganglia (DRG) o f  12-month-old mice 
reached the level that was approximately seven times higher 
than the level o f endogenous y-synuclein mRNA in these 
ganglia (Fig. IB). Offspring from intercrosses o f  hemizygous 
parents showed a normal M endelian distribution o f genotypes. 
H omozygous anim als appeared normal during the first few 
months o f  life despite a very high level o f y-synuclein
mRNA expression throughout their nervous system. For 
instance, in the spinal cord o f young adult homozygous trans­
genic anim als, the level o f this mRNA was approxim ately 16 
times higher than in the trigeminal ganglion o f  wild-type mice 
that was used for reference due to the high endogenous level 
o f  y-synuclein mRNA expression and homogeneity o f  cell 
population in this structure (Fig. IB , top panel). In the 
spinal cord o f  wild-type animals, only m otor neurons 
express y-synuclein (31), but in T hylm ySN  mice, m otomeur- 
ons and additional types o f spinal neurons expressed 
y-synuclein, w hich explains, in part, the robust increase o f 
both y-synuclein m RNA (Fig. IB , bottom panel) and protein 
(Fig. 1C and D) levels. The same applied to other regions 
(Fig. ID  and data not shown) where endogeneous y-synuclein 
expression is restricted to certain neuronal populations (32) 
but the transgene is expressed in the majority o f neurons. Sub­
stantial accum ulation o f  y-synuclein did not affect the levels 
o f  expression o f  the other two members o f synuclein family 
(Fig. ID).
Overexpression of y-synuclein is associated with a severe 
neurological phenotype and early lethality of transgenic 
mice
The health o f  hom ozygous anim als started to deteriorate sub­
stantially from the age o f  6 - 9  months. The first signs o f path­
ology were sim ilar to those observed in the older hemizygous 
mice, including clasping reflex, hunchback posture and abnor­
mal gait (Fig. 2 A -C  and Supplem entary Material movie). In 
contrast to hem izygous anim als, clinical signs o f pathology 
in homozygous anim als progressed rapidly with all animals 
developing pareses o f  their lim bs by the age o f 9 -1 6  
months followed by paralyses and loss o f  the righting reflex 
(Fig. 2D). A t this stage, the anim als were sacrificed to 
prevent further suffering. Typically, the paraparesis o f the 
forelimbs becam e obvious earlier than that o f  the hindlimbs. 
Lifespan o f  hom ozygous transgenic mice was also limited; 
not a single mouse survived beyond the age o f 16 months in 
two independent cohorts (total 74 mice) housed in two 
animal facilities (Fig. 2E).
The onset and progression o f  m otor dysfunction was quan­
tified using several different tests. Balance and coordination 
were already significantly im peded in homozygous 
T hylm ySN  mice younger than 6  m onths before they displayed 
obvious clinical signs o f  pathology (Fig. 3 and Supplementary 
M aterial Tables SI and S2). T heir ability to turn on an 11 mm 
diam eter beam  and their perform ance on a constant speed 
rotarod were both com prom ised by the age o f 4 months 
(Fig. 3A and Supplem entary M aterial Table SI). Using the 
accelerating rotarod test, it was possible to demonstrate 
m otor im pairm ents as early as at 2 months o f age. At this 
time point the hom ozygous T hy lm yS N  mice were indistin­
guishable from w ild-type m ice by any other criteria examined 
(Fig. 3B). H em izygous T hy lm yS N  mice developed a similar 
m otor dysfunction but w ith a much greater latency and 
slower progression. This is exemplified by their performance 
on the rotarod that only declined significantly after the age 
o f  18 months (Fig. 3). In the footprint test, the length o f 
stride o f hem izygous 18-m onth-old animals was significantly 
shorter than that o f  their wild-type littermates, while
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Figure 1. Expression of y-synuclein in wild-type and transgenic mice. (A) A map of DNA fragment used for producing transgenic animals. A mouse y-synuclein 
cDNA fragment was inserted between exons II and IV of the mouse Thy-1 gene. (B ) Expression of y-synuclein mRNA in neuronal tissues of wild-type and 
transgenic animals measured by quantitative real-time RT-PCR. Bar charts show the fold y-synuclein mRNA level increase (mean ±  SEM) in the spinal 
cord of homozygous and heterozygous 8-week-old ThylmySN mice compared with the level in the trigeminal ganglion of newborn wild-type mice (top 
chart) and in the DRG and spinal cord of homozygous 12-month-old ThylmySN mice compared with the level in the DRG of 12-month-old wild-type mice 
(bottom chart). (C) Western blot analysis of y-synuclein in the spinal cord of 1-year-old wild-type and homozygous ThylmySN animals. The top panel 
shows a normalization western blot simultaneously probed with antibodies against GAPDH and y-synuclein. The same undiluted wild-type samples and 
1:1000, 1:500 or 1:250 diluted transgenic samples were analysed on a western blot shown in the bottom panel. (D ) Western blot analysis of three synucleins 
in the spinal cord and brain regions of 1-year-old wild-type and ThylmySN transgenic (hemi- and homozygous) animals. More y-synuclein accumulates in 
neuronal tissues of homozygous than hemizygous mice but a ladder of multimeric y-synuclein-positive bands is not observed even on overexposed western 
blots (top panels).
homozygous mice already showed this impairment at the age 
o f  6  months (Supplementary Material Fig. SI and data not 
shown). The horizontal beam test was most sensitive for 
detecting early signs o f motor deficit in hemizigous 
T hylm ySN  animals; their ability to perform both parts o f 
the task was already obviously compromised at the age o f 
12 months (Supplementary Material Tables 1 and 2).
In summary, pan-neuronal overexpression o f mouse 
y-synuclein in transgenic mice was associated with a progressive 
age- and gene dose-dependent motor phenotype that recapitulates
phenotypes described earlier for several lines expressing human 
a-synuclein under control o f the same Thy-1 promoter or other 
pan-neuronal promoters (27,30,33-39).
A ggregation  and  fibrilla tion  of y-synuclein in the nervous 
system  o f tran sgen ic  m ice
It was feasible to suggest that pathological changes in the 
nervous system o f  T hylm ySN  transgenic mice would also 
be similar to the changes observed in the nervous system o f
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Figure 2. Transgenic animals develop pathology that leads to premature death. Typical appearance of ThylmySN transgenic mice at the initial stage of path­
ology development with clasping of all limbs when hanging by the tail (A) and a hunchback posture (B). Examples of severe gait abnormality in 9- and 
12-month-old homozygous y-synuclein transgenic mice detected by the footprint test. Forefeet prints are blue and hindfeet prints are red (C). At the advanced 
stage of pathology, the righting reflex is substantially impaired (D). Kaplan-Meier plot of wild-type (squares, n =  49), hemizygous ThylmySN (triangles, 
n =  87) and homozygous ThylmySN (circles, n =  74) mice survival over the 26 months period (E).
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Figure 3. Rotarod performance of -y-synuclein transgenic mice. Groups of mice of different ages and genotypes were tested on Ugo Basile rotarod using constant 
speed (A) or accelerating (B) modes as described in Material and methods. Line graphs show mean ±  SEM of latency to fall for wild-type (diamonds), hemi­
zygous ThylmySN (squares) and homozygous (triangles) ThylmySN mice at different age. Statistically significant difference (P < 0.01, Student’s /-test) in 
performance between transgenic and wild type groups at particular age is denoted by asterisks.
a-synuclein transgenic animals and might be accompanied by 
aggregation o f y-synuclein in neurons and their processes. 
Therefore, we looked for signs o f y-synuclein aggregation 
throughout the nervous system o f  homozygous Thylm ySN  
mice that developed obvious pathology.
Immunohistochemical analysis o f T hylm ySN  brain and 
spinal cord sections stained with highly specific SK23 anti­
body (31) revealed increased production o f y-synuclein in 
many neurons expressing endogenous y-synuclein as well as 
ectopic production in other neurons normally devoid o f this 
protein. In contrast to the predom inantly neuritic localization 
o f endogenous y-synuclein in the brain o f adult wild-type 
mice (32), overproduced protein also accum ulated in the neur­
onal cell bodies (Supplementary Material Fig. S2). Although 
immunostaining in the majority o f transgenic mouse brain 
neurons was diffusely distributed throughout the cytoplasm, 
in subsets o f  neurons, we detected y-synuclein-positive
cytoplasm ic inclusions which, in some cases, were clearly 
eosinophilic and also showed some remarkable resemblance 
to the a-synuclein-positive structures seen in Lewy body dis­
eases (Fig. 4A and Supplem entary M aterial Fig. S2D and E). 
However, m uch more typical was the presence of 
y-synuclein-positive spheroids and dystrophic neurites 
(Fig. 4A and Supplem entary M aterial Fig. 2D and E) that 
were not seen in the nervous system o f wild-type littermates 
(Fig. 4A and data not shown).
These abnorm al structures were observed throughout the 
nervous system but were most abundant in the spinal cord 
(Fig. 4A), which is consistent with the observed clinical 
pattern o f  pathology. Therefore, the spinal cord was used to 
determine w hether aggregated and fibrillated forms o f 
y-synuclein were present in neuronal tissues o f animals over­
expressing this protein. Sequential fractionation o f  the spinal 
cord tissues dem onstrated that, in contrast to endogenous
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Figure 4. 7-Synuclein-positive aggregates and fibrils in the spinal cord of 12-month-old transgenic mice detected by anti-mouse y-synuclein SK23 antibody. (A) 
Immunostained transverse sections through the spinal cord of wild-type and homozygous y-synuclein transgenic mice. Higher magnification images of the 
ventral horn region are shown on lower panels, scale bars =  50 pm. A y-synuclein-positive cytoplasmic inclusion (further magnified in the left inset) is indicated 
by the small arrowheads, spheroids by large arrowheads, dystrophic and ballooned neurites by small and large arrows, correspondingly. The right insert shows a 
hematoxylin and eosin-stained spinal cord motor neuron with an eosinophilic cytoplasmic inclusion, scale bar =  20 pm. (B) Western blot analysis of y-synuclein 
in high salt (HS), HS/Triton X-100 (HS/T), RIPA- and SDS-soluble fractions of the spinal cord of wild-type, hemizygous and homozygous mice. (C) 
Immuno-electron microscopy detection of y-synuclein fibrils in a sarcosyl-insoluble fraction of the homozygous ThylmySN mouse spinal cord.
y-synuclein, which was completely soluble in salt/non-ionic 
detergent buffers, a substantial fraction o f y-synuclein in the 
spinal cord o f Thylm ySN  mice remained insoluble after 
extraction with these solutions but could be partially solubil­
ized in the ionic detergent-containing buffers (Fig. 4B) or in 
formic acid (data not shown). Immuno-electron microscopy 
o f sarcosyl-insoluble material revealed the presence o f fila­
ments decorated with antibody against y-synuclein (Fig. 4C). 
These results demonstrate that increased expression o f 
y-synuclein in mouse neurons can cause aggregation and 
fibrillation o f this protein followed by formation o f large intra­
cellular inclusions.
H istopathology in the spinal cord  of transgenic mice
Amyloid-like inclusions were detected by Congo Red 
(Fig. 5 B -D ) or thioflavine S (data not shown) staining o f 
spinal cord or brain tissue o f hemi- and homozygous mice, 
even at a stage when clinical signs o f pathology were mild
(only clasping reflex). The number o f the Congo Red-positive 
inclusions substantially increased as disease progressed 
(Fig. 5E).
Neuronal degeneration is commonly associated with the 
activation o f  microglia and astroglia in affected regions o f 
the nervous system. A large number o f GFAP-positive cells 
with morphology typical for activated astrocytes were found 
in the spinal cord gray m atter o f  severely affected homozygous 
T hylm ySN  mice (Fig. 6 A). The level o f  GFAP was also sub­
stantially increased in the spinal cord tissue o f homozygous 
and, to a lesser extent, age-m atched hemizygous animals 
w ithout obvious signs o f pathology (Fig. 6 B) but not in the 
spinal cord o f young homozygous mice. However, using anti­
bodies against two different markers, Ibal and C D llb , we 
failed to detect clear signs o f microglia activation (data not 
shown).
A nother common feature o f synucleinopathies is the pre­
sence o f  ubiquitin-positive inclusions in affected regions o f 
the nervous system. In the spinal cord o f y-synuclein
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Figure 5. Amyloid deposits in the spinal cord of y-synuclein transgenic mice. Representative images of Congo Red-stained spinal cord sections of 12-month-old 
wild-type mouse (A), hemizygous ThylmySN mouse (B), homozygous ThylmySN mouse at the advance stage of pathology (C) and homozygous ThylmySN 
mouse with mild signs of pathology (D) are shown. Scale bar =  200 pm for all main panels and 25 pm  for all insets. The bar chart shows mean ±  SEM. of the 
number of deposits per randomly selected 0.1 mm2 area of the spinal cord gray matter. Sections for counting [ 104 for (A), 121 for (B), 93 for (C) and 72 for (D)] 
were randomly selected throughout the length of cervical, thoracic and lumbar parts of the spinal cord of at least four animals per group. One-way ANOVA with 
post hoc Fisher’s protected f-test demonstrated significant (**P <  0.01) difference between all four experimental groups.
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transgenic animals, we detected multiple abnormal ubiquitin- 
positive structures (Fig. 6 C). However, double immunofluor­
escence revealed only partial overlap between 'y-synuclein- 
positive and ubiquitin-positive profiles (Fig. 6 D). Furthermore, 
western blot analysis did not reveal y-synuclein-laddered 
staining patterns reminiscent o f different degrees o f ubiquiti- 
nation (for example, see Fig. ID). Therefore, most o f the 
aggregated y-synuclein in the spinal cord o f T hylm ySN  
mice are probably not ubiquitinated, but ubiquitin and/or 
some ubiquitinated proteins are present in the inclusions that 
appear in the nervous system o f these mice.
t / /
Y-synuclein
GFAP 
GAPDH
Loss o f m o to r neurons in the spinal cord of transgenic mice
The emergence o f  pathological inclusions and astrogliosis in 
T hylm ySN  mice coincides with the loss o f motor neurons 
in the spinal cord (Fig. 7). Twelve-month-old homozygous 
animals with severe motor impairments possessed less than 
40%  o f their wild-type littermates spinal motor neuron comp­
lement (Fig. 7E). Age-matched hemizygous and homozygous 
mice that developed milder motor impairment (clasping 
reflex and pareses o f  one limb but normal righting, for 
example see Supplementary Material movie) also displayed 
motor neuron loss but to a far lesser extent (Fig. 7E). 
Similar results were obtained in cervical, thoracic and 
lumbar parts o f  the spinal cord (data not shown).
Neurodegeneration in the spinal cord o f motor neuron disease 
patients is often associated with dysfunction o f intracellular 
systems that are responsible for correct folding o f protein mol­
ecules. Survival o f  spinal motor neurons seems to rely on mol­
ecular chaperons including small heat shock proteins (40-44). 
Therefore, we used western blot analysis to examine the levels 
o f  large (HSP70) and small (H SPB 1 also known as HSP27 or, in 
mouse, HSP25) heat shock proteins in the spinal cords of 
T hylm ySN  mice. W hile the levels o f HSP70 were similar in 
age-matched transgenic and wild-type animals, the levels of 
HSPB1 were dram atically increased in all ageing transgenic 
animals and particularly in those that displayed severe motor 
impairment (Supplementary M aterial Fig. S3). However, this 
increase was due to high levels o f HSPB 1 in activated astrocytes 
(Fig. 7F and Supplementary Material Fig. S4), whereas in spinal 
motor neurons o f  transgenic animals the level o f this protein 
was substantially lower than in spinal motor neurons o f wild- 
type mice (Fig. 7F).
Figure 6. Astrogliosis and ubiquitin-positive inclusions in the spinal cord of 
y-synuclein transgenic mice. (A) Transverse sections through the spinal 
cord of wild-type and severely affected homozygous ThylmySN mice immu- 
nostained for GFAP. Higher magnification images are shown on lower panels, 
scale bars =  20 pm. (B ) Western blot of total protein extracts from 
12-month-old wild-type, hemizygous and homozygous transgenic mice 
probed with antibodies against y-synuclein, GFAP and GAPDH as a loading 
control. (C) Transverse sections through the spinal cord of severely affected 
homozygous ThylmySN mouse immunostained for ubiquitin. Boxed areas 
of gray and white matter are shown at higher magnification on the right top 
and right bottom panels, correspondingly. (D) Double immunofluorescent 
staining of severely affected ThylmySN mouse spinal cord section with anti­
bodies against ubiquitin (green) and y-synuclein (red). Examples of dystrophic 
neuritis and spheroids positive only for y-synuclein are marked with large 
arrows, positive only for ubiquitin—with small arrows and positive for both 
proteins—with arrowheads. Scale bar =  50 pm.
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Neurofilaments in the spinal cord and peripheral nerves of 
transgenic mice
HSPB1 is thought to be involved in regulation o f the neurofila­
ment network assembly in normal motor neurons and its mutant 
variants affect neurofilament-L (NF-L) aggregation in certain 
forms o f C harco t-M arie -T o o th  disease (4 5 -4 7 ). An acute 
overexpression o f y-synuclein in cultured neurons also perturbs 
their neurofilament network integrity (15). Therefore, we ana­
lysed neurofilaments in the spinal motor neurons o f transgenic 
mice chronically overexpressing y-synuclein. W estern blot 
analysis o f the non-ionic detergent soluble fraction o f 
T hylm ySN  mouse spinal cord revealed not only monomeric 
full-length 67 kDa NF-L but also distinct lower m olecular 
weight NF-L species (Fig. 8 A), possibly products o f  specific 
and restricted breakdown that were not seen in similar fractions 
o f wild-type mouse spinal cord tissue. Decrease o f these trun­
cated species in the spinal cord o f severely affected animals 
probably reflects loss o f neurons that produced them. Overex­
pressed y-synuclein co-imm unoprecipitated with soluble 
NF-L, although substantially less amount o f this protein was 
pulled-down from spinal cord lysates o f animals at the 
advance stages o f pathology than from similar lysates o f 
less-affected animals (Fig. 8 B).
Immunostaining o f histological sections with antibody 
against NF-L did not reveal accumulation o f  this protein in 
y-synuclein-positive or any other pathological profiles in the 
spinal cord o f transgenic animals (Fig. 8 C). However, substan­
tial reduction in staining intensity in the spinal cord o f 
T hylm ySN  mice when compared with wild-type tissue was 
observed (Fig. 8 C). This reduction was mainly confined to 
neuronal processes and not the motor neuron cell bodies 
(Fig. 8 D, upper panels). It was even more obvious in longi­
tudinal sections through peripheral nerves o f Thylm ySN  
mice where only thin and wavy neurofilament-positive 
strings were found (Fig. 8 D, lower panels). In addition, 
severe axonal pathology in the form o f multiple nerve fibre 
swellings was revealed in the sciatic nerve o f ageing hom ozy­
gous T hylm ySN  mice (Fig. 8 D, lower panels). Similar 
changes were also observed in tissue sections stained with 
antibodies against two other neurofilament proteins (data not 
shown). These results suggest that overexpression o f 
y-synuclein in transgenic mouse neurons seriously compro­
mises the organization o f neurofilaments in neuronal processes 
and, consequently, the architecture and function o f  axons.
DISCUSSION
Previous studies o f transgenic mice overexpressing members 
o f the synuclein family have revealed the contrasting effects 
o f a-synuclein and (3-synuclein on the development o f patho­
logical changes in the nervous system o f  these animals. High 
levels o f a-synuclein in neurons cause a prom inent neurologi­
cal phenotype although the manifestations are variable and 
dependent on the a-synuclein isoform and type o f  promoter 
used for production o f that particular transgenic line (reviewed 
in Refs. 4 8 -5 0 ) . In contrast, overexpression o f  (3-synuclein 
does not have a harmful effect on animal health and even 
counteracts a-synuclein neurotoxicity (5 -7 ) . These results 
echo differences in aggregation propensity, cytotoxicity and
certain structural features o f these two proteins. As discussed 
in the Introduction, y-synuclein has m olecular features shared 
with both a -  and (3-synuclein. Therefore, it was not possible to 
predict the consequences o f y-synuclein overexpression in the 
nervous system o f  transgenic animals. Revealing the effects o f 
aberrant expression o f y-synuclein in vivo is important not 
only for better understanding o f relationships between struc­
ture and function within synuclein family. This information 
would also be valuable for development o f new therapeutic 
approaches to combat synucleinopathies.
No disease-associated mutations o f y-synuclein gene or 
obvious cases o f  idiopathic human y-synucleinopathies have 
been reported so far and the amino acid similarity between 
hum an and mouse proteins is high. Taking these facts into 
consideration, we decided to create a simple homologous 
model in which mouse y-synuclein was overexpressed in the 
m ajority o f  neurons o f  the mouse nervous system. To 
achieve this we produced Thylm ySN  transgenic mice, expres­
sing high levels o f  mouse y-synuclein under control o f the 
Thy-1 prom oter cassette that has previously been used for pro­
ducing several a-synuclein  (2 7 -3 0 ) and a (3-synuclein (5) 
transgenic animal lines. In relatively homogeneous popu­
lations o f  neurons that norm ally express y-synuclein, for 
example the DRG, there was approximately a 7-fold increase 
o f  y-synuclein mRNA expression in homozygous T hylm ySN  
transgenic mice com pared with wild-type mice.
In hom ozygous transgenic mice, y-synuclein aggregates and 
accum ulates in abnorm al structures within neuronal cell 
bodies and neurites. These y-synuclein-positive structures 
resemble pathological hallmarks o f synucleinopathies, 
namely dystrophic, beaded and ballooned neurites, spheroids, 
and even, occasionally, Lewy bodies. Like aggregated 
a-synuclein, aggregated y-synuclein could not be extracted 
from transgenic mouse neural tissues using non-ionic deter­
gents, but is partially soluble in sarcosyl-containing buffers. 
At least a fraction o f  aggregated y-synuclein forms linear 
fibrils that are structurally similar, although not identical to 
products o f  a-synuclein  fibrillation in vivo or in vitro.
M ultimeric forms o f  a-synuclein  are commonly detected on 
western blots o f  SDS-soluble proteins extracted from neural 
tissues o f  patients suffered from synucleinopathies or 
a-synuclein transgenic m ice (35,37,38,51-55). These higher 
m olecular w eight bands represent either SDS-resistant 
a-synuclein  oligom ers or ubiquinated forms o f the protein. 
We did not observe sim ilar concatomeric y-synuclein 
species in extracts o f  y-synuclein transgenic mouse brain or 
spinal cord. This m ight suggest that the oligomeric intermedi­
ates o f y-synuclein aggregates are either not accumulating to a 
significant level in neurons o f  transgenic mice or that they are 
readily solubilized to monomeric y-synuclein in 
SD S-containing buffers. It also suggests that even aggregated 
y-synuclein is rarely ubiquitinated, which is consistent with 
our observation that y-synuclein-positive inclusions in the 
spinal cord o f  transgenic mice often do not co-localize with 
ubiquitin-positive structures. The most probable explanation 
o f  our results is that ubiqutination is neither required for nor 
accom panies y-synuclein aggregation but ubiquitin or certain 
ubiquitinated proteins may accumulate in pathological 
inclusions. M oreover, pathological changes in the nervous 
system o f  transgenic mice may trigger secondary events,
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including aggregation o f  ubiquitinated proteins and formation 
o f ubiquitin-positive/y-synuclein-negative inclusions that we 
have observed on double-im munostained sections o f the 
spinal cord. Similar partial overlap o f a-synuclein and ubiqui- 
tin staining patterns has been found previously in the nervous 
systems o f patients with synucleinopathies and a-synuclein 
transgenic mice, though ubiquinated a-synuclein is relatively 
abundant in these tissues (56).
The common features o f  a-synuclein pathology in human 
patients and transgenic mice are abundant amyloid deposits 
and activated glial cells in affected areas o f the nervous 
system. In the brain and spinal cord o f y-synuclein transgenic 
mice, we also observed multiple amyloid (Congo Red- and 
Thioflavin S-positive) deposits and prominent astrogliosis, 
but no activated microglia was detected.
Although all pathological changes described above were 
observed throughout the central nervous system o f 
T hylm ySN  mice, the spinal cord was noticeably more affected 
than any other region, which is similar to the reports on trans­
genic mice expressing a-synuclein under control o f the same 
Thy-1 promoter (Refs 27,29,57 and our unpublished obser­
vations). This probably reflects the higher sensitivity o f  spinal 
cord neurons, particularly motor neurons, to high levels o f 
both members o f the synuclein family.
The ultimate consequence o f  y-synuclein overexpression in 
transgenic mice is death o f motor neurons. Correspondingly, 
these mice display clinical signs typical for motor neuron 
disease, namely a gradual developm ent o f motor deficit fol­
lowed by pareses and paralyses, which are most obvious in 
limb muscles. At this terminal stage o f the disease, 
y-synuclein transgenic animals lose more than 60% of 
ventral horn motor neurons.
The development o f  neurological phenotype and histopatho- 
logical findings in our mice suggests that pan-neuronal overex­
pression o f  y-synuclein in mice could trigger pathological 
changes typical for synucleinopathies and most apparent in 
the spinal cord. The burden o f pathology increases with age, 
which leads to a gradual loss o f  spinal motor neurons and the 
development o f  motor dysfunction. The onset, penetrance and 
degree o f neuropathology directly correlate with the level o f 
transgene expression because the hemizygous animals, which 
express 50% less transgenic y-synuclein than the homozygous 
animals, develop clinical signs later in their life and show less 
pronounced histopathological changes in their nervous system.
One intriguing question is which m olecular and cellular pro­
cesses previously linked to the developm ent o f neurodegenera­
tion become compromised in the nervous system o f y-synuclein 
transgenic mice? Recent studies on the mechanisms o f neurode­
generation in humans and in various model organisms dem on­
strate that simultaneous dysfunction o f several systems 
safeguarding cell homeostasis is required for the development
o f  a full-scale pathology. However, some types o f neurons are 
particularly sensitive to dysfunction in certain intracellular 
systems. Pathogenesis o f motor neuron diseases often involves 
disruption o f neurofilament networks in motor neuron cell 
bodies and axons (reviewed in Refs 5 8 -6 1 ). While this disrup­
tion could be triggered by various mechanisms, in the majority 
o f  cases changes in the structure or metabolism o f NF-L, a 
subunit required for assembly o f neurofilaments in vivo, play 
a crucial role (45 ,62-67). We have demonstrated that chronic 
overexpression o f  y-synuclein in mouse motor neurons leads 
to substantial depletion o f neurofilaments in neuronal processes. 
This might be an essential event in pathogenesis o f axonal path­
ology in peripheral nerves and consequent developm ent o f 
m otor dysfunction in y-synuclein transgenic mice. This result 
is consistent with our previous findings that acute overexpres­
sion o f  y-synuclein affects neurofilament network integrity in 
cultured neurons, particularly their axons (15). The exact mech­
anism o f  the disruptive effect o f  overexpressed y-synuclein on 
neurofilaments rem ains to be elucidated but its ability to 
interact with soluble NF-L and accumulation o f abnormal 
N F-L-reactive soluble polypeptides in the spinal cord o f 
T hy lm yS N  mice suggest that normal homeostasis, including 
transport o f  NF-L to axons, might be at least partially prevented 
by trapping this protein in complexes with y-synuclein and/or 
abnormal degradation. D isruption o f axonal neurofilaments 
follows the reduction o f  NF-L axonal traffic. Moreover, trun­
cated NF-L species could also affect neurofilament assembly 
and/or stability.
Some histopathological changes observed in T hylm ySN  
mice, including astrocytosis and loss o f  motor neurons and 
their axons, are sim ilar to those observed in aged NF-L null 
mutant mice (67). H ow ever in y-synuclein transgenic mice, 
the pathological phenotype develops much earlier and is sub­
stantially more severe. This suggests that, in addition to the dis­
rupted neurofilament network, other intracellular systems are 
also com prom ised in the m otor neurons o f these animals. M ol­
ecular chaperons belonging to the family o f heat shock proteins 
play an im portant protective role in m otor neurons. These cells 
seem to be particularly vulnerable to dysfunction o f the small 
heat shock protein HSPB1 (4 0 -4 4 ) and mutations o f the 
HSPB1 gene cause certain types o f motor neuron diseases 
(4 5 -4 7 ). In m otor neurons o f  y-synuclein transgenic mice, 
the level o f  HSP25, a mouse ortholog o f  HSPB1, is substantially 
reduced, potentially com prom ising the survival o f these cells.
A lthough some a-synuclein  transgenic mice develop similar 
clinical signs o f  the spinal cord pathology to y-synuclein trans­
genic mice, neither dow n-regulation o f  HSPB1 nor changes o f 
the neurofilam ent netw ork in their motor neurons has been 
reported. Taken together w ith other data, this suggests that 
diverse but partially overlapping mechanisms underlie devel­
opment o f  pathology in these two mouse models.
Figure 7. Loss of motor neurons and changes of HSPB1 expression in the spinal cord of "y-synuclein transgenic mice. Representative images of cresyl fast violet- 
stained spinal cord sections of 12-month-old wild-type mouse (A), hemizygous ThylmySN mouse (B), homozygous ThylmySN mouse at the advance stage of 
pathology (C) and homozygous ThylmySN mouse with mild pathology (D) are shown. (E) The bar chart shows mean ±  SEM. of the number of motor neurons 
per section expressed as percent of the average number of motor neurons per section of the wild-type mouse spinal cord. Sections for counting [160 for (A), 332 
for (B), 215 for (C) and 139 for (D)] were randomly selected throughout the length of cervical, thoracic and lumbar parts of the spinal cord of at least four 
animals per group. One-way ANOVA with post hoc Fisher’s protected /-test demonstrated significant (**P<0.01) difference between all four experimental 
groups. (F) Double immunofluorescent staining of spinal cord sections from a wild-type mouse and severely affected homozygous ThylmySN mouse with anti­
bodies against neurofilament-L (green) and HSPB1 (red). Scale bar =  20 p.m.
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Figure 8. Neurofilaments in the spinal cord and peripheral nerve of y-synuclein transgenic animals. (A) Western blot analysis of soluble neurofilament-L in the 
cytosolic (10 OOOg supernatant) fraction of the spinal cord of 12-month-old wild-type mice, hemizygous ThylmySN mice, homozygous ThylmySN mice with 
mild clinical signs of pathology and homozygous ThylmySN mice at the advance stage of pathology. (B ) Co-immunoprecipitation of y-synuclein and soluble 
neurofilament-L from the same cytosolic fractions. (C) Double immunofluorescent staining of severely affected ThylmySN mouse spinal cord section with anti­
bodies against neurofilament-L (green) and y-synuclein (red) shows the absence of NF-L accumulation in y-synuclein-positive pathological profiles. (D ) Sub­
stantial reduction of neurofilament-L staining in the ventral horns of the spinal cord (upper panels) and sciatic nerve (lower panels) of 12-month-old homozygous 
ThylmySN mice at the advance stage of pathology compared with their wild-type littermates. Scale bars =  20 |xm for (C) and 50 p.m for (D).
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In conclusion, we have demonstrated that transgenic mice 
expressing high levels o f  y-synuclein in their neurons 
develop a severe neurodegenerative pathology. It is feasible 
that, under certain conditions, 7 -synuclein could be involved 
in the development o f pathological changes in human 
neurons. Further studies on the role o f this synuclein in 
normal and degenerating neurons might therefore provide 
additional insight into the mechanisms leading to human neu­
rodegenerative diseases.
MATERIALS AND METHODS
Generation of transgenic animals
A fragment o f  mouse 7 -synuclein cDNA including 34 bp o f 
5'-UTR and 64 bp o f 3'-UTR was PCR amplified using 
pD53 plasmid DNA (31) as a template and oligonucleotides 
with Xhol linkers (mySN Xhol-F: 5'-CTACTGTCCGCTCG 
AGCTTGCAGCAGCCAGGTTC-3' and mySN Xhol-R: 
5-CTACTGTCCGCTCGAGGCCTTCTAGTCTTCTCCA- 
C-3') to facilitate subsequent cloning into Xhol site o f T hy-1 
promoter plasmid 323-pTSC21k (27). The fragment for micro- 
injecting mouse oocytes was isolated by digestion o f the 
resulting plasmid DNA with Notl. Transgenic founders were 
produced on C57B16 genetic background. Animals positive 
for transgene expression were crossed with C57B16 wild-type 
mice. Transgenic and wild-type animals were identified by 
PCR analysis o f  DNA from ear biopsies. The presence o f a
I  kb product in the amplification reaction with primers 
HP45 Thyl f2 (5'-ACACCCCTAAAGCATACAGTCAGAC 
C-3') and HP84 m ySN (5'-GGCCTTCTAGTCTTCTCCA 
CTCTTG-3') indicated the presence o f transgene in the 
mouse genome. Experimental cohorts were formed from 
litters produced by intercrossing hemizygous animals. Hemi- 
and homozygous animals were discrim inated by quantitative 
real-time PCR analysis o f DNA from ear biopsies and verified 
by analytical backcrossing followed by offspring genotyping. 
All animal work was carried in accordance with the United 
Kingdom Animals (Scientific Procedures) Act (1986).
Motor performance tests
Rotarod tests. Animals were tested on Ugo Basile 7650 
rotarod at 2, 4, 6 , 9, 12, 18 and 24 months o f age. A constant 
(24 rpm) speed test was carried out for 4 min and accelerating 
(4 -4 0  rpm) speed test for 5 min as described previously (6 8 ). 
Each mouse was tested three times in each mode with at least 
30 min rest between trials. The mean o f  latency to fall for 
these three trials was included in final statistics. Eleven wild 
type, 12 hemizygous and 13 homozygous mice were tested 
at 2 months: 28, 27 and 21, at 4 months; 35, 40 and 23, at 6  
months; 34, 36 and 23, at 9 months; 25, 26 and 14, at 12 
months o f age. No homozygous animals survived beyond 16 
months therefore at this age and at 24 months only wild-type 
( 1 2  and 15, respectively) and hemizygous ( 2 1  and 15, respect­
ively) animals were tested.
Horizontal beam test. Animal coordination was tested on an
II mm diameter and 50 cm long horizontal wooden rod at 4, 
6 , 9 and 12 months o f age. A mouse was placed at the free
hanging end o f the rod facing its end. The ability to turn 
180 and to reach an escape black box at the other end of 
the rod was recorded.
Footprint test. Animals were trained to run along a narrow 
passage lined with a strip of white paper before carrying out 
the test run. For this run, mouse forefeet were coated with blue 
ink and hindfeet with red ink. Different parameters o f the stride 
were measured and analysed as described previously (69).
RNA expression analysis
Total RNA from various regions o f the nervous system was 
extracted using R N A E asy+  kit as recommended by the m an­
ufacturer (Qiagen). First-strand cDNA was synthesized using 
random prim ers (Prom ega) and SuperScriptHI reverse tran­
scriptase (Invitrogen). Quantitative PCR was performed on 
StepOne Real-Tim e PCR System (Applied Biosystems) with 
DyNAmo HS SYBR Green supermix (Finnzymes) and ROX 
as a passive reference dye. Reactions were carried out in one- 
piece thin-wall 48-well PCR plates (Bioplastics). GAPDH 
mRNA was used as a norm alization standard. Primers 
5'-CCATGG ACG TCTTCA AG A AA GG -3' and 5'-CGTTCTC 
CTTG GTTTTG GTG -3' were used for amplification of 
7 -synuclein cDNA, and prim ers 5'-CACTGAGCATCTCC 
CTCACA-3' and 5'-GTGGGTGCAGCGAACTTTAT-3' for 
amplification o f  GAPDH mRNA. After hot start (10 min at 
95°C), 40 cycles o f  1 5 s at 95°C and 6 0 s  at 60°C were 
carried out follow ed by m elting curve determination with 
0.3CC steps. Fold change was determined by 2 _AACT method 
as described previously (70) using StepOne v2.0 software.
Protein extraction
Total tissue proteins were extracted by homogenization of 
tissues directly in S D S -P A G E  loading buffer followed by 
incubation for 10 m in at 100°C. For analysis o f cytosolic pro­
teins, tissues were hom ogenized in 50 mM T ris-H C l, pH 7.5; 
150 mM NaCl; 1% Triton X-100 buffer with protease inhibi­
tors (Com plete M ini from Roche) and cytosolic fraction was 
obtained by centrifugation for 10 min at 10 OOOg.
Sequential protein extraction
A previously described protocol (37) was used with minor 
modifications. Briefly, neuronal tissues were homogenized in 
5 volum es o f  high salt (HS) buffer (50 mM T ris-H C l, pH 
7.5; 750 mM NaCl; 5 mM EDTA) with protease inhibitors 
(Com plete Mini from Roche) and centrifuged at lOOOOOg 
for 20 min at 4°C. Pellets were washed in the same buffer 
and then re-extracted in HS buffer containing 1% Triton 
X-100 (H S/T-soluble fraction). Subsequent centrifugations 
and re-extractions produced RIPA-soluble and SDS-soluble 
fractions. The presence o f 7 -synuclein in these fractions was 
analysed by SD S-PA G E /w estem  blotting.
Isolation and visualization of 7-synuclein filaments
Sarcosyl-insoluble filaments were extracted from mouse spinal 
cords as described previously for human neuronal tissues (71).
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Final 100 OOOg pellets were resuspended in 50 mM T ris-H C l 
(pH 7.5) buffer and aliquots were applied onto glow- 
discharged carbon-coated 400-m esh copper grids. After block­
ing in 1% BSA/PBS, grids were incubated in 1:50 diluted 
affinity purified rabbit anti-m ouse y-synuclein SK23 antibody 
(31) for 60 min at room tem perature followed by goat anti­
rabbit immunoglobulin secondary antibody (Amersham) con­
jugated to lO nm  gold particles. Fibrils were negatively 
stained with 1% dodeca-tungstophosphoric acid neutralized 
with KOH to pH 6.2 as described previously (72) and observed 
at x  40 000 or x 50 000 magnification under a Philips TEM 
208 transmission electron microscope.
Western blotting and antibodies
Proteins separated by S D S -P A G E  were transferred to PVDF 
membrane using iBlot technology according to manufacturer 
(Invitrogen) instructions. M em brane blocking, incubation 
with antibodies, washing and chemiluminescent detection 
using ECL or ECL+ techniques were carried out as described 
previously (31,68). Intensities o f  bands obtained using Alphal- 
mager 2200 were analysed using AlphaEase 2200 Analysis 
Software (Alphalnnotech Corporation). Primary antibodies 
against GAPDH (mouse monoclonal, clone 6C5, Santa Cruz 
Biotechnology), a-synuclein (m ouse monoclonal, clone 42, 
BD Transduction Laboratories), (3-synuclein (mouse mono­
clonal, clone 8, BD Transduction Laboratories), y-synuclein 
(rabbit polyclonal SK23, affinity purified), GFAP (rabbit poly­
clonal, Sigma), Ibal (mouse m onoclonal, clone 1022-5, Santa 
Cruz), C D llb  (rat monoclonal, clone M l/70.15, Serotec), 
NF-L (rabbit monoclonal, clone C28E10, and mouse mono­
clonal, clone DA2, both Cell Signalling), neurofilament H 
(rabbit polyclonal, Sigma), heat shock protein B1 (rabbit 
monoclonal, Cell Signalling) and heat shock protein 70 
(rabbit monoclonal, Cell Signalling) were used.
Immunoprecipitation
Freshly dissected spinal cords from individual anim als were 
homogenized in 0.5 ml o f IP buffer (50 mM T ris -H C l, pH 
7.5, 300 mM NaCl, 1.5 mM M gCl2, 1% Triton X-100) w ith pro­
tease inhibitors (Complete Mini from Roche) and Triton- 
soluble fraction was obtained by xlOOOOg centrifugation 
for 10 min at 4 CC. After presorption on Protein G Sepharose 
(Amersham) for 30 min at 4°C and removal o f  beads by cen­
trifugation for 1 min at lOOOg, 5 |xl o f antibody against NF-L 
(mouse monoclonal, clone DA2, Cell Signalling) or 20 julI o f  
antibody against y-synuclein (rabbit polyclonal SK23) were 
added, followed by 50 jjlI o f fresh Protein G Sepharose. The 
suspension was rotated at 4CC for 2 h Sepharose beads were 
collected by centrifugation for 1 min at lOOOg and washed 
four times with IP buffer. Bound proteins were eluted by 
boiling beads in 50 p.1 o f SD S-P A G E  loading buffer for 
10 min.
Histological techniques
Dissected tissues were post-fixed in 4% paraformaldehyde/ 
PBS or C am oy’s fixative and embedded in paraffin wax. 
Eight micrometre thick sections were cut and immunostained
as described previously (32) using Elite plus kits (Vector lab­
oratories) and 3,3'-diaminobenzidine as a substrate. For double 
immunofluorescence, secondary Alexa Fluor-conjugated anti­
body (Invitrogen) were used. Images were prepared using 
laser scanning confocal microscope Leica TCS SP2 (Leica 
M icrosystems) and LEICA CONFOCAL 2.00 software. For 
detection and counting o f amyloid aggregates, spinal cord sec­
tions (four to five animals per age/genotype/condition group) 
were stained in 0.5% Congo red solution in 50% ethanol for 
7 min followed by a b rief differentiation in potassium hydrox­
ide (0.2% in 80% ethanol) and, after several washes in dH20 , 
were mounted using Immu-mount (Thermo Electron Corpor­
ation). Fluorescent microscopy was used to analyse the 
number o f  aggregates within a random ly selected 0.1 m m 2 
area o f the spinal cord gray matter. For assessing num ber o f 
spinal motor neurons, transverse spinal cord sections were 
stained in 0.5% cresyl fast violet (CFV) solution in dH20  
and dissociated in acidified ethanol (0.25%  acetic acid in 
ethanol). The number o f  motor neurons (identified by a large 
cell body containing Nissl granules, with a clear nuclear envel­
ope containing a strongly stained nucleolus) w ithin the ventral 
horn was counted. Results were expressed as per cent o f the 
average num ber o f  m otor neurons per ventral horn section in 
the wild-type animals.
SUPPLEMENTARY MATERIAL
Supplementary M aterial is available at H M G  online.
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